



(51) International Patent Classification:

A61P 25/28 (2006.01)

A61K 39/00 (2006.01)

C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2022/028920

(22) International Filing Date:

12 May 2022 (12.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/188,800

14 May 2021 (14.05.2021)

US

(71) Applicant: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US).

(72) Inventors: ECHEVERRIA LARRAZA, Ainhoa; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). HANSEN, David Verne; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). HOTZEL, Isidro; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). HSIAO, Yi-Chun; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). LIN, Zhonghua; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). SESHASAYEE, Dhaya; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). CHIH, Benny; c/o

Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US).

(74) Agent: DOHERTY, Elizabeth A. et al.; 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: AGONISTS OF TREM2

Campaign	Species	Immunogen and method	Animals fused	Human TREM2 ELISA positives	Human TREM2 FACS positives	Unique clones
1	SD rats	Human TREM2 pDNA genegun	3	88	71	15
3	SD rats	Human TREM2 ECD protein	3	900	346	174
5	SD rats	Human TREM2 EV	2	366	270	5
6	TREM2 KO mice	Human TREM2 ECD TREM2	5	18	18	5
8	TREM2 KO mice	Human TREM2 pDNA HTV	6	278	242	30

Fig. 1

(57) Abstract: This application discloses, *inter alia*, certain antibodies that specifically bind to human TREM2 (triggering receptor expressed on myeloid cells 2). In some embodiments, the antibodies act as TREM2 agonists. In some embodiments, antibodies herein specifically bind to the stalk region of intact, human TREM2, without binding to soluble TREM2, which is the product of TREM2 cleavage between residues H157 and S158. In some embodiments, the antibodies act as TREM2 agonists, specifically bind to the stalk region of TREM2 with dissociation constants ranging from 10 nM to as low as 100-500 pM, 10-50pM, or 1-10 pM, specifically bind to a TREM2 epitope spanning the H157-S158 cleavage site, and do not bind to soluble TREM2. In some embodiments, antibodies herein also inhibit shedding of soluble TREM2 in a human microglia cell model and *in vivo* in a mouse model, decrease levels of soluble TREM2 in plasma, CSF and/or the brain, enhance survival of human microglia cells, and increase A β plaque formation and compaction in a human microglia model (for example, as measured by increased Ab plaque intensity and/or increased X04 plaque intensity in human microglia), and thus, may provide a number of neuroprotective activities.

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

AGONISTS OF TREM2

CROSS-REFERENCE TO RELATED APPLICATIONS

[001] This application claims priority to U.S. Provisional Application No. 63/188,800, filed May 14, 2021, the disclosure of which is hereby incorporated by reference in its entirety.

SEQUENCE LISTING

[002] This application contains a Sequence Listing in computer readable form entitled “01164-0014-00PCT_ST25”, created May 9, 2022, having a size of 115 KB, which is incorporated by reference herein.

FIELD

[003] This application discloses, *inter alia*, certain antibodies that specifically bind to TREM2. In some embodiments, the antibodies act as TREM2 agonists.

BACKGROUND

[004] TREM2 (triggering receptor expressed on myeloid cells 2) is an activating immune cell receptor expressed in the brain in microglia (Hickman et al., *Nat. Neurosci.* 16(12): 1896-1905 (2013); Zhang et al., *Neuron* 89: 37-53 (2016); Deczkowska et al., *Cell* 181:1207-1217 (2020); Hansen et al., *J. Cell Biology* 217(2) : 459-472 (2018); Yeh et al., *Trends Mol. Med.* 23:512-533 (2017)). Certain TREM2 mutations have been identified as risk factors for Alzheimer’s disease (AD) (Guerreiro et al., *N. Engl. J. Med.* 368: 117-27 (2013); Jonsson et al., *N. Engl. J. Med.* 368: 107-116 (2013)). Studies have also been performed in mouse models to understand how TREM2 influences the development of AD pathologies such as β -amyloid (A β) plaques and phosphorylated aggregates of the tau protein. An emerging consensus is that A β plaques have a less compacted morphology and are more damaging to surrounding neurites when TREM2 function is impaired (Meilandt et al., *J Neurosci.* 40:1872-19 (2020); Wang et al., *J. Exp. Medicine* 213:667-675 (2016); Yuan et al., *Neuron* 90:724-739 (2016)).

[005] A β aggregates have been found to bind directly to recombinant TREM2 extracellular domain, although other studies suggest that certain phospholipids are the relevant ligand for TREM2. TREM2 also binds to APOE or APOJ when they are lipidated and facilitates uptake of APOE/APOJ-containing lipoparticles. (Yeh et al., *Neuron* 91: 328-340 (2016).) Furthermore, microglial uptake and degradation of A β are accelerated when A β oligomers are bound to APOE/APOJ lipoparticles, a process that is partially mediated by TREM2. After ligation, TREM2 elicits a DAP12/Fyn/Syk signaling cascade that influences a host of microglial processes, including phagocytosis, endocytosis, chemotaxis, CSF-1-mediated survival, aggregate degradation, and metabolic changes. Thus, TREM2 appears to be central to microglial activity in response to amyloid and lipids.

SUMMARY

[006] The present disclosure relates to antibodies that specifically bind to TREM2 and act as TREM2 agonists, and that may have a particularly unique set of features, useful for the treatment of neurodegenerative diseases such as Alzheimer's Disease (AD) and multiple sclerosis (MS).

[007] The TREM2 protein is a cellular transmembrane protein that is cleaved in an extracellular region referred to as the stalk region, leading to a soluble peptide, termed "soluble TREM2" or "sTREM2". TREM2 cleavage *in vivo* is thought to occur between residues H157 and S158, giving rise to sTREM2. This disclosure describes antibodies having the unique property of specifically binding to the stalk region in non-soluble, intact TREM2, without binding to the cleavage product, sTREM2. For example, certain antibodies herein not only act as TREM2 agonists, but also specifically bind to the stalk domain of TREM2 with dissociation constants ranging from 10 nM to as low as 100-500 pM, 10-50pM, or 1-10 pM, and specifically bind to a TREM2 epitope spanning the H157-S158 cleavage site. These antibodies specifically bind to the TREM2 stalk region while not binding to soluble TREM2.

[008] The specificity of these antibodies for uncleaved TREM2 may have several potential benefits *in vivo*, including avoiding unwanted binding of antibodies to soluble TREM2 in the periphery and brain after *in vivo* dosing and/or blocking the cleavage site and reducing the amount of sTREM2 that is shed from the cell surface. The lack of

soluble TREM2 binding could be beneficial *in vivo*, e.g., by allowing more of the dosed anti-TREM2 antibody to reach the desired target of uncleaved TREM2 on the surface of cells. By way of example, and not limitation, this unique binding profile may prevent antibodies from unwanted binding to soluble TREM2 *in vivo* and ensure that antibodies more specifically target TREM2 on the surface of cells within the central nervous system rather than sTREM2 in the periphery.

[009] Thus, the present disclosure encompasses certain antibodies that: (a) bind specifically to the TREM2 stalk domain and more specifically to a TREM2 epitope spanning the H157-S158 cleavage site, and (b) do not bind to soluble TREM2, and thus, may not present a risk of soluble TREM2 binding *in vivo*. In some embodiments, the antibodies of the present disclosure also (c) act as TREM2 agonists, for example, by inducing NFAT-controlled gene expression and/or Syk kinase phosphorylation in cultured cells, and (d) exhibit very high affinity for TREM2, e.g., specifically binding to TREM2 with dissociation constants of, for example, 100-500 pM, 10-50 pM, or 1-10 pM. In some embodiments, antibodies herein also inhibit shedding of soluble TREM2 in a human microglia cell model and *in vivo* in a mouse model, decrease levels of soluble TREM2 in plasma, CSF and/or the brain, enhance survival of human microglia cells, and increase A β plaque formation and compaction in a human microglia model (for example, as measured by increased A β plaque intensity and/or increased X04 plaque intensity in human microglia), and thus, may provide a number of neuroprotective activities.

The present disclosure encompasses, *inter alia*, an isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 11, 19, or 62; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 10, 12, 20, 55, 63, 65, or 73; and a CDR-H3 comprising the amino acid sequence as follows: X₁-X₂-X₃-Y, wherein X₁ and X₂ together are either I-L or L, and wherein X₃ is either D or E.

[0010] The disclosure also encompasses, for example, an isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 11, 19, or 62; a CDR-H2

comprising the amino acid sequence of SEQ ID NO: 2, 10, 12, 20, 55, 63, 65, or 73; and a CDR-H3 comprising the amino acid sequence as follows: X_1 - X_2 - X_3 -Y, wherein X_1 and X_2 together are either I-L or L, and wherein X_3 is either D or E; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, 27, 37, 47, 57, or 67; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, 29, 39, 49, 59, or 69. The disclosure further encompasses, for example, an isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 11, or 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 10, 12, or 20; and a CDR-H3 comprising the amino acid sequence as follows: X_1 - X_2 - X_3 -Y, wherein X_1 and X_2 together are either I-L or L, and wherein X_3 is either D or E; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0011] In some embodiments herein, the antibody has one or more, two or more, three or more, four or more, five or more, six or more, or all of the following properties:

- (a) specifically binds to the stalk domain of TREM2;
- (b) does not bind to soluble TREM2 (sTREM2);
- (c) specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);
- (d) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site;
- (e) shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry);
- (f) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM at 37 °C by surface plasmon resonance (SPR); and

(g) specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM at 37 °C by surface plasmon resonance (SPR).

[0012] Furthermore, in some embodiments, the antibody has a VH sequence derived from rat IGHV6-8 germline segments and/or wherein the antibody has a VL sequence derived from rat IGKV2S11 germline segments. In some embodiments, the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, 27, or 67; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, 29, or 69. In some embodiments, the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the heavy chain variable region (VH) comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 or 9; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2 or 10; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and wherein the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; or the heavy chain variable region (VH) comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11 or 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12 or 20; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; and wherein the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the antibody comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7, 17, 30, 40, 50, 60, 70, 76, 77, 78, 81, 82, 83, 133, 135, 137, 139, 146, 148, 150, or 152. In some embodiments, the antibody comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7, 17, 133, 135, 137, 139, 146, 148, 150, or 152. In some embodiments, the antibody comprises a VL that is at least 90%, at least 95%, at least

97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8, 18, 31, 41, 51, 61, 71, 79, 80, 84, 85, 132, 134, 136, 138, 145, 147, 149, or 151. In some embodiments, the antibody comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8, 18, 132, 134, 136, 138, 145, 147, 149, or 151. In some embodiments, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7, 17, 133, 135, 137, 139, 146, 148, 150, or 152. In some embodiments, the antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 8, 18, 132, 134, 136, 138, 145, 147, 149, or 151.

[0013] The present disclosure also encompasses, *inter alia*, an isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises:

- (a) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6;
- (b) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6;
- (c) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16;
- (d) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19, a CDR-H2 comprising the amino acid sequence of

SEQ ID NO: 20, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16;

(e) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 24, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 25, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 27, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 29;

(f) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 34, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 35, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 36; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 37, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 38, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 39;

(g) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 48, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 49;

(h) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 54, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 55, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 56; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 57, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 59; or

(i) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 64, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 65, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 66;

and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 67, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 69.

[0014] In some embodiments, the antibody

comprises the CDRs of part (a) above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7;

comprises the CDRs of part (b) above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7;

comprises the CDRs of part (c) above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 17;

comprises the CDRs of part (d) above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 17;

comprises the CDRs of part (e) above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 30;

comprises the CDRs of part (f) above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 40;

comprises the CDRs of part (g) above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 50;

comprises the CDRs of part (h) above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 60; or

comprises the CDRs of part (i) above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 70.

[0015] In some embodiments, the antibody comprises the CDRs of part (a) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8;

comprises the CDRs of part (b) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8;

comprises the CDRs of part (c) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 18;

comprises the CDRs of part (d) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 18;

comprises the CDRs of part (e) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 31;

comprises the CDRs of part (f) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 41;

comprises the CDRs of part (g) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 51;

comprises the CDRs of part (h) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 61; or

comprises the CDRs of part (i) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 71.

[0016] In some cases, the antibody comprises the CDRs of part (a) above and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 7;

comprises the CDRs of part (b) above and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 7;

comprises the CDRs of part (c) above and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 17;

comprises the CDRs of part (d) above and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 17;

comprises the CDRs of part (e) above and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 30;

comprises the CDRs of part (f) above and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 40;

comprises the CDRs of part (g) above and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 50;

comprises the CDRs of part (h) above and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 60; or

comprises the CDRs of part (i) above and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 70.

[0017] In some cases, the antibody

comprises the CDRs of part (a) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 8;

comprises the CDRs of part (b) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 8;

comprises the CDRs of part (c) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18;

comprises the CDRs of part (d) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18;

comprises the CDRs of part (e) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 31;

comprises the CDRs of part (f) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 41;

comprises the CDRs of part (g) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 51;

comprises the CDRs of part (h) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 61; or

comprises the CDRs of part (i) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 71.

[0018] In some cases, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 8. In some cases, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 18. In some cases, the antibody comprises a VL comprising from 1 to 5 amino acid substitutions in the framework region compared to human IGKV2-28*01 germline, optionally wherein the amino acid substitutions comprise Q100P and/or V104L. In some cases, the antibody: comprises the CDRs of part (a) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 145; comprises the CDRs of part (b) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 145; comprises the CDRs of part (a) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 147; comprises the CDRs of part (b) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 147; comprises the CDRs of part (a) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 149; comprises the CDRs of part (b) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 149; comprises the CDRs of part (a) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 151; comprises the CDRs of part (b) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 151; comprises the CDRs of part (c) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 132; comprises the CDRs of part (d) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 132;

comprises the CDRs of part (c) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 134;

comprises the CDRs of part (d) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 134;

comprises the CDRs of part (c) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 136;

comprises the CDRs of part (d) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 136;

comprises the CDRs of part (c) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 138; or

comprises the CDRs of part (d) above and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 138.

[0019] In some embodiments, an antibody herein has one or more, two or more, three or more, four or more, five or more, six or more, or all of the following properties:

- (a) specifically binds to the stalk domain of TREM2;
- (b) does not bind to soluble TREM2 (sTREM2);
- (c) specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);
- (d) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site;
- (e) shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry);
- (f) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or 100-500 pM or 100-200 pM at 37 °C by surface plasmon resonance (SPR); and
- (g) specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR).

[0020] The application also encompasses, for instance, an isolated antibody that specifically binds triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises:

a VH comprising the amino acid sequence of SEQ ID NO: 146 and a VL comprising the amino acid sequence of SEQ ID NO: 145;

a VH comprising the amino acid sequence of SEQ ID NO: 148 and a VL comprising the amino acid sequence of SEQ ID NO: 147;

a VH comprising the amino acid sequence of SEQ ID NO: 150 and a VL comprising the amino acid sequence of SEQ ID NO: 149; or

a VH comprising the amino acid sequence of SEQ ID NO: 152 and a VL comprising the amino acid sequence of SEQ ID NO: 151. In some embodiments, the antibody has one or more, two or more, three or more, four or more, five or more, or all of the following properties:

- (a) specifically binds to the stalk domain of TREM2;
- (b) does not bind to soluble TREM2 (sTREM2);
- (c) specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);
- (d) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site;
- (e) shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry); and
- (f) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or 100-500 pM or 100-200 pM at 37 °C by surface plasmon resonance (SPR).

[0021] The application further encompasses, for example, an isolated antibody that specifically binds triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises:

a VH comprising the amino acid sequence of SEQ ID NO: 133 and a VL comprising the amino acid sequence of SEQ ID NO: 132;

a VH comprising the amino acid sequence of SEQ ID NO: 135 and a VL comprising the amino acid sequence of SEQ ID NO: 134;

a VH comprising the amino acid sequence of SEQ ID NO: 137 and a VL comprising the amino acid sequence of SEQ ID NO: 136; or

a VH comprising the amino acid sequence of SEQ ID NO: 139 and a VL comprising the amino acid sequence of SEQ ID NO: 138. In some embodiments, the antibody has one or more, two or more, three or more, four or more, five or more, or all of the following properties:

- (a) specifically binds to the stalk domain of TREM2;
- (b) does not bind to soluble TREM2 (sTREM2);
- (c) specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);
- (d) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site;
- (e) shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry); and
- (f) specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR).

[0022] In some cases, an antibody herein has one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the following characteristics:

- (a) induces luciferase reporter activity in Jurkat-NFAT luciferase reporter cells expressing human TREM2;
- (b) decreases levels of sTREM2 *in vivo* in plasma;
- (c) inhibits shedding of sTREM2 in Jurkat-NFAT luciferase reporter cells expressing human TREM2;
- (d) induces tyrosine phosphorylation in human MDM cells;

(e) SYK phosphorylation in human MDM cells;
(f) enhances survival of human iPSC-derived microglia in absence of IL-34 and CSF-1;
(g) inhibits shedding of sTREM2 in human iPSC-derived microglia;
(h) induces SYK phosphorylation in human iPSC-derived microglia; and
(i) increases total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia (e.g., as described in the assay of Example 17 herein). In some embodiments, the antibody herein also has a low off-target binding score (e.g. a score of < 1) in an off-target binding assay (e.g., as described in Example 10 herein).

[0023] In some embodiments, the antibody is an antibody fragment, such as an Fv, single-chain Fv (scFv), Fab, Fab', or (Fab')₂. In some embodiments, the antibody is an IgG antibody, such as an IgG1, IgG2, IgG3, or IgG4 antibody. In some such cases, the antibody comprises a wild-type, human IgG1 or IgG4 Fc region. In some such cases, the antibody comprises a human IgG1 Fc region comprising (a) an N297G substitution, (b) L234A, L235A, and P329G substitutions (LALAPG substitutions), or (c) N297G, M428L, and N434S substitutions. In some embodiments herein, the antibody has reduced effector function, or is effectorless, or does not bind to Fc γ R. In some embodiments, the antibody comprises a human IgG1 Fc region comprising an N297G substitution. In some embodiments herein, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 144 and/or a light chain comprising the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 but lacking the C-terminal lysine of SEQ ID NO: 144 or lacking the C-terminal glycine and lysine of SEQ ID NO: 144 and/or a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 144 and/or a light chain consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments herein, the antibody comprises a human IgG4 Fc region comprising an S228P substitution or comprising S228P, M252Y, S254T, and T256E substitutions. In some embodiments herein, the antibody is a full length antibody. In some embodiments herein, the antibody is an IgG antibody lacking a C-terminal lysine in the heavy chain constant region.

[0024] The disclosure herein also encompasses, for instance, an isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 17 and/or a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 18. The disclosure herein further encompasses an isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 and/or a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. The disclosure herein also encompasses an isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 but lacking the C-terminal lysine of SEQ ID NO: 144 or lacking the C-terminal glycine and lysine of SEQ ID NO: 144 and/or a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. The disclosure also encompasses an isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 144 and/or a light chain consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody specifically binds to the TREM2 stalk domain and does not bind to soluble TREM2 (sTREM2), and wherein the antibody specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site and/or specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94). In some embodiments, the antibody specifically binds to the TREM2 stalk domain and does not bind to soluble TREM2 (sTREM2), and wherein the antibody is a TREM2 agonist. In some embodiments herein, the antibody has one or more, two or more, three or more, four or more, five or more, six or more, or all of the following properties:

- (a) specifically binds to the stalk domain of TREM2;
- (b) does not bind to soluble TREM2 (sTREM2);

- (c) specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);
 - (d) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site;
 - (e) shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry);
 - (f) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM at 37 °C by surface plasmon resonance (SPR); and
- [0025] (g) specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM at 37 °C by surface plasmon resonance (SPR). In some embodiments, for example, the antibody shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry) and/or specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR). And in some embodiments, the antibody has one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the following characteristics:
- (a) induces luciferase reporter activity in Jurkat-NFAT luciferase reporter cells expressing human TREM2;
 - (b) decreases levels of sTREM2 *in vivo* in plasma;
 - (c) inhibits shedding of sTREM2 in Jurkat-NFAT luciferase reporter cells expressing human TREM2;
 - (d) induces tyrosine phosphorylation in human MDM cells;
 - (e) SYK phosphorylation in human MDM cells;
 - (f) enhances survival of human iPSC-derived microglia in absence of IL-34 and CSF-1;

(g) inhibits shedding of sTREM2 in human iPSC-derived microglia;
(h) induces SYK phosphorylation in human iPSC-derived microglia; and
[0026] (i) increases total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia (e.g., as described in the assay of Example 17 herein). In some embodiments, the antibody also has a low off-target binding score (e.g. a score of < 1) in an off-target binding assay (e.g., as described in Example 10 herein).

[0027] The disclosure herein also encompasses an isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11 or 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12 or 20; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13, and further wherein the antibody specifically binds to the TREM2 stalk domain and does not bind to soluble TREM2 (sTREM2), wherein the antibody is a TREM2 agonist, and wherein the antibody specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site and/or specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94). In some embodiments, for example, the antibody shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry) and/or specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR). And in some embodiments, the antibody has one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the following characteristics:

(a) induces luciferase reporter activity in Jurkat-NFAT luciferase reporter cells expressing human TREM2;
(b) decreases levels of sTREM2 *in vivo* in plasma;

(c) inhibits shedding of sTREM2 in Jurkat-NFAT luciferase reporter cells expressing human TREM2;

(d) induces tyrosine phosphorylation in human MDM cells;

(e) SYK phosphorylation in human MDM cells;

(f) enhances survival of human iPSC-derived microglia in absence of IL-34 and CSF-1;

(g) inhibits shedding of sTREM2 in human iPSC-derived microglia;

(h) induces SYK phosphorylation in human iPSC-derived microglia; and

[0028] (i) increases total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia (e.g., as described in the assay of Example 17 herein). In some embodiments, the antibody also has a low off-target binding score (e.g. a score of < 1) in an off-target binding assay (e.g., as described in Example 10 herein). Further, in some embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 17, 133, 135, 137, or 139, or wherein the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144. In some cases, the antibody comprises a human IgG1 Fc region comprising (a) an N297G substitution, (b) L234A, L235A, and P329G substitutions (LALAPG substitutions), or (c) N297G, M428L, and N434S substitutions. In some cases, the antibody has reduced effector function, or is effectorless, or does not bind to Fc γ R.

[0029] In some embodiments herein, an antibody is a bispecific or multispecific antibody, or is conjugated covalently or noncovalently to at least one other molecule. In some cases, the antibody is conjugated covalently or noncovalently to at least one other molecule, wherein the at least one other molecule comprises a detection label and/or a drug.

[0030] The present disclosure also includes a pharmaceutical composition comprising an antibody as described herein and a pharmaceutically acceptable carrier. The disclosure also encompasses an isolated nucleic acid or set of two or more nucleic acids encoding the antibody disclosed herein. The disclosure also includes an isolated vector comprising one or more nucleic acids encoding the heavy chain and the light chain of the antibody herein. The disclosure further encompasses an isolated host cell comprising the nucleic acid or vector. The disclosure also encompasses a method of producing an antibody that specifically binds to TREM2 comprising culturing the host cell under conditions suitable

for the expression of the antibody. In some cases, the method includes recovering the antibody from the host cell. The disclosure also encompasses an antibody produced by the method.

[0031] The present disclosure further includes a method of treating a condition associated with TREM2 loss of function in a subject in need thereof, comprising administering an antibody herein or a pharmaceutical composition herein to the subject. In some embodiments, the disclosure includes a method of reducing levels of sTREM2 in a subject in need thereof, comprising administering an antibody herein or a pharmaceutical composition herein to the subject. In some cases, the condition is, or the subject suffers from, a neuroinflammatory or neurodegenerative disease. In some cases, the neuroinflammatory or neurodegenerative disease is Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Nasu-Hakola disease, Guillain-Barré Syndrome (GBS), lysosomal storage disease, sphingomyelinlipidosis (Neimann-Pick C), mucopolysaccharidosis II/IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, neuro-Behcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, stroke, transverse myelitis, traumatic brain injury, or spinal cord injury. In some cases, the disease is Alzheimer's disease. In some cases, the disease is MS.

[0032] The present disclosure also encompasses an antibody or a pharmaceutical composition herein for use in treating a condition associated with TREM2 loss of function in a subject in need thereof. In some embodiments, the disclosure herein encompasses an antibody or a pharmaceutical composition herein for use in reducing levels of sTREM2 in a subject in need thereof. In some cases, the condition is, or the subject suffers from, a neuroinflammatory or neurodegenerative disease. In some cases, the neuroinflammatory or neurodegenerative disease is Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Nasu-Hakola disease, Guillain-Barré Syndrome (GBS), lysosomal storage disease, sphingomyelinlipidosis (Neimann-Pick C), mucopolysaccharidosis II/IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, neuro-Behcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis,

stroke, transverse myelitis, traumatic brain injury, or spinal cord injury. In some cases, the disease is Alzheimer's disease. In some cases, the disease is MS.

[0033] The present disclosure further includes use of an antibody herein or a pharmaceutical composition herein in the preparation of a medicament for treating a condition associated with TREM2 loss of function in a subject in need thereof. The disclosure herein also includes use of an antibody or a pharmaceutical composition herein in the preparation of a medicament for reducing levels of sTREM2 in a subject in need thereof. In some cases, the condition is, or the subject suffers from, a neuroinflammatory or neurodegenerative disease. In some cases, the neuroinflammatory or neurodegenerative disease is Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Nasu-Hakola disease, Guillain-Barré Syndrome (GBS), lysosomal storage disease, sphingomyelinlipidosis (Neimann-Pick C), mucopolysaccharidosis II/IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, neuro-Behcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, stroke, transverse myelitis, traumatic brain injury, or spinal cord injury. In some cases, the disease is Alzheimer's disease. In some cases, the disease is MS.

[0034] Additional objects and advantages will be set forth in part in the description which follows, and in part will be understood from the description, or may be learned by practice. The objects and advantages will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the claims. For example, in addition to the various embodiments depicted and claimed herein, the disclosed subject matter is also directed to other embodiments having other combinations of the features disclosed and claimed herein. As such, the particular features presented herein, especially presented as aspects or embodiments, can be combined with each other in other manners within the scope of the disclosed subject matter such that the disclosed subject matter includes any suitable combination of the features disclosed herein. The description of specific embodiments of the disclosed subject matter herein is presented

for purposes of illustration and description. It is not intended to be exhaustive or to limit the disclosed subject matter to those embodiments disclosed.

BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Fig. 1 shows a summary of anti-TREM2 clones obtained by hybridoma with different immunization strategies.

[0036] Figs. 2A-B provide various TREM2 stalk peptide sequences and strength of binding to each peptide by three different antibodies. Fig. 2A shows the sequence of peptide fragments within the TREM2 stalk region. The TREM2 residues flanking the TREM2 cleavage site between residues 157 and 158 are shown in boldface. Fig. 2B shows binding data (in nM) for three antibodies to the peptides of Fig. 2A. Binding is shown in shades of gray (with darker shades indicating stronger binding) along with A₆₂₀ absorbance values.

[0037] Figs. 3A-B show light and heavy chain variable region amino acid sequences of anti-TREM2 antibodies. Amino acid differences relative to the 3.10C2 variable region sequences are indicated in black. CDR regions according to Chothia or Kabat are indicated above the sequences, with the Kabat CDR definitions also underlined. Fig. 3A shows light chain variable region sequences for 5 clones. Fig. 3B shows heavy chain variable region sequences for 6 clones.

[0038] Fig. 4 shows an ELISA screen of antibodies with IGHV6-8 clones from a rat repertoire deep sequencing dataset combined with different light chains. Stalk, 149-158, 159-175 and Inhibin in the table refer to the stalk region of TREM2, fragments 149-158 and 159-175 of the stalk and a 30-mer inhibin control peptide, respectively. ELISA signal is shown in shades of gray. CDR H3 sequences of clones in the IMGT definition (length 5) are shown in the column to the left. Clone 3.10C2 was paired only to its own cognate light chain. KV2S11 refers to a light chain with the IGK2S11 germline segment in the germline sequence configuration and a similar VJ junctional sequence as the 3.10C2 antibody group.

[0039] Fig. 5 shows a summary of alanine/glycine mutations impacting binding of anti-TREM2 antibodies. Grey boxes indicate mutations impacting either the off-rate binding or the total binding of different antibodies. The amino acid residue and position in

TREM2 are shown in top rows of the table. The two residues in TREM2 that flank the cleavage site in the protein are highlighted in grey in the same row. Antibody AL2p-31 is a humanized, high-affinity variant of mouse antibody 9F5. Antibody Para.09 has the antibody 3.2H7 light chain.

[0040] Figs. 6A-B show humanized 3.10C2 CDR graft variant sequences. Variable region sequences are aligned to human framework sequences used for humanization. Differences with framework sequences (top sequences) are highlighted in black. CDR regions in the Kabat definition are underlined. “3.10C2” in each figure refers to the rat 3.10C2 variable region sequence. Fig. 6A shows light chain variable region sequences for 3 variants. Fig. 6B shows heavy chain variable region sequences for 4 variants.

[0041] Figs. 7A-B show expression yields of 3.10C2 CDR graft clones. Fig. 7A shows expression yields as measured by titer (mg/L) of humanized IgG variants with different heavy and light chain humanized variants. Clones L9 and L10 are identical to clones L1 and L5 respectively (see Fig. 6A) but with a Q100P mutation in framework 4. Fig. 7B shows expression yields of Fab fragments (mg) with the humanized 3.10C2-H1 heavy chain variants combined to the humanized 3.10C2-L1 variant or rat 3.10C2 light chain.

[0042] Figs. 8A-B show humanized 3.27H7 light chain and Para.09 heavy chain CDR graft variant sequences. Variable region sequences are aligned to human framework sequences used for humanization. Differences with framework sequences (top sequences) are highlighted in black. CDR regions in the Kabat definition are underlined. “3.27H7” and “Para.09” are the rat variable region sequences. Fig. 8A shows light chain variable region sequences of three variants. Fig. 8B shows heavy chain variable region sequences of four variants.

[0043] Figs. 9A-B show sequences of the variable region and CDRs of antibody h3.10C2.v1. Kabat CDR regions are underlined. Fig. 9A shows light chain variable region sequence. Fig. 9B shows heavy chain variable region sequence.

[0044] Fig. 10 shows scanning mutagenesis of antibody 3.10C2. Fig. 10 shows a distribution of dissociation rates of antibody 3.10C2 heavy chain CDR single point mutants at 37°C. The dissociation rate of antibody 3.10C2 determined in the same set of experiments is shown with the dotted line. Two 3.10C2 point mutants with lower

dissociation rates relative to wild-type 3.10C2 are indicated, with the fold-improvement for each one shown in parentheses. Data for 440 mutants shown.

[0045] Fig. 11 shows expression yields (mg/L) after protein A chromatography of rat and humanized variants of Para.09 produced in CHO cells. The isotype of each antibody is indicated.

[0046] Figs. 12A-B show amino acid sequences of the variable regions of antibody hPara.09.v2. Kabat CDR regions are underlined. Fig. 12A shows light chain variable region sequence. Fig. 12B shows heavy chain variable region sequence.

[0047] Figs. 13A and B show sequence and CDR regions of the light chains (Fig. 13A) and heavy chains (Fig. 13B) of hPara.09.v2 and hPara.09.v2 mutants. The Q100P, I58V, and V104L mutations and other mutations in the light chain relative to hPara.09.v2 are highlighted. Kabat CDR regions are underlined.

[0048] Figs. 14A-B show sequence and CDR regions of the variable regions of the light chains (Fig. 14A) and the heavy chains (Fig. 14B) antibody h3.10C2.v1 and h3.10C2.v1 mutants. The Q100P, I58V, and L104V mutations in the light chain are highlighted. Kabat CDR regions are underlined.

[0049] Fig. 15 shows normalized baculovirus (BV) ELISA reactivity of four anti-TREM2 antibodies (parental and humanized): chimeric clones with rat variable regions and human IgG1 constant regions and humanized variants h3.10C2.v1 and hPara.09.v2 with human IgG1 constant regions with a N297G mutation to eliminate Fc receptor binding.

[0050] Fig. 16 shows antibodies that bind and do not bind to soluble TREM2 (sTREM2) *in vitro*. Fig. 16 shows normalized values for sTREM2 binding for tested antibodies:

Control antibody 1.16B8 (CTL), rat Para.09 – LC 3.27H7 mIgG2a LALAPG (Para09), rat 3.10C2 mIgG2a LALAPG (3.10C2), rat 3.18E5 mIgG2a LALAPG (3.18E5), rat 3.50G1 mIgG2a LALAPG (3.50G1), rat 3.27H7 mIgG2a LALAPG (3.27H7), rat 3.36F5 mIgG2a LALAPG (3.36F5), A.9F5 (also called 9F5 herein), AL2p-12, AL2p-31, AL2p-58, BM.3D3, BM.42E8, BM.RS9, BM.14D3, and BM.14D8.

[0051] Fig. 17 shows Jurkat reporter activities of recombinant antibodies in mIgG2a format. Jurkat cells were engineered to express luciferase under the control of NFAT (nuclear factor of activated T cells) and to express human TREM2. Fig. 17 shows 8

antibodies that induced modest to strong luciferase expression in the cells: 3.10C2, 3.18E5, 3.27H7, 3.50G1, 3.17G12, 3.27H5, 3.41B10, and 3.47B1.

[0052] Figs. 18A-B show the effect of increasing concentrations of rat anti-human and humanized anti-TREM2 antibodies expression of luciferase in the Jurkat-NFAT luciferase reporter cells expressing human TREM2. Luciferase signal in the presence of various concentrations of rat anti-human antibodies in mIgG2 LALAPG format (Fig. 18A) and humanized hPara.09.v2 and h3.10C2.v1 antibodies (Fig. 18B) is shown after 24 hours.

[0053] Figs. 19A-C show induction of luciferase expression by rat anti-human 3.10C2, 3.18E5, 3.27H7 and 3.50G1 mIgG2a LALAPG antibodies in a Jurkat-NFAT luciferase reporter cell line expressing hTREM2 mutant R47H (Fig. 19A), R62H (Fig. 19B), or H157Y (Fig. 19C).

[0054] Figs. 20A-B and D show the effect of rat anti-human and humanized antibodies on sTREM2 shedding in the Jurkat-NFAT luciferase reporter cell line expressing hTREM2 after 24 hours, as measured by ELISA. Fig. 20A shows the effect of increasing concentrations of rat 1.20A2 mIgG2a LALAPG, rat Para.09 mIgG2a LALAPG, and rat 3.10C2 mIgG2a LALAPG antibodies on sTREM2 levels. Fig. 20B shows the effect of humanized h3.10C2.v1 and hPara.09.v2 antibodies in human IgG1 N297G format. Figs. 20D shows the effect of humanized antibodies hPara.09 v2, hPara.09.v2 Q100P/V104L, and hPara.09.v2 Q100P. Fig. 20C shows luciferase expression induced by the hPara.09 v2, hPara.09.v2 Q100P/V104L, and hPara.09.v2 Q100P antibodies.

[0055] Fig. 21 shows the effect of antibodies 3.10C2, 3.18E5, 3.27H7, 3.50G1, and 9F5 with murine IgG2 LALAPG on TREM2 shedding in human induced pluripotent stem cell (iPSC)-derived microglia.

[0056] Figs. 22A-C show pan phospho-tyrosine (pY) levels (Fig. 22A) and phospho-SYK (pSYK) levels (Fig. 22B-C) in primary human monocyte derived macrophage (hMDM) cells after incubation with humanized anti-TREM2 antibodies for the stated 10-20 minute time periods (Fig. 22A-B) or dose ranges (Fig. 22C). In Fig. 22B, phosphorylation was also compared to hMDM cells modified to reduce TREM2 expression (gTREM2). Fig. 22C shows the effect of SYK phosphorylation with increasing doses of humanized antibodies hPara.09.v2 N297G or hPara.09.v2

Q100P/V104L N297G, or a control antibody. pSYK levels were measured and normalized to total SYK amounts. $n = 6$ from 3 independent biological specimens. [0057] Figs. 23A-E show that rat anti-human and humanized anti-TREM2 antibodies promote human induced pluripotent stem cell (iPSC) microglia survival. Fig. 23A shows survival of Wild-type (WT, thin line) or TREM2 KO (KO, dotted line) iPSC microglia induced by treatment with increasing doses of hPara.09 v2, h3.10C2.v1, measured as fold of response induced by control antibody (gD hIgG1 N297G) treatment. Error bar +/- SEM. Fig. 23B shows survival of iPSC-MG cells in response to treatment with antibodies at increasing doses (0, 1, 10, 100 ng). Antibodies are grouped according to TREM2 binding (residue spans shown at top of figure). Error bar +/- SEM. Fig. 23C shows pSYK induction by humanized antibodies (hPara09.v2 N297G, hPara09.v2.Q100P/V104L N297G) in the iPSC-MG at 1, 4, and 24 hour time points. Error bar +/- SEM. * $P < 0.05$, ** $P < 0.01$, **** $P < 0.0001$. Fig. 23D shows the effect of increasing concentrations of humanized Para.09.v2 antibody or an anti-gD control antibody on microglia survival in the presence and absence of a SYK inhibitor (SYKi). Error bar +/- SEM. Fig. 23E shows microglia survival and EC_{50} (in nM, shown in table below graph) of the listed anti-TREM2 antibodies as compared to a control anti-gD antibody. Error bar +/- SEM.

[0058] Fig. 24A-C show that humanized anti-TREM2 antibodies increase iPSC-MG amyloid beta plaque formation and compaction. Fig. 24A shows immunofluorescence images of A β plaque-like structure and A β aggregate formation around iPSC microglia treated with hPara.09.Q100P hIgG1 N297G or control gD.hIgG1.N297G. From left to right, panels show: staining for A β , amyloid plaque (Methoxy X04 staining), microglia staining (IBA1 staining), and merged images from all three stains, showing colocation of staining for IBA1 positive microglia, A β , and amyloid plaque. Fig. 24B shows total A β plaque intensity in the presence of increasing concentrations of several humanized anti-TREM2 antibodies or a control anti-gD antibody, all in human IgG1 N297G format. EC_{50} values are provided in nM for each antibody in the table below the graph. Error bar +/- SEM. Fig. 24C shows average X04 iPSC-MG plaque intensity at increasing antibody concentrations of several humanized anti-TREM2 antibodies or a control anti-gD

antibody, all in human IgG1 N297G format. EC₅₀ values are provided in nM for each antibody in the table below the curve.

[0059] Figs. 25A-25C show sTREM2 levels in mice treated with anti-TREM2 or control antibodies. Figs. 25A-B show percent sTREM2 relative to control antibody (gp120) in plasma (Fig. 25A) and brain homogenates (Fig. 25B) samples from mice treated with 3.10C2 and Para.09 antibodies in murine IgG2 LALAPG format. Fig. 25C shows sTREM2 levels (pg/ml) in plasma from mice treated with increasing doses of Para.09 and AL2p58 antibodies in murine IgG2a LALAPG format, as compared to an isotype control.

[0060] Figs. 26A-F show sTREM2 levels over time in CSF, plasma, and brain lysate samples from cynomolgus monkeys dosed with h3.10C2.v1.hIgG1.N297G, hPara.09.v2.hIgG1.N297G or anti-gD.hIgG1.N297G control antibody. Figs. 26A-C show sTREM2 levels measured over 2 days in CSF (Fig. 26A), plasma (Fig. 26B), and brain (Fig. 26C). Figs. 26D-F show sTREM2 levels measured over 28 days in CSF (Fig. 26D), plasma (Fig. 26E), and brain (Fig. 26F).

[0061] Fig. 27 shows brain sections from mice treated with 3.10C2, Para.09, or a control antibody that were stained for the proliferation marker Ki67. Cell proliferation is represented as the average number of Ki67+ cells per number of 4',6-diamidino-2-phenylindole (DAPI)-positive cells.

DESCRIPTION OF EXEMPLARY EMBODIMENTS

Definitions

[0062] As used herein, the term about refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated. The term about generally refers to a range of numerical values (e.g., +/-5-10% of the recited range) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). When terms such as at least and about precede a list of numerical values or ranges, the terms modify all of the values or ranges provided in the list. In some instances, the term about may include numerical values that are rounded to the nearest significant figure.

[0063] Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of

ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0064] In this application, the use of “or” means “and/or” unless stated otherwise. In the context of a multiple dependent claim, the use of “or” refers back to more than one preceding independent or dependent claim in the alternative only. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise.

[0065] Exemplary techniques used in connection with recombinant DNA, oligonucleotide synthesis, tissue culture and transformation (e.g., electroporation, lipofection), enzymatic reactions, and purification techniques are described, e.g., in Sambrook et al. *Molecular Cloning: A Laboratory Manual* (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), among other places.

[0066] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0067] “TREM2” or “Triggering receptor expressed on myeloid cells-2,” as used herein, refers to a human TREM2 protein (“hTREM2”), unless expressly noted otherwise (i.e., murine TREM2, or cynomolgus TREM2, or the like). An exemplary hTREM2 amino acid sequence, including the signal sequence of amino acids 1-18, is shown in SEQ ID NO: 21, while an exemplary sequence without the signal sequence is shown in SEQ ID NO: 22. TREM2 including the signal sequence may also be referred to as the “precursor” or “preprotein” form of the protein, while TREM2 without the signal sequence may be referred to as the “mature” form of the protein. The membrane-bound form of the protein includes a V-type immunoglobulin (Ig) domain (at amino acids 19-128) followed by a TREM2 “stalk” domain (at amino acids 129-174; SEQ ID NO: 90), which collectively form the “extracellular domain” of the protein, followed by a transmembrane domain (residues 175-197), and a cytosolic domain (residues 198-230). A soluble form of the protein, “soluble TREM2” or “sTREM2” herein, may be generated in the body either by cleavage in the stalk domain or by alternative splicing. For example, proteases may cleave the protein between H157 and S158, cleaving of soluble TREM2, comprising the N-terminal portion of the protein up to the H157, e.g., residues 19-157. An exemplary

sTREM2 amino acid sequence is shown in SEQ ID NO: 23. The portion of the protein that may get cleaved off to form sTREM2 is also known as the “ectodomain,” and comprises residues 19-157. In general herein, the term “TREM2” as used herein refers to the membrane-bound form of the protein unless the context explicitly clarifies that both forms of the protein are being referenced. In addition, hTREM2 comprises several isoforms or alleles whose native sequences or splicing may differ from that shown in SEQ ID Nos: 21 and 22 and as described in the Examples section herein. The term TREM2 comprises all of these native forms of TREM2 unless a particular isoform or sequence is referred to.

[0068] “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K_D). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary methods for measuring binding affinity are described in the following.

[0069] The term “antibody” herein refers to a molecule comprising at least complementarity-determining region (CDR) 1, CDR2, and CDR3 of a heavy chain and at least CDR1, CDR2, and CDR3 of a light chain, wherein the molecule is capable of binding to antigen. The term is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies, diabodies, etc.), full length antibodies, single-chain antibodies, antibody conjugates, and antibody fragments, so long as they exhibit the desired TREM2-specific binding activity.

[0070] An “isolated” antibody is one that has been separated from a component of its natural environment. In some aspects, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) methods. For a review of methods for assessment of antibody purity, see, e.g., Flatman et al., *J. Chromatogr. B* 848:79-87 (2007).

[0071] An “antigen” refers to the target of an antibody, i.e., the molecule to which the antibody specifically binds. The term “epitope” denotes the site on an antigen, either proteinaceous or non-proteinaceous, to which an antibody binds. Epitopes on a protein can be formed both from contiguous amino acid stretches (linear epitope) or comprise non-contiguous amino acids (conformational epitope), e.g., coming in spatial proximity due to the folding of the antigen, i.e. by the tertiary folding of a proteinaceous antigen. Linear epitopes are typically still bound by an antibody after exposure of the proteinaceous antigen to denaturing agents, whereas conformational epitopes are typically destroyed upon treatment with denaturing agents. In some cases, a TREM2 “epitope” herein may “span” a site, such as a natural proteinase cleavage site or break point, in the molecule, meaning that there are close contacts between one or more antibody residues and the antigen on either side of the cleavage site, or that the antibody binds to TREM2 peptides that span the site. In such cases, the TREM2 epitope includes residues on each side of the cleavage site or break point.

[0072] In this disclosure, “specifically binds” or “specific binding” and similar terms means that the binding affinity is sufficiently strong that the interaction between the members of the binding pair cannot be due to random molecular associations (i.e. “nonspecific binding”). Specific binding typically requires a dissociation constant (K_D) of 1 μ M or less. Specific binding may often, for example, involve a K_D for TREM2 of 10 nM or less.

[0073] An “anti-TREM2 antibody” or a “TREM2-antibody” or an “antibody that specifically binds TREM2” or an “antibody that binds to TREM2” and similar phrases refer to an antibody that specifically binds to TREM2 as defined herein.

[0074] Certain antibodies herein “do not bind to soluble TREM2.” As used herein, this means that the antibodies, when assayed in an ELISA assay, may not show any more than 10% binding to sTREM2, and in some cases do not show any more than 5% binding to sTREM2, wherein % binding is normalized against that of positive control antibody 1.16B8, whose binding to sTREM2 is set to 100%. The control antibody 1.16B8 light chain sequence is shown in SEQ ID NO: 170, and its heavy chain sequence is shown in SEQ ID NO: 171. In some embodiments, the ELISA assay may be performed as shown in Example 11 below and Fig. 16. In some embodiments, antibody 3.17A9 is used as a

detection agent in the assay. The detection antibody 3.17A9 light chain sequence is shown in SEQ ID NO: 168, and its heavy chain sequence shown in SEQ ID No: 169. Certain antibodies herein “do not bind to FcγR,” or have a heavy chain constant region or Fc region that “does not bind to FcγR,” which means that binding is not detected above trace levels in a suitable *in vitro* binding assay.

[0075] The term “heavy chain” refers to a polypeptide comprising at least a heavy chain variable region, with or without a leader sequence. In some embodiments, a heavy chain comprises at least a portion of a heavy chain constant region. The term “full-length heavy chain” refers to a polypeptide comprising a heavy chain variable region and a heavy chain constant region, with or without a leader sequence.

[0076] The term “light chain” refers to a polypeptide comprising at least a light chain variable region, with or without a leader sequence. In some embodiments, a light chain comprises at least a portion of a light chain constant region. The term “full-length light chain” refers to a polypeptide comprising a light chain variable region and a light chain constant region, with or without a leader sequence.

[0077] The term “hypervariable region” or “HVR” as used herein refers to each of the regions of an antibody variable region which are hypervariable in sequence and which determine antigen binding specificity, for example “complementarity determining regions” (“CDRs”). Generally, antibodies comprise six CDRs: three in the VH (CDR-H1 or heavy chain CDR1, CDR-H2, CDR-H3), and three in the VL (CDR-L1, CDR-L2, CDR-L3). Unless otherwise indicated, the CDRs are determined according to the sequence table herein, and the amino acid positions of regions and domains of the heavy and light chain are numbered according to the Kabat numbering system described in Kabat, et al., *Sequences of Proteins of Immunological Interest*, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). In some cases, both Kabat and Chothia heavy chain CDR1 and CDR2 are provided in the sequence table. In the case of SEQ ID Nos: 1-6 and 9-10, and 11-16 and 19-20, the Kabat and Chothia CDRs differ in the CDR-H1 and CDR-H2 but are the same in the remaining four CDRs. One of skill in the art will understand that the CDR designations can also be determined according to McCallum, or any other scientifically accepted nomenclature system. See,

e.g., Chothia and Lesk, *J. Mol. Biol.* 196:901-917 (1987); Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991); MacCallum et al. *J. Mol. Biol.* 262: 732-745 (1996)).

Antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) constitute MacCallum CDRs.

[0078] “Framework” or “FR” refers to the residues of the variable region residues that are not part of the complementary determining regions (CDRs). The FR of a variable region generally consists of four FRs: FR1, FR2, FR3, and FR4. Accordingly, the CDR and FR sequences generally appear in the following sequence in VH (or VL): FR1-CDR-H1(CDR-L1)-FR2- CDR-H2(CDR-L2)-FR3- CDR-H3(CDR-L3)-FR4.

[0079] The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three complementary determining regions (CDRs). See, e.g., Kindt et al. *Kuby Immunology*, 6th ed., W.H. Freeman and Co., page 91 (2007). A variable domain may comprise heavy chain (HC) CDR1-FR2-CDR2-FR3-CDR3 with or without all or a portion of FR1 and/or FR4; and light chain (LC) CDR1-FR2-CDR2-FR3-CDR3 with or without all or a portion of FR1 and/or FR4. That is, a variable domain may lack a portion of FR1 and/or FR4 so long as it retains antigen-binding activity. A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., *J. Immunol.* 150 :880-887 (1993) ; Clarkson et al., *Nature* 352 :624-628 (1991).

[0080] The light chain and heavy chain “constant regions” of an antibody refer to additional sequence portions outside of the FRs and CDRs and variable regions. Certain antibody fragments may lack all or some of the constant regions. From N- to C-terminus, each heavy chain has a variable domain (VH), also called a variable heavy domain or a heavy chain variable region, followed by three constant heavy domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable domain (VL),

also called a variable light domain or a light chain variable region, followed by a constant light (CL) domain.

[0081] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one aspect, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, antibodies produced by host cells may undergo post-translational cleavage of one or more, particularly one or two, amino acids from the C-terminus of the heavy chain. Therefore, an antibody produced by a host cell by expression of a specific nucleic acid molecule encoding a full-length heavy chain may include the full-length heavy chain, or it may include a cleaved variant of the full-length heavy chain. This may be the case where the final two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, numbering according to EU index). Therefore, the C-terminal lysine (Lys447), or the C-terminal glycine (Gly446) and lysine (Lys447), of the Fc region may or may not be present. Thus, a “full-length IgG1” for example, includes an IgG1 with Gly446 and Lys447, or without Lys447, or without both Gly446 and Lys447. Amino acid sequences of heavy chains including an Fc region are denoted herein without C-terminal glycine-lysine dipeptide if not indicated otherwise. In one aspect, a heavy chain including an Fc region as specified herein, comprised in an antibody according to the invention, may comprise Gly446 and Lys447 (numbering according to EU index). In one aspect, a heavy chain including an Fc region as specified herein, comprised in an antibody according to the invention, may comprise Gly446 (numbering according to EU index). Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0082] “Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC);

phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation. Antibodies with “intact effector function,” for example, comprise a heavy chain constant region or Fc region that possesses the native, intact effector functions of its particular isotype, such as a wild-type heavy chain constant region or Fc region, or one that possesses modification that have not been shown to impact effector functions. In contrast, antibody heavy chain constant regions or Fc regions may be modified in various ways, such as by amino acid substitution, insertion, or deletion, or by glycosylation modifications, to either reduce or enhance effector function, depending upon the use of an antibody. Herein, some antibodies may have “intact effector function,” while others may be “effectorless,” meaning that they do not show detectable CDC or ADCC activity or that they comprise a heavy chain constant region or Fc region that has previously been shown to have no detectable CDC or ADCC activity. In other cases, antibodies may have a mutant Fc region or heavy chain constant region with “reduced effector function” compared to the corresponding wild-type Fc or heavy chain constant region (e.g., that has previously been shown to have reduced effector function, or that has reduced effector function in the context of the antibodies here). Such antibodies with reduced effector function may, for example, show a lower degree of CDC and/or ADCC activity and/or FcγR binding activity compared to the corresponding wild-type Fc region, and/or may retain some effector functions such as binding to particular Fc receptors such as FcRn, but combined with low or no detectable CDC or ADCC or FcγR binding activity, for example.

[0083] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂. In certain aspects, the antibody is of the IgG₁ isotype. In certain aspects, the antibody is of the IgG₁ isotype with the P329G, L234A and L235A mutation to reduce Fc-region effector function. In other aspects, the antibody is of the IgG₂ isotype. In certain aspects, the antibody is of the IgG₄ isotype with the S228P mutation in the hinge region to improve stability of IgG₄ antibody. In some aspects, the antibody may have a non-human IgG constant region, and may be, for example, a murine IgG2a antibody such as a murine IgG2a LALAPG antibody. The

heavy chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

[0084] An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen (i.e. TREM2) to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')₂; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv, and scFab); single domain antibodies (dAbs); and multispecific antibodies formed from antibody fragments. For a review of certain antibody fragments, see Holliger and Hudson, *Nature Biotechnology* 23:1126-1136 (2005).

[0085] The terms “full length antibody”, “intact antibody”, and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or, in the case of an IgG antibody, having heavy chains that contain an Fc region as defined herein.

[0086] The term “chimeric” antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

[0087] A “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs. In certain aspects, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDRs correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[0088] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during

production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

[0089] A “multispecific” antibody is one that binds specifically to more than one target antigen, while a “bispecific” antibody is one that binds specifically to two antigens. An “antibody conjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a therapeutic agent or a label.

[0090] “Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity for the purposes of the alignment. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software or the FASTA program package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Alternatively, the percent identity values can be generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office,

Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087 and is described in WO 2001/007611.

[0091] Unless otherwise indicated, for purposes herein, percent amino acid sequence identity values are generated using the ggsearch program of the FASTA package version 36.3.8c or later with a BLOSUM50 comparison matrix. The FASTA program package was authored by W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448; W. R. Pearson (1996) "Effective protein sequence comparison" Meth. Enzymol. 266:227- 258; and Pearson et. Al. (1997) Genomics 46:24-36 and is publicly available from www.fasta.bioch.virginia.edu/fasta_www2/fasta_down.shtml or www.Ebi.ac.uk/Tools/sss/fasta. Alternatively, a public server accessible at fasta.bioch.virginia.edu/fasta_www2/index.cgi can be used to compare the sequences, using the ggsearch (global protein:protein) program and default options (BLOSUM50; open: -10; ext: -2; Ktup = 2) to ensure a global, rather than local, alignment is performed. Percent amino acid identity is given in the output alignment header.

[0092] The term "nucleic acid molecule" or "polynucleotide" includes any compound and/or substance that comprises a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine- or pyrimidine base (i.e. cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e. deoxyribose or ribose), and a phosphate group. Often, the nucleic acid molecule is described by the sequence of bases, whereby said bases represent the primary structure (linear structure) of a nucleic acid molecule. The sequence of bases is typically represented from 5' to 3'. Herein, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA) including e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), in particular messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules. The nucleic acid molecule may be linear or circular. In addition, the term nucleic acid molecule includes both sense and antisense strands, as well as single stranded and double stranded forms. Moreover, the herein described nucleic acid molecule can contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derivatized sugars or phosphate backbone linkages or chemically

modified residues. Nucleic acid molecules also encompass DNA and RNA molecules which are suitable as a vector for direct expression of an antibody of the invention *in vitro* and/or *in vivo*, e.g., in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors, can be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and/or expression of the encoded molecule so that mRNA can be injected into a subject to generate the antibody *in vivo* (see e.g., Stadler et al, Nature Medicine 2017, published online 12 June 2017, doi:10.1038/nm.4356 or EP 2 101 823 B1).

[0093] An “isolated” nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0094] “Isolated nucleic acid encoding an anti-TREM2 antibody” refers to one or more nucleic acid molecules encoding anti-TREM2 antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

[0095] The term “vector”, as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors”.

[0096] The terms “host cell”, “host cell line”, and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.

[0097] The term “signal sequence” or “leader sequence” refers to a sequence of amino acid residues located at the N terminus of a polypeptide that facilitates secretion of a polypeptide from a mammalian cell. A leader sequence may be cleaved upon export of the polypeptide from the mammalian cell, forming a mature protein. Leader sequences may be natural or synthetic, and they may be heterologous or homologous to the protein

to which they are attached. Nonlimiting exemplary leader sequences also include leader sequences from heterologous proteins. In some embodiments, an antibody lacks a leader sequence. In some embodiments, an antibody comprises at least one leader sequence, which may be selected from native antibody leader sequences and heterologous leader sequences.

[0098] The term “shedding” as used herein refers to the process of creating a soluble TREM2 from a membrane-bound TREM2 by proteolytic cleavage of the stalk region of the protein. *In vivo*, “shedding” may occur at the cell surface, for example, due to cleavage of TREM2 on the cell membrane by a metalloproteinase or other enzyme. In some cases, cleavage occurs between H157 and S158 of the protein, forming sTREM2 from the ectodomain residues 19-157.

[0099] The term “agonist” as used herein refers to a substance, such as an antibody, that causes an increase in at least one activity or function of a molecule to which it binds, or otherwise activates or helps to activate the molecule. The term “antagonist” as used herein refers to a substance, such as an antibody, that causes a decrease in at least one activity or function of a molecule to which it binds, or that otherwise blocks or inhibits at least one activity or function of the molecule.

[00100] An “agonist anti-TREM2 antibody” or similar phrases herein, for example, refers to an antibody that induces luciferase reporter activity in Jurkat-NFAT reporter cells expressing human TREM2 and/or that induces SYK phosphorylation (p-SYK) in Jurkat-NFAT reporter cells expressing human TREM2, in human monocyte-derived macrophage (MDM) cells and/or in human induced pluripotent stem cell (iPSC)-derived microglia cells. Agonist anti-TREM2 antibodies may also have further activities, as described herein, such as enhancing survival of human iPSC-derived microglia in the absence of IL-34 and CSF-1, and activating TREM2 signaling in human macrophages and microglia, among other activities, for example.

[00101] The terms “subject” and “patient” are used interchangeably herein to refer to a human. In some embodiments, methods of treating other mammals, including, but not limited to, rodents, simians, felines, canines, equines, bovines, porcines, ovines, caprines, mammalian laboratory animals, mammalian farm animals, mammalian sport animals, and mammalian pets, are also provided.

[00102] “Treatment,” as used herein, covers any administration or application of a therapeutic for disease in a human, or other mammal, and includes inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting or slowing its development, inhibiting, reducing, or slowing development of at least one symptom of the disease, slowing the time to onset of the disease, preventing onset of at least one disease symptom, slowing the time to onset of at least one disease symptom, partially or fully relieving the disease, or curing the disease, for example, by causing regression, or restoring or repairing a lost, missing, or defective function; or stimulating an inefficient process. The terms “inhibition” or “inhibit” refer to a decrease or cessation of any symptom or phenotypic characteristic or to the decrease or cessation in the incidence, degree, or likelihood of that symptom or characteristic.

[00103] A “pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid, or liquid filler, diluent, encapsulating material, formulation auxiliary, or carrier conventional in the art for use with a therapeutic agent that together comprise a “pharmaceutical composition” for administration to a subject. A pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. The pharmaceutically acceptable carrier is appropriate for the formulation employed. For example, if the therapeutic agent is to be administered orally, the carrier may be a gel capsule. If the therapeutic agent is to be administered subcutaneously, the carrier ideally is not irritable to the skin and does not cause injection site reaction.

[00104] The term “effective amount” herein refers to an amount that is sufficient to result in a desired outcome, such as treatment, inhibition, or reduction as described above.

Development of Unique Anti-TREM2 Antibodies

[00105] The disclosure herein encompasses anti-TREM2 antibodies. In some embodiments herein, the antibodies have a unique set of properties. For example, certain antibodies herein (a) bind specifically to the TREM2 stalk domain at an epitope spanning the cleavage site between residues 157 and 158, and also bind specifically to a polypeptide consisting of residues 151-165 of TREM2, (b) do not bind to soluble TREM2, and thus, may not present a significant risk of soluble TREM2 binding *in vivo*,

(c) act as TREM2 agonists, and (d) specifically bind to TREM2 with dissociation constants of, for example, 100-500 pM, 10-50pM, or 1-10 pM.

[00106] As described in the Examples section below, particular exemplary antibodies herein were obtained in part following an initial screen of rat anti-human TREM2 antibodies. A particular set of rat anti-human TREM2 antibodies that specifically bind to a binding epitope in the region of amino acids 151-165 of TREM2 were found to have both relatively high affinity and a lack of binding to soluble TREM2, unlike other antibodies found in the screen and unlike other previously described anti-TREM2 antibodies. This set of antibodies includes rat anti-human antibodies 3.10C2, 3.50G1, 3.18E5, 3.27H7 (also called the “3.10C2 group antibodies”) and 3.36F5. (See Figs. 3A-3B, and also Figs. 2A-2B and 16.)

[00107] Further TREM2-immunized rat immune repertoire deep sequencing experiments were conducted on the heavy chain variable region to obtain antibodies with yet higher affinity for TREM2. This experiment led to the identification of the Para.09 heavy chain variable region, which is clonally unrelated to the 3.10C2 group antibodies and differs in the heavy chain CDR3 compared to the previously identified antibodies of the 3.10C2 group. (See Figs. 4 and 8B.) The Para.09 heavy chain variable region was combined with light chain variable regions from the previously identified 3.10C2 group antibodies. The affinity of the resulting Fab fragments for human and cynomolgus TREM2 was on the order of 1-5 pM (i.e. $1-5 \times 10^{-12}$ M). (See Table 1 and Example 5.)

[00108] The rat anti-human antibodies were then humanized. Antibodies h3.10C2.v1 and hPara.09.v2 are examples of humanized antibodies herein. (See Figs. 9A-B and 12A-B.) Further modifications of the light chain framework regions of the humanized antibodies were then conducted, for example, to improve properties such as expression yield. Particular modifications at positions 58, 100, and/or 104, for example, of the light chain framework regions (e.g., I58V, Q100P, and/or V104L, (as used herein, the nomenclature convention is “amino acid-position- new amino acid,” i.e., I58V denotes amino acid I at position 58 is changed to amino acid V)) resulted in humanized antibodies that not only retain the features of the starting rat anti-human antibodies, such as high affinity for the TREM2 stalk domain, but that also express in relatively high yield. Such exemplary antibodies are shown in Figs. 13A-B and 14A-B. As further

described in Examples 11 and 13-17 below, for instance, antibodies herein are TREM2 agonists and also display a number of other beneficial biological properties *in vitro* and *in vivo*.

Exemplary Anti-TREM2 Antibody Sequences

[00109] In some embodiments, the disclosure encompasses an isolated antibody that specifically binds to TREM2, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 11, 19, or 62 and a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 10, 12, 20, 55, 63, 65, or 73. In some embodiments, the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, 27, 37, 47, 57, or 67; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, 29, 39, 49, 59, or 69. In some embodiments, the VH comprises a CDR-H3 comprising the amino acid sequence as follows: X_1 - X_2 - X_3 -Y, wherein X_1 and X_2 together are either I-L or L, and wherein X_3 is either D or E. In some embodiments, the antibody comprises a VH derived from rat IGHV6-8 germline segments. In some embodiments, the antibody comprises a VL derived from rat IGKV2S11 germline segments. In some embodiments, the antibody comprises a VH derived from rat IGHV6-8 and a VL derived from rat IGKV2S11.

[00110] In some embodiments, the disclosure encompasses an isolated antibody that specifically binds to TREM2, wherein the antibody comprises a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 11, 19, or 62; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 10, 12, 20, 55, 63, 65, or 73; and a CDR-H3 comprising the amino acid sequence as follows: X_1 - X_2 - X_3 -Y, wherein X_1 and X_2 together are either I-L or L, and wherein X_3 is either D or E; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, 27, 37, 47, 57, or 67; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, 29, 39, 49, 59, or 69. For example, such antibodies are shown in Fig 3A-3B. Examples include antibodies comprising the heavy chain Kabat CDRs of 3.10C2, 3.50G1, 3.18E5, 3.36F5, and 3.27H7, as well as Para.09. In some cases, the antibody

comprises a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 11, or 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 10, 12, or 20; and a CDR-H3 comprising the amino acid sequence as follows: $X_1-X_2-X_3-Y$, wherein X_1 and X_2 together are either I-L or L, and wherein X_3 is either D or E; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[00111] In some cases, the light chain variable region (VL) comprises the light chain CDRs of either 3.10C2 or 3.27H7. For example, the antibody light chain variable region may comprise a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, 27, or 67; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, 29, or 69. In some cases, the antibody comprises the light chain CDRs of 3.27H7, i.e., a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[00112] In some cases, the heavy chain variable region (VH) comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 or 9; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2 or 10; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and wherein the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In other cases, the heavy chain variable region (VH) comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11 or 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12 or 20; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; and wherein the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[00113] In some embodiments, an antibody herein may comprise a heavy chain variable region amino acid sequence that is at least 90%, 95%, 97%, or 99% identical to

that of a sequence shown in Fig. 3B. In some embodiments, an antibody herein may comprise a heavy chain variable region amino acid sequence that is at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 6B. In some embodiments, an antibody herein may comprise a heavy chain variable region amino acid sequence that is at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 8B. In some embodiments, an antibody herein may comprise a heavy chain variable region amino acid sequence that is at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 9B. In some embodiments, an antibody herein may comprise a heavy chain variable region amino acid sequence that is at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 12B. In some embodiments, an antibody herein may comprise a heavy chain variable region amino acid sequence that is at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 13B. In some embodiments, an antibody herein may comprise a heavy chain variable region amino acid sequence that is at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 14B. In some embodiments, the antibody framework regions may be chimeric or humanized.

[00114] In some cases, the antibody comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7 or 17. In some embodiments, the antibody comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7, 17, 30, 40, 50, 60, 70, 76, 77, 78, 81, 82, 83, 133, 135, 137, 139, 146, 148, 150, or 152. In some embodiments, the antibody comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7, 17, 133, 135, 137, 139, 146, 148, 150, or 152. In other cases, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7, 17, 30, 40, 50, 60, 70, 76, 77, 78, 81, 82, 83, 133, 135, 137, 139, 146, 148, 150, or 152. In some embodiments, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7, 17, 133, 135, 137, 139, 146, 148, 150, or 152.

[00115] In some embodiments, the antibody light chain variable region comprises an amino acid sequence at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 3A. In some embodiments, the antibody light chain variable region

comprises an amino acid sequence at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 6A. In some embodiments, the antibody light chain variable region comprises an amino acid sequence at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 8A. In some embodiments, the antibody light chain variable region comprises an amino acid sequence at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 9A. In some embodiments, the antibody light chain variable region comprises an amino acid sequence at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 12A. In some embodiments, the antibody light chain variable region comprises an amino acid sequence at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 13A. In some embodiments, the antibody light chain variable region comprises an amino acid sequence at least 90%, 95%, 97%, or 99% identical to that of a sequence shown in Fig. 14A. In some embodiments, the light chain variable region frameworks are humanized or chimeric.

[00116] In some embodiments, the antibody comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8 or 18. In some embodiments, the antibody comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8, 18, 31, 41, 51, 61, 71, 79, 80, 84, 85, 132, 134, 136, 138, 145, 147, 149, or 151. In some embodiments, the antibody comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8, 18, 132, 134, 136, 138, 145, 147, 149, or 151. In some embodiments, the antibody comprises a VL comprising amino acid sequence of SEQ ID NO: 8 or 18. In some embodiments, the antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 8, 18, 31, 41, 51, 61, 71, 79, 80, 84, 85, 132, 134, 136, 138, 145, 147, 149, or 151. In some embodiments, the antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 8, 18, 132, 134, 136, 138, 145, 147, 149, or 151.

[00117] In some embodiments, the antibody comprises the heavy chain CDRs of antibody 3.10C2, 3.50G1, 3.18E5, 3.36F5, 3.27H7 or Para.09 and the light chain CDRs of antibody 3.27H7. In some embodiments, the antibody comprises the heavy chain

CDRs of antibody 3.10C2 or Para.09 and the light chain CDRs of antibody 3.27H7. (See Figs. 3A-B.) In some embodiments, the antibody is humanized or chimeric.

[00118] In some embodiments, the antibody comprises one of the following sets of CDRs:

- (a) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6;
- (b) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6;
- (c) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16;
- (d) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14, a CDR-L2 comprising

the amino acid sequence of SEQ ID NO: 15, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16;

(e) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 24, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 25, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 27, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 29;

(f) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 34, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 35, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 36; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 37, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 38, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 39;

(g) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 48, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 49;

(h) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 54, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 55, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 56; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 57, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 59; or

(i) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 64, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 65, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 66; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 67, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 69. CDRs (a) through (i) are also referred to in the subsequent four paragraphs.

[00119] In some embodiments, the antibody:

- (a) comprises the CDRs of (a) or (b) from the paragraph above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7;
- (c) comprises the CDRs of (c) or (d) from the paragraph above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 17;
- (e) comprises the CDRs of (e) from the paragraph above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 30;
- (f) comprises the CDRs of (f) from the paragraph above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 40;
- (g) comprises the CDRs of (g) from the paragraph above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 50;
- (h) comprises the CDRs of (h) from the paragraph above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 60; or
- (i) comprises the CDRs of (i) from the paragraph above and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 70

[00120] In some embodiments, the antibody:

- (a) comprises the CDRs of (a) or (b) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8;
- (c) comprises the CDRs of (c) or (d) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 18;
- (e) comprises the CDRs of (e) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 31;
- (f) comprises the CDRs of (f) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 41;
- (g) comprises the CDRs of (g) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 51;
- (h) comprises the CDRs of (h) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 61; or
- (i) comprises the CDRs of (i) above and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 71.

[00121] In some cases, the antibody:

- (a) comprises the CDRs of (a) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 7;
- (b) comprises the CDRs of (b) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 7;
- (c) comprises the CDRs of (c) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 17;
- (d) comprises the CDRs of (d) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 17;

- (e) comprises the CDRs of (e) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 30;
- (f) comprises the CDRs of (f) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 40;
- (g) comprises the CDRs of (g) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 50;
- (h) comprises the CDRs of (h) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 60; or
- (i) comprises the CDRs of (i) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 70

[00122] In some cases, the antibody:

- (a) comprises the CDRs of (a) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 8;
- (b) comprises the CDRs of (b) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 8;
- (c) comprises the CDRs of (c) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18;
- (d) comprises the CDRs of (d) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18;
- (e) comprises the CDRs of (e) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 31;
- (f) comprises the CDRs of (f) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 41;
- (g) comprises the CDRs of (g) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 51;
- (h) comprises the CDRs of (h) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 61; or
- (i) comprises the CDRs of (i) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 71.

[00123] As noted above, in some embodiments, the VH and/or VL are humanized. In some embodiments, the antibody comprises a light chain and heavy chain as shown in

Fig. 6A-B, for example, e.g. combining 3.10C2L1 with 3.10C2H1, H3 or H5, or combining 3.10C2L5 with 3.10C2H1, H3, or H5. In some embodiments, the antibody comprises a light chain and heavy chain as shown in Figs. 8A-B, for example, e.g. combining 3.27H7L1 with Para.09H1, H5, or H7, or combining 3.27H7L6 with Para.09H1, H5, or H7. In some embodiments, the antibody comprises a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 or 11; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2 or 12; and a CDR-H3 comprising the amino acid sequence as follows: $X_1-X_2-X_3-Y$, wherein X_1 and X_2 together are either I-L or L, and wherein X_3 is either D or E; and further comprises VH framework regions that are at least 90%, at least 95%, at least 97%, or at least 99% identical to those of human IGHV-73*01 (SEQ ID NO: 74). (See Figs. 6B and 8B.) In some embodiments, the antibody comprises a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, 14 or 27; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, 15, or 28; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, 16, or 29; and further comprising VL framework regions that are at least 90%, at least 95%, at least 97%, or at least 99% identical to those of human IGKV-28*01 (SEQ ID NO: 75). (See Figs. 6A and 8A.) In some embodiments, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 76, 77, or 78. In some embodiments, the antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 79 or 80. In some embodiments, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 76, 77, or 78 and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 79 or 80. (See Figs. 6A-B.) In some embodiments, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 81, 82, or 83. In some embodiments, the antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 84 or 85. In some embodiments, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 81, 82, or 83 and comprises a VL comprising the amino acid sequence of SEQ ID NO: 84 or 85. (See Figs. 8A-B.)

[00124] In some embodiments as described above, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 8. (See Figs. 9A-B; i.e., h3.10C2.v1.) In some

embodiments as described above, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 18. (See Figs. 10A-B; i.e., hPara.09.v2.) In any of the embodiments above, the antibody may be humanized or chimeric (i.e., having humanized or chimeric framework regions).

[00125] In some embodiments, the framework regions of the antibodies are further modified after humanization, for example, to improve properties such as expression yield. In some embodiments, the antibody comprises a light chain according to SEQ ID NO: 18, but with a substitution at one to five residues in the framework regions. In some embodiments, the antibody comprises a light chain according to SEQ ID NO: 18, but with a substitution at one or more of I58, Q100, and V104, such as I58V, Q100P, and/or V104L in the framework regions. In some embodiments, the antibody comprises a light chain according to SEQ ID NO: 18, but with a Q100P substitution, both an I58V and Q100P substitution, or both a Q100P and V104L substitution. (See, e.g., Figs. 13A and 14A.) In some such embodiments, the antibody comprises one of the following sets of VH and VL: (a) SEQ ID Nos: 133 and 132 (antibody hPara.09.v2 Q100P); (b) SEQ ID Nos: 135 and 134 (antibody hPara.09.v2 I58V/Q100P); (c) SEQ ID Nos: 137 and 136 (antibody hPara.09.v2 Q100P/V104L); (d) SEQ ID Nos: 146 and 145 (antibody h3.10C2.v1 Q100P); (e) SEQ ID Nos: 148 and 147 (antibody h3.10C2.v1 I58V/Q100P); or (f) SEQ ID Nos: 150 and 149 (antibody h3.10C2.v1 Q100P/V104L). In other embodiments, the antibody comprises the VH and VL of SEQ ID Nos: 139 and 138 (h3.10C2.H1-3.10C2.L10). In yet other embodiments, the antibody comprises the VH and VL of SEQ ID NO: 152 and 151 (hPara.09.H5-3.10C2.L10).

[00126] In some embodiments, the antibody comprises a VL comprising from 1 to 10 amino acid substitutions in the framework region compared to human IGKV2-28*01 germline (see Fig. 8A, showing the Kabat/Chothia framework and CDR regions of IGKV2-28*01). In some cases, the antibody comprises a VL comprising from 1 to 5 amino acid substitutions in the framework region compared to human IGKV2-28*01. In some embodiments, these amino acid substitutions comprise Q100P or V104L or both Q100P and V104L. In some such cases, the VL comprises a Val at position 58, while in

other cases, the VL comprises an Ile at position 58 (e.g., Q100P and 58V or Q100P and V58I in comparison to IGKV2-28*01).

[00127] In any of the embodiments herein, the antibody may be an antibody fragment, such as an Fv, single-chain Fv (scFv), Fab, Fab', or (Fab')₂. In other embodiments, the antibody may be a whole antibody (i.e., comprising heavy and light chain constant regions.) In other embodiments, the antibody may be an IgG, IgA, or IgM antibody. In some embodiments, the antibody may have a wild-type human IgG1 Fc region or a wild-type human IgG4 Fc region, a human IgG4 S228P Fc region, a human IgG4 S228P/M252Y/S254T/T256E Fc region, a human IgG1 N297G Fc region, a human IgG1 LALAPG (L234A/L235A/P329G) Fc region, or a human IgG1 N297G/M428L/N434S Fc region. If a murine IgG antibody, the antibody may be an mIgG1 or mIgG2 or mIgG2 LALAPG antibody. An antibody may, in some cases, comprise a full-length heavy chain and/or a full-length light chain. In some cases, the antibody may lack the C-terminal Lys or the C-terminal Lys and Gly residues of the heavy chain constant region. In other cases, the antibody contains one or both of those C-terminal residues.

[00128] In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody comprises a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 and a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 but lacking the C-terminal lysine of SEQ ID NO: 144 or lacking the C-terminal glycine and lysine of SEQ ID NO: 144 and a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at

least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 144 and a light chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144, optionally without the C-terminal lysine or glycine-lysine, and a light chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 144 and a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 144 and a light chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144, optionally without the C-terminal lysine or glycine-lysine, and a light chain comprising an amino acid sequence with 1, 2, 3, 4, or 5

amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 144 and a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In any of the above cases allowing for sequence variation in SEQ ID NO: 144 and/or SEQ ID NO: 176, in some embodiments such sequence variation is limited to the antibody framework and/or constant regions, such that the antibody also comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 or alternatively 19, 20, and 13, and/or light chain CDRs of SEQ ID NOS: 14, 15, and 16. In other embodiments, such sequence variation in SEQ ID NO: 144 and/or SEQ ID NO: 176 is limited to the antibody constant regions, such that the antibody also comprises SEQ ID NO: 17 and/or 18.

[00129] In some cases, the antibody may be bispecific or multispecific. In some cases, the antibody may be conjugated to another molecule, such as a label or drug either directly or through a linker.

[00130] In some cases, the antibody has intact effector function. In some cases, the antibody has an Fc region with reduced effector function. In other cases, the antibody has an Fc region that is effectorless. For example, the Fc region of antibody therapeutics can bind to complement component C1q and Fc-gamma receptors (FcγR) to elicit cellular effector responses such as phagocytosis, cytokine release, and production of reactive oxygen species. (See, e.g., X. Wang, et al., *Protein & Cell* 9: 63-73 (2018); S.B. Mkaddem et al., *Frontiers in Immunology*, available at <https://doi.org/10.3389/fimmu.2019.00811> (2019).) Hyperactivation of these pathways may be detrimental in the CNS, particularly in the context of pathology. (D.J. DiSabato et al., *J. Neurochemistry* 139(S2): 136-153 (2016).) Clinically, antibody therapeutics directed against amyloid beta that have intact effector function and bind to amyloid beta aggregates greatly increase incidence of a potentially harmful side-effect, ARIA (amyloid-related imaging abnormalities), whereas ARIA has not been observed from antibodies that bind only to monomeric forms of amyloid beta or antibodies that have reduced effector function. (M. Filippi et al., *JAMA Neurol.* 79(3): 291-304 (2022).) In some embodiments, for instance as described in the Examples and figures herein,

antibodies herein with reduced effector function (such comprising a human IgG1 heavy chain constant region with either a LALAPG or an N297G mutation, as described above) were sufficient to elicit microglial responses in the CNS via TREM2 stimulation.

Exemplary Antibody Variants, Fragments, and Constant Regions

[00131] In a further aspect, an antibody specifically binding to TREM2 herein may incorporate any of the features, singly or in combination, as described in the sections below.

Antibody Fragments

[00132] In certain embodiments, an antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')₂, Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, *see* Hudson et al. *Nat. Med.* 9:129-134 (2003). For a review of scFv fragments, *see, e.g.*, Pluckthün, in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); *see also* WO 93/16185; and U.S. Patent Nos. 5,571,894 and 5,874,458. For discussion of Fab and F(ab')₂ fragments comprising salvage receptor binding epitope residues and having increased *in vivo* half-life, *see* U.S. Patent No. 5,869,046.

[00133] Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. *See, for example*, EP 404,097; WO 1993/01161; Hudson et al., *Nat. Med.* 9:129-134 (2003); and Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., *Nat. Med.* 9:129-134 (2003).

[00134] Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; *see, e.g.*, U.S. Patent No. 6,248,516).

[00135] Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (*e.g. E. coli* or phage), as described herein.

Chimeric and Humanized Antibodies

[00136] In certain embodiments, an antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, *e.g.*, in U.S. Patent No. 4,816,567; and Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1984)). In one example, a chimeric antibody comprises a non-human variable region (*e.g.*, a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[00137] In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, *e.g.*, CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (*e.g.*, the antibody from which the HVR residues are derived), *e.g.*, to restore or improve antibody specificity or affinity.

[00138] Humanized antibodies and methods of making them are reviewed, *e.g.*, in Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008), and are further described, *e.g.*, in Riechmann et al., *Nature* 332:323-329 (1988); Queen et al., *Proc. Nat'l Acad. Sci. USA* 86:10029-10033 (1989); US Patent Nos. 5, 821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri *et al.*, *Methods* 36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan, *Mol. Immunol.* 28:489-498 (1991) (describing “resurfacing”); Dall’Acqua et al., *Methods* 36:43-60 (2005) (describing “FR shuffling”); and Osbourn et al., *Methods* 36:61-68 (2005) and Klimka et al., *Br. J. Cancer*, 83:252-260 (2000) (describing the “guided selection” approach to FR shuffling).

[00139] Human framework regions that may be used for humanization include but are not limited to framework regions selected using the “best-fit” method (*see, e.g.*, Sims et al. *J. Immunol.* 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable

regions (*see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA*, 89:4285 (1992); and Presta et al. *J. Immunol.*, 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (*see, e.g., Almagro and Fransson, Front. Biosci.* 13:1619-1633 (2008)); and framework regions derived from screening FR libraries (*see, e.g., Baca et al., J. Biol. Chem.* 272:10678-10684 (1997) and Rosok et al., *J. Biol. Chem.* 271:22611-22618 (1996)).

[00140] In some embodiments, the humanized antibodies may comprise a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant region.

Bispecific or Multispecific Antibodies

[00141] In certain embodiments, an antibody provided herein is a multispecific antibody, for example, a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is TREM2 and the other is for any other antigen. In certain embodiments, bispecific antibodies may bind to two different epitopes of TREM2. Bispecific antibodies may also be used to localize drugs such as cytotoxic agents or to localize detection labels to cells that express TREM2. In some embodiments, the multispecific antibody (*e.g., bispecific antibody*) comprises a first variable domain comprising the CDRs or variable regions as described herein. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.

[00142] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (*see Milstein and Cuello, Nature* 305: 537 (1983)), WO 93/08829, and Traunecker et al., *EMBO J.* 10: 3655 (1991)), and “knob-in-hole” engineering (*see, e.g., U.S. Patent No. 5,731,168*). Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (*see, e.g., US Patent No. 4,676,980*, and Brennan et al., *Science*, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (*see, e.g., Kostelny et al., J. Immunol.*, 152:1547-1553 (1992)); using “diabody” technology for making bispecific antibody fragments (*see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (*see, e.g. Gruber et al., J. Immunol.*, 152:5368

(1994)); and preparing trispecific antibodies as described, *e.g.*, in Tutt et al. *J. Immunol.* 147: 60 (1991).

[00143] Engineered antibodies with three or more functional antigen binding sites, including “Octopus antibodies,” are also included herein (*see, e.g.* US 2006/0025576).

Further Antibody Variants

[00144] In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, *e.g.*, antigen-binding. Specific examples of humanized variants that were generated are described, for example, in Figs. 6A-B, 8A-B, 9A-B and 12A-B herein.

Substitution, Insertion, and Deletion Variants

[00145] In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Conservative substitutions are shown in Table A under the heading of “preferred substitutions.” More substantial changes are provided in Table A under the heading of “exemplary substitutions,” and as further described below in reference to amino acid side chain classes. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, *e.g.*, retained/improved antigen binding, decreased immunogenicity, or increased or reduced ADCC or CDC activity.

TABLE A

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	Val; Leu; Ile	Val

Original Residue	Exemplary Substitutions	Preferred Substitutions
Arg (R)	Lys; Gln; Asn	Lys
Asn (N)	Gln; His; Asp; Lys; Arg	Gln
Asp (D)	Glu; Asn	Glu
Cys (C)	Ser; Ala	Ser
Gln (Q)	Asn; Glu	Asn
Glu (E)	Asp; Gln	Asp
Gly (G)	Ala	Ala
His (H)	Asn; Gln; Lys; Arg	Arg
Ile (I)	Leu; Val; Met; Ala; Phe; Norleucine	Leu
Leu (L)	Norleucine; Ile; Val; Met; Ala; Phe	Ile
Lys (K)	Arg; Gln; Asn	Arg
Met (M)	Leu; Phe; Ile	Leu
Phe (F)	Trp; Leu; Val; Ile; Ala; Tyr	Tyr
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Val; Ser	Ser
Trp (W)	Tyr; Phe	Tyr
Tyr (Y)	Trp; Phe; Thr; Ser	Phe
Val (V)	Ile; Leu; Met; Phe; Ala; Norleucine	Leu

[00146] Amino acids may be grouped according to common side-chain properties:

- (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
- (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- (3) acidic: Asp, Glu;
- (4) basic: His, Lys, Arg;
- (5) residues that influence chain orientation: Gly, Pro;
- (6) aromatic: Trp, Tyr, Phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

[00147] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (*e.g.* a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (*e.g.*, improvements) in certain biological properties (*e.g.*, increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, *e.g.*, using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (*e.g.* binding affinity).

[00148] Alterations (*e.g.*, substitutions) may be made in HVRs, *e.g.*, to improve antibody affinity. Such alterations may be made in HVR “hotspots,” *i.e.*, residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (*see, e.g.*, Chowdhury, *Methods Mol. Biol.* 207:179-196 (2008)), and/or residues that contact antigen, with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, *e.g.*, in Hoogenboom et al. in *Methods in Molecular Biology* 178:1-37 (O’Brien et al., ed., Human Press, Totowa, NJ, (2001).) In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (*e.g.*, error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (*e.g.*, 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, *e.g.*, using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.

[00149] In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (*e.g.*, conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may, for example, be outside of antigen

contacting residues in the HVRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.

[00150] A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) *Science*, 244:1081-1085. In this method, a residue or group of target residues (*e.g.*, charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced by a neutral or negatively charged amino acid (*e.g.*, alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.

[00151] Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (*e.g.*, for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

Glycosylation variants

[00152] Alterations in glycosylation of an Fc region, as well as certain Fc region mutations, can impact the effector function of an antibody, by enhancing or reducing effector function, or in some cases may render an antibody effectorless.

[00153] In certain embodiments, an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.

[00154] Where the antibody comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. *See, e.g., Wright et al. TIBTECH 15:26-32 (1997).* The oligosaccharide may include various carbohydrates, *e.g.,* mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.

[00155] In one aspect, antibodies may be modified to reduce or eliminate glycosylation at Asn297, such as by mutating that residue to a glycine or another amino acid (N297G). In other cases, other residues in an Fc region may be modified to reduce ADCC activity and/or CDC activity or to reduce or modify Fc-gamma receptor binding.

[00156] In another embodiment, antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example. Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ± 3 amino acids upstream or downstream of position 297, *i.e.,* between positions 294 and 300 (EU numbering), due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. *See, e.g.,* US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to “defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778;

WO2005/053742; WO2002/031140; Okazaki et al. *J. Mol. Biol.* 336:1239-1249 (2004); Yamane-Ohnuki et al. *Biotech. Bioeng.* 87: 614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. *Arch. Biochem. Biophys.* 249:533-545 (1986); US Pat Appl No US 2003/0157108, Presta, L; and WO 2004/056312 A1, Adams *et al.*, especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, *FUT8*, knockout CHO cells (*see, e.g.*, Yamane-Ohnuki et al. *Biotech. Bioeng.* 87: 614 (2004); Kanda, Y. et al., *Biotechnol. Bioeng.*, 94(4):680-688 (2006); and WO2003/085107). In some embodiments, antibodies may have a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant region, for example, comprising a mutation at Asn297 (EU numbering) to decrease fucosylation or alternatively, to eliminate glycosylation. In some embodiments, antibodies may have an Asn297Ala or Asn297Gly mutation.

[00157] Antibody variants are further provided with bisected oligosaccharides, *e.g.*, in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, *e.g.*, in WO 2003/011878 (Jean-Mairet et al.); US Patent No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana *et al.*). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, *e.g.*, in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).

Fc region variants

[00158] In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (*e.g.*, a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (*e.g.*, a substitution) at one or more amino acid positions.

[00159] In certain embodiments, the invention contemplates an antibody variant that possesses some but not all effector functions (i.e. to produce an antibody with reduced effector function or to produce an effectorless antibody), which may make it a desirable candidate for applications in which the half-life of the antibody *in vivo* is

important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious. *In vitro* and/or *in vivo* cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcγR binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express Fc(RI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, *Annu. Rev. Immunol.* 9:457-492 (1991). Non-limiting examples of *in vitro* assays to assess ADCC activity of a molecule of interest are described in U.S. Patent No. 5,500,362 (*see, e.g.,* Hellstrom, I. et al. *Proc. Nat'l Acad. Sci. USA* 83:7059-7063 (1986)) and Hellstrom, I et al., *Proc. Nat'l Acad. Sci. USA* 82:1499-1502 (1985); 5,821,337 (*see* Bruggemann, M. et al., *J. Exp. Med.* 166:1351-1361 (1987)). Alternatively, non-radioactive assays methods may be employed (*see, for example, ACTI™* non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo, e.g.,* in an animal model such as that disclosed in Clynes et al. *Proc. Nat'l Acad. Sci. USA* 95:652-656 (1998). C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. *See, e.g.,* C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (*see, for example, Gazzano-Santoro et al., J. Immunol. Methods* 202:163 (1996); Cragg, M.S. et al., *Blood* 101:1045-1052 (2003); and Cragg, M.S. and M.J. Glennie, *Blood* 103:2738-2743 (2004)). FcRn binding and *in vivo* clearance/half-life determinations can also be performed using methods known in the art (*see, e.g.,* Petkova, S.B. et al., *Int'l. Immunol.* 18(12):1759-1769 (2006)).

[00160] Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056; EU numbering of residues). Such Fc mutants include Fc mutants with

substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581; EU numbering). In some embodiments, the antibody comprises an engineered alanine at amino acid position 265 according to EU numbering convention. In some embodiments, the antibody comprises an engineered alanine at amino acid position 297 according to EU numbering convention.

[00161] Certain antibody variants with improved or diminished binding to FcRs are described. (*See, e.g.*, U.S. Patent No. 6,737,056; WO 2004/056312, and Shields et al., *J. Biol. Chem.* 9(2): 6591-6604 (2001).)

[00162] In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, *e.g.*, substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).

[00163] In some embodiments, alterations are made in the Fc region that result in altered (*i.e.*, either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), *e.g.*, as described in US Patent No. 6,194,551, WO 99/51642, and Idusogie et al. *J. Immunol.* 164: 4178-4184 (2000).

[00164] Antibodies with increased half-lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., *J. Immunol.* 117:587 (1976) and Kim et al., *J. Immunol.* 24:249 (1994)), are described in US2005/0014934 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434 (EU numbering), *e.g.*, substitution of Fc region residue 434 (US Patent No. 7,371,826). *See also* Duncan & Winter, *Nature* 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.

[00165] In some embodiments, the antibody may have a wild-type human IgG1 Fc region or a wild-type human IgG4 Fc region, a human IgG4 S228P Fc region, a human IgG4 S228P/M252Y/S254T/T256E Fc region, a human IgG1 N297G Fc region, a human

IgG1 LALAPG (L234A/L235A/P329G) Fc region, or a human IgG1 N297G/M428L/N434S Fc region. (All positions are in EU numbering.)

Cysteine engineered antibody variants

[00166] In certain embodiments, it may be desirable to create cysteine engineered antibodies, *e.g.*, “thioMAbs,” in which one or more residues of an antibody are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated as described, *e.g.*, in U.S. Patent No. 7,521,541.

Antibody Derivatives and Conjugates

[00167] In certain embodiments, an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (*e.g.*, glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to,

the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.

[00168] In another embodiment, conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam et al., *Proc. Natl. Acad. Sci. USA* 102: 11600-11605 (2005)). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody-nonproteinaceous moiety are killed.

[00169] In some embodiments, an anti-TREM2 antibody is conjugated to a detection label and/or a drug. As used herein, a detection label is a moiety that facilitates detection of the antibody and/or facilitates detection of a molecule to which the antibody binds. Nonlimiting exemplary detection labels include, but are not limited to, radioisotopes, fluorescent groups, enzymatic groups, chemiluminescent groups, biotin, epitope tags, metal-binding tags, etc.

Exemplary Properties of Particular Anti-TREM2 Antibodies

[00170] As described in the Examples herein, a set of rat anti-human anti-TREM2 antibodies were identified from screens herein followed by deep sequencing analysis that have a unique set of properties, including, for example, (a) binding specifically to the TREM2 stalk domain at an epitope spanning the cleavage site between residues 157 and 158, and also specifically binding to a polypeptide consisting of residues 151-165, and more specifically binding within residues 151-161 of hTREM2, (b) not binding to soluble TREM2, (c) acting as TREM2 agonists, and (d) specifically binding to TREM2 with high affinity. These rat anti-human antibodies, 3.10C2, 3.27H7, 3.50G1, 3.18E5 (the “3.10C2 group”), 3.36F5, and Para.09, and their humanized variants, may have these and additional properties, which are described in more detail below.

Binding Affinity

[00171] In some embodiments, antibodies herein specifically bind to both human and cynomolgus TREM2 with high affinity. For example, in some embodiments, an anti-TREM2 antibody herein may bind to human TREM2 with a K_D of less than 1 nM, less than 0.5 nM, less than 100 pM, less than 50 pM, less than 25 pM, less than 10 pM, less

than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, for example, at 37 °C by surface plasmon resonance (SPR). In some embodiments, an anti-TREM2 antibody herein may bind to cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.5 nM, less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, for example, at 37 °C by SPR.

[00172] In some embodiments, an anti-TREM2 antibody herein binds to hTREM2 with a K_D of less than 500 pM (i.e., less than 0.5 nM). In some embodiments, an anti-TREM2 antibody herein binds to hTREM2 with a K_D of less than 200 pM (i.e., less than 0.2 nM). In some embodiments, an anti-TREM2 antibody herein binds to hTREM2 with a K_D of less than 100 pM (i.e., less than 0.1 nM). In some embodiments, an anti-TREM2 antibody herein binds to hTREM2 with a K_D of less than 50 pM (i.e., less than 5E-11M or less than 0.05 nM). In some embodiments, an anti-TREM2 antibody herein binds to hTREM2 with a K_D of 10-100 pM, 10-50 pM, 10-25 pM, or 1-10 pM. In some embodiments, an anti-TREM2 antibody herein binds to cynomolgus TREM2 with a K_D of less than 500 pM (i.e. less than 5E-10M or less than 0.5 nM). In some embodiments, an anti-TREM2 antibody herein binds to cyno TREM2 with a K_D of less than 200 pM (i.e. less than 2E-10M or less than 0.2 nM). In some embodiments, an anti-TREM2 antibody herein binds to cyno TREM2 with a K_D of less than 100 pM (i.e., less than 1E-10M or less than 0.1 nM). In some embodiments, an anti-TREM2 antibody herein binds to cyno TREM2 with a K_D of less than 50 pM (i.e. less than 5E-11M or less than 0.05 nM). In some embodiments, an anti-TREM2 antibody herein binds to cyno TREM2 with a K_D of 10-100 pM, 10-50 pM, or 10-25 pM. In some embodiments, an anti-TREM2 antibody herein binds to both human and cyno TREM2 with a K_D of 100-500 pM, 10-100 pM, 10-50 pM, 10-25 pM, or 1-10 pM.

[00173] For example, both Fab and IgG versions of the original rat anti-human 3.10C2 antibody bound to hTREM2 with K_D of about 200 pM. For example, h3.10C2.v1 bound to both human and cyno TREM2 with K_D of between 100 and 500 pM. For example, rat anti-human antibodies with the Para.09 heavy chain with different light chains based on the 3.10C2 antibody group bound to human and cyno TREM2 with a K_D of between 1 and 5 pM. Humanized hPara.09.v2 bound to human and cyno TREM2 with

a K_D of 10-25 pM. Further humanized versions of 3.10C2 bound to human and cyno TREM2 with a K_D of 100-200 pM and further humanized versions of Para.09 bound to human and cyno TREM2 with a K_D of 10-50 pM.

[00174] A K_D herein may be measured by SPR, for example, using a BIACORE® SPR assay. For example, an assay using a BIACORE®-2000 or a BIACORE®-3000 or a BIACORE®-T200 (BIAcore, Inc., Piscataway, NJ) can be performed with immobilized antibody chips. Association rates (k_{on}) and dissociation rates (k_{off}) can be calculated using a simple one-to-one Langmuir binding model (e.g., by BIACORE® Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (K_D) is calculated as the ratio k_{off}/k_{on} . *See, e.g.,* Chen et al., *J. Mol. Biol.* 293:865-881 (1999).

[00175] In the Examples below, affinity was measured by SPR in one of two formats. In one format TREM2-Fc was immobilized on protein A chips and soluble anti-TREM2 Fab fragments used as ligands. In the second format, anti-TREM2 IgG was immobilized on anti-CH1 Biacore™ chips and used soluble monomeric TREM2 as ligand. For example, K_D measurements shown in Tables 1, 4, and 6 were determined by SPR at 37 °C.

Epitope and lack of soluble TREM2 Binding, and Inhibition of TREM2 Shedding

[00176] As shown in the Examples section, the present disclosure provides antibodies that specifically bind within the stalk domain of TREM2 which spans residues 129-174 of hTREM2 (See SEQ ID NO: 90) but do not bind to soluble TREM2 (sTREM2; residues 19-157 of hTREM2), in contrast to other anti-TREM2 antibodies previously described in the literature as stalk binders. sTREM2 is formed through cleavage of TREM2 between residues H157 and S158, and generally comprises residues 19-157 of TREM2. In some embodiments, binding to the stalk domain of TREM2 may be shown by conducting a binding assay to a polypeptide comprising residues 129-174 (SEQ ID NO: 90) or residues 129-175 of TREM2 (SEQ ID NO: 177; Fig. 2A), which comprises the stalk domain and the first transmembrane domain residue. The results provided herein show that the 3.10C2, Para.09, 3.50G1, 3.18E5, 3.36F5, or 3.27H7 antibodies of the present disclosure, as well as the humanized versions of those antibodies

described herein such as Para.09.v2, 3.10C2.v1, likely bind to an epitope that spans the H157-S158 cleavage site, that is disrupted upon cleavage of TREM2 at the H157-S158 cleavage site, and that is not present in sTREM2. (See, for example, Figs. 2A-B and 5.) In contrast, a number of anti-TREM2 antibodies described in the literature show binding to soluble TREM2 and likely recognize a different epitope that is not disrupted by cleavage of intact TREM2, even though, in some cases, they may contact residues around the cleavage site (see, e.g., Fig. 5). Therefore, the present disclosure provides antibodies with a property not found in other anti-TREM2 antibodies – the ability to bind to intact TREM2 but not sTREM2, despite seeming to interact with a similar region of the protein as prior antibodies that bind sTREM2.

[00177] As noted previously, certain antibodies herein do not bind to soluble TREM2. As used herein, this means that the antibodies, when assayed in an ELISA assay, may not show any more than 10% binding to sTREM2, and in some cases do not show any more than 5% binding to sTREM2, wherein % binding is normalized against that of positive control antibody 1.16B8, whose binding to sTREM2 is set to 100%. The control antibody 1.16B8 light chain sequence is shown in SEQ ID NO: 170, and its heavy chain sequence is shown in SEQ ID NO: 171. In some embodiments, antibody 3.17A9 is used as a detection agent in the ELISA assay. The detection antibody 3.17A9 light chain sequence is shown in SEQ ID NO: 168, and heavy chain sequence shown in SEQ ID No: 169. In some embodiments, a polypeptide comprising residues 19-157 of hTREM2 may be used to assay the binding (e.g., residues 19-157 of SEQ ID NO: 21). In some embodiments, antibodies do not bind to soluble TREM2 in an ELISA assay in which binding is normalized against that of control antibody 1.16B8, in which detection antibody 3.17A9 is used as a detection reagent, and in which sTREM2 is a polypeptide comprising residues 19-157 of SEQ ID NO: 21. In some embodiments, the ELISA assay may be performed as shown in Example 11 below and in Fig. 16.

[00178] For example, as shown in an Example 11 herein, the human TREM2 ELISA assay measured binding of antibodies to sTREM2 by coating onto plate wells the antibody to be tested as capture reagents and with biotinylated IgV-reactive monoclonal antibody 3.17A9 used as the detection reagent. Control antibody 1.16B8 was used as a positive control antibody to establish the standard for sTREM2 binding. For example, in

this assay, rat Para.09 – LC 3.27H7 mIgG2a LALAPG (Para09), rat 3.10C2 mIgG2a LALAPG (3.10C2), rat 3.18E5 mIgG2a LALAPG (3.18E5), rat 3.50G1 mIgG2a LALAPG (3.50G1), rat 3.27H7 mIgG2a LALAPG (3.27H7), rat 3.36F5 mIgG2a LALAPG (3.36F5) all did not show any binding to sTREM2 (see Fig. 16, showing normalized sTREM2 binding of near zero for those antibodies in contrast to the 1.116B8 control). The humanized antibody Para.09.v2 antibody with a hIgG1 N297G constant region was also tested for sTREM2 binding and, like rat Para.09 with mIgG2 LALAPG, did not show any binding to sTREM2. Accordingly, in some embodiments, antibodies herein, such as those shown in Fig. 16 and humanized variants of such antibodies such as such as Para.09.v2, 3.10C2.v1, do not bind to soluble TREM2. In some embodiments, those antibodies bind to the TREM2 stalk domain but do not bind to soluble TREM2.

[00179] Lack of binding to sTREM2 may be advantageous *in vivo* as it might significantly reduce or eliminate the possibility of unwanted binding between antibody and sTREM2 *in vivo*. For example, without being limited by mechanism, sTREM2 could act as a “decoy” to an anti-TREM2 antibody otherwise, so that antibody molecules *in vivo* are less available to bind to TREM2 on the cell surface.

[00180] As shown in the Examples and accompanying Figures herein, antibodies herein may also bind to residues within the stalk region of TREM2 at a region spanning the H157-S158 cleavage site, specifically within residues ranging from 149-168, 146-169, 146-161, and 151-165 of TREM2. This unique cleavage-site spanning epitope may explain why antibodies herein may both bind to the TREM2 stalk and also not bind to soluble TREM2. (See, e.g., Fig. 5.) In some embodiments, an antibody herein binds specifically to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) and/or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94). In some cases, an antibody herein binds specifically to a TREM2 polypeptide consisting of amino acids 149-168 (SEQ ID NO: 93), 146-169 (SEQ ID NO: 95), 146-161 (SEQ ID NO: 96), and/or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94). In some embodiments, an antibody herein binds specifically to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) and/or 151-165 (SEQ

ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and to one consisting of 159-175 (SEQ ID NO: 94). In some cases, an antibody herein binds specifically to a TREM2 polypeptide consisting of amino acids 149-168 (SEQ ID NO: 93), 146-169 (SEQ ID NO: 95), 146-161 (SEQ ID NO: 96), and/or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and to one consisting of 159-175 (SEQ ID NO: 94).

[00181] As shown in the Examples provided herein, the data suggest that the antibodies of the present disclosure specifically bind to an epitope within residues 151-161 of TREM2. (See Figs. 2A and 2B.) In some embodiments, antibodies herein bind to an epitope including one or more of Asp-152, His-154, Val-155, Glu-156, His-157, Ser-158, Ile-159 and Ser-160, spanning the TREM2 cleavage site at H157-S158. (See Fig. 5.) In some embodiments, antibodies herein bind to an epitope comprising residues 152, 154, 157, 158 and 159. In some embodiments, antibodies herein specifically bind to an epitope including Asp-152, His-157, and Ile-159. In certain embodiments, antibodies herein bind to an epitope including one or more of residues Asp-152, His-154, Val-155, Glu-156, His-157 and Ile-159. In some embodiments, antibodies herein bind to an epitope including Glu-156 and Ser-160. Alanine scanning analysis shows that TREM2 binding of antibody Para.09, comprising the Para.09 heavy chain variable region paired with the light chain variable region of antibody 3.27H7, is impacted by alanine mutations at Asp-152, His-157, and Ile-159, for example. (Fig. 5.) Para.09 and 3.10C2 have a similar pattern in the alanine scanning assay, except that binding of 3.10C2 is additionally impacted by alanine mutations at H154 and S158. (Fig. 5.)

[00182] In some embodiments, an antibody herein, such as Para.09 or 3.10C2 including humanized variants of such antibodies such as Para.09.v2 and 3.10C2.v1, also decreases levels of sTREM2 *in vivo*, such as in murine plasma, CSF, or brain tissue, compared to a control antibody that does not specifically bind to TREM2 (e.g., an isotype control), as measured by an ELISA assay. For example, in some embodiments, an ELISA assay may be performed by determining a change in the level of soluble TREM2 from a plasma, CSF, or brain tissue sample incubated in the presence of anti-TREM2

antibodies compared to an isotype control antibody. Reduced levels of sTREM2 in the presence of anti-TREM2 antibodies are indicative of inhibition of sTREM2 shedding.

[00183] As shown in Example 18A-B below, the lack of binding to sTREM2 is also correlated with this depletion of sTREM2 *in vivo* (in murine plasma, CSF, and brain tissue). In contrast to a comparator antibody, treatment with exemplary antibody Para.09 led to substantially lower levels of plasma sTREM2 below baseline control levels, whereas treatment with the comparator anti-TREM2 antibody increased levels of sTREM2 in plasma by several fold. (Example 18B and Fig. 25C.) For example, Para.09 antibodies in a mIgG2 LALAPG background in mice caused a 70-85% decrease in soluble TREM2 levels in plasma for at least 7 days after administration, while the comparator antibody increased sTREM2 levels over the same period by more than 2-fold. (Fig. 25C.) Thus, in some embodiments, antibodies herein such as Para.09 and 3.10C2 and their humanized variants such as Para.09.v2 and 3.10C2.v1, cause a decrease in soluble TREM2 levels in murine plasma for at least 7 days after administration to mice. Antibodies of the present disclosure with increased specificity for intact TREM2 and lack of binding to sTREM2 *in vivo*, therefore, may have particular utility in situations where elevated sTREM2 levels are undesirable.

[00184] Accordingly, antibodies herein such as Para.09 and 3.10C2 and their humanized variants may possess any one or more of the following properties: (a) specific binding to the stalk domain of TREM2; (b) not binding to soluble TREM2 (sTREM2); (c) specific binding to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94); (d) specific binding to a TREM2 epitope spanning the H157-S158 cleavage site; (e) reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry); and (f) specific binding to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR). In some cases, and antibody may possess two or more of the above properties, three or more of

the above properties, four or more of the above properties, five or more of the above properties, or all of the above properties. For example, in some cases, an antibody herein does not bind to soluble TREM2 and also shows specific binding to a TREM2 epitope spanning the H157-S158 cleavage site and/or shows specific binding to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94). In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR). For example, in some cases, an antibody herein does not bind to soluble TREM2 and specifically binds to the stalk domain of TREM2. In some cases, an antibody herein does not bind to soluble TREM2 and has reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR). Furthermore, in some cases, the antibody also has intact effector function. In some cases, the antibody also has an Fc region with reduced effector function. In other cases, the antibody also has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution.

[00185] In certain exemplary embodiments, the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11 or 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12 or 20; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13, and further wherein the antibody does not bind to soluble TREM2 (sTREM2), wherein the antibody is a TREM2 agonist as described further in the following section. In some embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 17, 133, 135, 137, or 139 or an amino acid sequence

that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 17, 133, 135, 137, or 139; or the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 with or without the C-terminal lysine or C-terminal glycine-lysine, or comprises an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 144. In some cases, antibody also specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site and/or specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94). In some cases, the antibody does not bind to soluble TREM2 and has reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). In some cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR). Furthermore, in some cases, the antibody also has intact effector function. In some cases, the antibody also has an Fc region with reduced effector function. In other cases, the antibody also has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution. In any of these cases, in some embodiments, the antibody may possess the light chain CDRs 1-3 of 3.10C2, 3.50G1, 3.18E5, 3.36F5, or 3.27H7.

[00186] Antibodies described herein may also have one or more of the additional biological activities described in the next section along with any combination of the above properties described in this section.

Additional Biological Activities

[00187] In some embodiments, antibodies herein, such as Para.09 and 3.10C2 and their humanized variants, may have one or more, two or more, three or more, four or more, five or more, or six or more, seven or more, eight or more, or all of the following

further characteristics: (a) inducing luciferase reporter activity in Jurkat-NFAT luciferase reporter cells expressing human TREM2; (b) decreasing levels of sTREM2 *in vivo* in plasma; (c) inhibiting shedding of sTREM2 in Jurkat-NFAT luciferase reporter cells expressing human TREM2; (d) inducing tyrosine phosphorylation in human MDM cells; (e) inducing SYK phosphorylation in human MDM cells; (f) enhancing survival of human iPSC-derived microglia in absence of IL-34 and CSF-1; (g) inhibiting shedding of sTREM2 in human iPSC-derived microglia; (h) inducing SYK phosphorylation in human iPSC-derived microglia; and (i) increasing total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia (e.g., as described in the assay of Example 17 herein).

[00188] Accordingly, in some embodiments, an antibody herein, such as Para.09 and 3.10C2 and their humanized variants, also reduces sTREM2 levels (i.e., inhibits sTREM2 shedding) in cultured cells, including in Jurkat cells that have been engineered to express human TREM2, or alternatively, in human monocyte-derived macrophages (MDMs) or in human induced pluripotent stem cell (iPSC)-derived microglia. In some cases, sTREM2 levels in cell culture assays may be measured by ELISA assays.

[00189] In some embodiments, an antibody herein is a TREM2 agonist. For example, in some embodiments, an antibody herein induces reporter gene expression in Jurkat-NFAT reporter cells expressing human TREM2. For example, TREM2 activity may result in cell signaling events that lead to enhanced gene expression under the control of NFAT (nuclear factor of activated T cells). NFAT activity can be assessed, for instance, using Jurkat cells engineered to express a reporter gene such as firefly luciferase in response to activation of gene expression by an NFAT transcription factor. To test the effect of anti-TREM2 antibodies on NFAT-controlled gene expression, Jurkat-NFAT reporter cells can be constructed that express human TREM2. In some embodiments, an antibody herein enhances reporter gene expression in a Jurkat-NFAT reporter cell expressing human TREM2. (See Figs. 18A-B.) In some embodiments, an antibody herein also enhances reporter gene expression in a Jurkat-NFAT reporter cell expressing a human TREM2 mutant, such as hTREM2 R47H, hTREM2 R62H, and/or H157Y. (See Figs. 19A-C.)

[00190] TREM2 activity, and accordingly, agonism by anti-TREM2 antibodies, may also be assessed by levels of phosphorylation of tyrosine residues generally or by levels of phosphorylation of Syk kinase, which is a kinase that becomes phosphorylated upon activation of TREM2-related cell signaling. Thus, in some embodiments, an antibody herein increases TREM2 activity as measured by an increase in one or both of pan phospho-tyrosine (pY) levels and phosphorylated Syk kinase (p-SYK) levels in one or more of Jurkat-NFAT reporter cells expressing human TREM2, human iPSC-derived microglia, or human MDM cells. In some embodiments, an antibody herein increases SYK phosphorylation in human iPSC-derived microglia, and human MDM cells.

[00191] In some embodiments, antibodies herein also enhance survival of human iPSC-derived microglia when those cells are cultured in the absence of IL-34 and CSF-1, which are ordinarily required to promote survival and growth of the cells. For example, humanized antibodies hPara.09.v2, h3.10C2.v1, hPara.09 Q100P V104L, and hPara.09 Q100P each enhanced iPSC-derived microglia survival with EC₅₀'s ranging from 65 pM to 610 pM (respectively 65 pM, 350 pM, 190 pM, and 610 pM). (See Example 17 and Fig. 23E.) Accordingly, in some embodiments, an antibody herein may enhance iPSC-derived microglia survival in the absence of IL-34 and CSF-1 with an EC₅₀ ranging from 60 pM to 700 pM, such as from 60 pM to 400 pM, or from 60 pM to 200 pM.

Furthermore, in some embodiments, an antibody may enhance microglia survival in the absence of IL-34 and CSF-1 by at least 3-fold, or by 3-8 fold over that of an isotype control antibody, such as by 3-6 fold, 3-5 fold, 5-8 fold, or 3-4 fold. (See Figs. 23D-E.)

[00192] In some embodiments, antibodies herein increase A β plaque intensity and/or increase X04 plaque intensity in the presence of A β oligomers in human iPSC-derived microglia. (See Example 17 and Figs. 24A-C.) Plaque formation and compaction, for example, may be measured as an increased intensity when staining iPSC-derived microglia with particular marker dyes, such as those recognizing A β (i.e., measuring "A β intensity" or "A β plaque intensity") or A β plaques (X04 marker, measuring "X04 intensity" or "X04 plaque intensity"). In some cases, a "total" A β plaque intensity may be determined. And in some cases, an "average" X04 plaque intensity may be measured. An example of an assay for measuring plaque formation and

compaction, total A β plaque intensity and average X04 plaque intensity is shown in Example 17 and Fig. 24A-C.

[00193] In some embodiments, antibodies herein increase A β plaque formation and compaction in iPSC-derived microglia, as shown by increases in one or both of total A β plaque intensity and average X04 intensity compared to an isotype control antibody. For example, in some embodiments, presence of an antibody increases total A β plaque intensity by 4-6 fold compared to an isotype control antibody. In some embodiments, an antibody herein has an EC₅₀ for increase in total A β plaque intensity of between 100 and 800 nM. For example, as shown in Fig. 24B, antibodies hPara.09.v2, h3.10C2.v1, hPara.09 Q100P V104L, and hPara.09 Q100P increased total A β plaque intensity in a human iPSC-derived microglia model plaque assay with EC₅₀'s of 330 nM, 130 nM, 770 nM, and 120 nM, respectively. Furthermore, in some embodiments, presence of an antibody increases average X04 plaque intensity in the assay by 2-3 fold compared to an isotype control antibody. In some embodiments, an antibody herein has an EC₅₀ for increase in average X04 plaque intensity of between 10 and 500 nM. For example, as shown in Fig. 24C, antibodies hPara.09.v2, h3.10C2.v1, hPara.09 Q100P V104L, and hPara.09 Q100P increased average X04 plaque intensity in a human iPSC-derived microglia model plaque assay with EC₅₀'s of 320 nM, 11 nM, 40 nM, and 500 nM, respectively.

[00194] Data from Jurkat-NFAT reporter cells expressing human TREM2, and from the MDM and iPSC-derived microglia models indicate that antibodies herein may have neuroprotective activities, for example. For instance, antibodies herein may have a combination of biological activities of enhancing survival of human iPSC-derived microglia, increasing p-SYK phosphorylation and/or NFAT-controlled gene expression, and promoting A β plaque formation and compaction in presence of A β oligomers in human iPSC-derived microglia. In some embodiments, an antibody herein also shows little to no significant off-target binding in a BV ELISA assay. (Hötzel et al., *Landes Bioscience* dx.doi.org/10.4161/mabs.22189 (2012).) An exemplary BV ELISA assay is as described in Example 10 below. In such an assay, for example, antibodies may have high (score > 5), medium (score of 1-5) and low (non-detectable, score < 1) off-target binding. In some embodiments, when antibodies herein were tested in parallel with

antibodies previously determined to have high medium, and low off-target binding scores, antibodies herein were found to have low off-target binding scores, i.e. below 1. (See Fig. 15.) In particular, 3.10C2.v1 and Para.09.v2 prepared in a human IgG1 N297G constant region background, showed low off-target binding in this assay (i.e., a score less than 1) despite also having affinity for TREM2 in the 100-500 pM and 10-50 pM range, respectively. A low score in this assay, for example, may indicate that the antibody is less likely to bind to incorrect targets *in vivo*, which correlates with favorable pharmacokinetic properties in human and cynomolgus monkeys and may be beneficial for reducing toxicity and side effects due to off-target binding *in vivo*.

Sequences and Properties of Certain Exemplary Humanized Antibodies

Antibody h3.10C2.v1

[00195] In some aspects, the disclosure relates to an antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence comprising the heavy chain CDRs of the 3.10C2 antibody, comprising SEQ ID NOS: 1, 2, and 3 (Kabat), or comprising SEQ ID Nos: 9, 10, and 3 (Chothia). (See Fig. 9B.) In some embodiments, the antibody comprises a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises an amino acid sequence comprising the light chain CDRs of the 3.10C2.v1 antibody, based on those of the 3.27H7 Fab, comprising SEQ ID NOS: 4, 5, and 6. (See Fig. 9A.) In some embodiments, the antibody comprises the heavy chain and the light chain CDRs of 3.10C2.v1, comprising SEQ ID NOS: 1-6. In some embodiments, the antibody comprises the heavy chain and the light chain CDRs of 3.10C2.v1, comprising SEQ ID NOS: 9, 10, 3, 4, 5, and 6.

[00196] In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 1, 2, and 3 or alternatively 9, 10, and 3, and/or the light chain CDRs of SEQ ID NOS: 4, 5, and 6, and further comprises a heavy chain variable region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 1, 2, and 3 or alternatively 9, 10, and 3, and/or light chain CDRs of SEQ ID NOS: 4, 5, and 6, and further comprises a light chain

variable region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 1, 2, and 3 or alternatively 9, 10, and 3, and/or light chain CDRs of SEQ ID NOS: 4, 5, and 6, and further comprises a heavy chain variable region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7, and a light chain variable region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 1, 2, and 3 or alternatively 9, 10, and 3, and/or light chain CDRs of SEQ ID NOS: 4, 5, and 6, and further comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 1, 2, and 3 or alternatively 9, 10, and 3, and/or light chain CDRs of SEQ ID NOS: 4, 5, and 6, and further comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 1, 2, and 3 or alternatively 9, 10, and 3, and/or light chain CDRs of SEQ ID NOS: 4, 5, and 6, and further comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7, but with up to 5, such as 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions, in the heavy chain framework regions of SEQ ID NO: 7. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 1, 2, and 3 or alternatively 9, 10, and 3, and/or light chain CDRs of SEQ ID NOS: 4, 5, and 6, and further comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8, but with up to 5, such as 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions, in the light chain framework regions of SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8, but with up to 5 amino acid substitutions, insertions, or deletions, such as 1, 2, 3,

4, or 5 amino acid substitutions, insertions, or deletions, in the framework regions of SEQ ID NO: 7 and/or SEQ ID NO: 8.

[00197] In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody further comprises a heavy chain and/or a light chain constant region.

[00198] In any of the embodiments herein, the antibody may be an antibody fragment, such as an Fv, single-chain Fv (scFv), Fab, Fab', or (Fab')₂. In other embodiments, the antibody may be a whole antibody (i.e., comprising heavy and light chain constant regions.) In other embodiments, the antibody may be an IgG, IgA, or IgM antibody. In some embodiments, the antibody may have a wild-type human IgG1 Fc region or a wild-type human IgG4 Fc region, a human IgG4 S228P Fc region, a human IgG4 S228P/M252Y/S254T/T256E Fc region, a human IgG1 N297G Fc region, a human IgG1 LALAPG (L234A/L235A/P329G) Fc region, or a human IgG1 N297G/M428L/N434S Fc region. If a murine IgG antibody, the antibody may be an mIgG1 or mIgG2 or mIgG2 LALAPG antibody. An antibody may, in some cases, comprise a full length heavy chain and/or a full length light chain. In some cases, the antibody may lack the C-terminal Lys or the C-terminal Lys and Gly residues of the heavy chain constant region. In other cases, the antibody contains one or both of those C-terminal residues. In some cases, the antibody may be bispecific or multispecific. In some cases, the antibody may be conjugated to another molecule, such as a label or drug either directly or through a linker. In some cases, the antibody has intact effector function. In some cases, the antibody has an Fc region with reduced effector function. In other cases, the antibody has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution.

[00199] In some embodiments, the antibody may have certain properties described in more detail below. For example, in some aspects, the antibody has one or more, two or more, three or more, four or more, five or more, or all of the following characteristics: (a) specifically binds to the stalk domain of TREM2 and specifically binds to a polypeptide consisting of residues 151-165 of hTREM2 (SEQ ID NO: 97); (b) does not bind to soluble TREM2 (sTREM2); and (c) specifically binds to human and cynomolgus TREM2

with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or from 100-500 pM or 100-200 pM at 37 °C by surface plasmon resonance (SPR). In further aspects, the antibody may also (d) specifically bind to an epitope spanning the H157-S158 cleavage site of TREM2; (e) specifically bind to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94); and (f) show reduced binding affinity to a TREM2 stalk domain polypeptides individually comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). Accordingly, in some cases, the antibody (a) does not bind to soluble TREM2 and (b) specifically binds to the stalk domain of TREM2. In some cases, the antibody (a) does not bind to soluble TREM2 and (b) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site of TREM2 and/or (c) specifically bind to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94). In some cases, the antibody (a) does not bind to soluble TREM2 and (b) shows reduced binding affinity to a TREM2 stalk domain polypeptides individually comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). In further cases, the antibody (c) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or from 100-500 pM or 100-200 pM at 37 °C by surface plasmon resonance (SPR) at 37 °C by surface plasmon resonance (SPR).

[00200] In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2 and does not bind to soluble TREM2. In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2; does not bind to soluble TREM2; and specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or from 100-500 pM or 100-200 pM at 37 °C by surface plasmon

resonance (SPR), at 37 °C by surface plasmon resonance (SPR). In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2; and does not bind to soluble TREM2. In any of these cases, the antibody may further have one or more of the further properties (a) to (i) listed below.

[00201] In some cases, the antibody also has a low off-target binding score (e.g. a score of < 1) in an off-target binding assay, such as a BV ELISA assay, (an example is an assay performed as described in Example 10 herein). In some cases, such antibodies may act as TREM2 agonists, and may also have one or more of properties (a) to (i) listed below as well.

[00202] Specifically, in some aspects, the antibody may also have one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the following characteristics: (a) induces luciferase reporter activity in Jurkat-NFAT reporter cells expressing human TREM2; (b) decreases levels of sTREM2 *in vivo* in plasma; (c) inhibits shedding of sTREM2 and/or induces internalization of human TREM2 in Jurkat-NFAT luciferase reporter cells; (d) induces tyrosine phosphorylation in human MDM cells expressing human TREM2; (e) induces SYK phosphorylation (p-SYK) in human MDM cells expressing human TREM2; (f) enhances survival of human iPSC-derived microglia; (g) inhibits shedding of sTREM2 in human iPSC-derived microglia; (h) activates TREM2 signaling in human iPSC-derived microglia; and (i) increases total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia.

h3.10C2.v1 Variant Antibodies

[00203] In some embodiments, an antibody herein may comprise the heavy and light chain CDRs of h3.10C2.v1 as well as the heavy chain framework regions of the h3.10C2.v1 antibody, as described above and shown in Figs. 9A-B, but have additional modifications in the antibody light chain, e.g., as shown in Fig. 14A. For example, in some embodiments, certain light chain modifications may be made in the framework regions to improve expression yield, and the like, as described in the Examples below.

[00204] In some embodiments, the antibody comprises one of the following sets of VH and VL: (a) SEQ ID Nos: 146 and 145 (antibody h3.10C2.v1 Q100P); (b) SEQ ID

Nos: 148 and 147 (antibody h3.10C2.v1 I58V/Q100P); or (c) SEQ ID Nos: 150 and 149 (antibody h3.10C2.v1 Q100P/V104L). In some embodiments, the antibody further comprises a heavy chain and/or a light chain constant region.

[00205] In any of the embodiments herein, the antibody may be an antibody fragment, such as an Fv, single-chain Fv (scFv), Fab, Fab', or (Fab')₂. In other embodiments, the antibody may be a whole antibody (i.e., comprising heavy and light chain constant regions.) In other embodiments, the antibody may be an IgG, IgA, or IgM antibody. In some embodiments, the antibody may have a wild-type human IgG1 Fc region or a wild-type human IgG4 Fc region, a human IgG4 S228P Fc region, a human IgG4 S228P/M252Y/S254T/T256E Fc region, a human IgG1 N297G Fc region, a human IgG1 LALAPG (L234A/L235A/P329G) Fc region, or a human IgG1 N297G/M428L/N434S Fc region. If a murine IgG antibody, the antibody may be an mIgG1 or mIgG2 or mIgG2 LALAPG antibody. An antibody may, in some cases, comprise a full length heavy chain and/or a full length light chain. In some cases, the antibody may lack the C-terminal Lys or the C-terminal Lys and Gly residues of the heavy chain constant region. In other cases, the antibody contains one or both of those C-terminal residues. In some cases, the antibody may be bispecific or multispecific. In some cases, the antibody may be conjugated to another molecule, such as a label or drug either directly or through a linker. In some cases, the antibody has intact effector function. In some cases, the antibody has an Fc region with reduced effector function. In other cases, the antibody has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution.

[00206] In some embodiments, the antibody may have certain properties described in more detail below. For example, in some aspects, the antibody has one or more, two or more, three or more, four or more, five or more, or all of the following characteristics: (a) specifically binds to the stalk domain of TREM2; (b) does not bind to soluble TREM2 (sTREM2); and (c) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or 100-500 pM or 100-200 pM at 37 °C by surface plasmon resonance (SPR). In further aspects, the antibody may also (d) specifically bind to an epitope spanning the H157-S158 cleavage site of TREM2; (e) specifically bind to a TREM2

polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94); and (f) show reduced binding affinity to a TREM2 stalk domain polypeptides individually comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). Accordingly, in some cases, the antibody (a) does not bind to soluble TREM2 and (b) specifically binds to the stalk domain of TREM2. In some cases, the antibody (a) does not bind to soluble TREM2 and (b) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site of TREM2 and/or (c) specifically bind to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94). In some cases, the antibody (a) does not bind to soluble TREM2 and (b) shows reduced binding affinity to a TREM2 stalk domain polypeptides individually comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). In some of these cases, the antibody also (c) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or 100-500 pM or 100-200 pM at 37 °C by surface plasmon resonance (SPR).

[00207] In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2 and does not bind to soluble TREM2. In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2; does not bind to soluble TREM2; and specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or 100-500 pM or 100-200 pM, at 37 °C by surface plasmon resonance (SPR). In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2; and does not bind to soluble TREM2.

[00208] In some cases, the antibody also has a low off-target binding score (e.g. a score of < 1) in an off-target binding assay (performed as described in Example 10 herein). In some cases, such antibodies may act as TREM2 agonists, and may also have one or more of properties (a) to (i) listed below as well.

[00209] Specifically, in some aspects, the antibody may also have one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the following further characteristics: (a) Induces luciferase reporter activity in Jurkat-NFAT reporter cells expressing human TREM2; (b) Decreases levels of sTREM2 *in vivo* in plasma; (c) Inhibits shedding of sTREM2 in Jurkat-NFAT luciferase reporter cells; (d) Induces tyrosine phosphorylation in human MDM cells; (e) Induces SYK phosphorylation in human MDM cells; (f) Enhances survival of human iPSC-derived microglia in the absence of IL34 and CSF1; (g) Inhibits shedding of sTREM2 in human iPSC-derived microglia; (h) Induces SYK phosphorylation in human iPSC-derived microglia; and (i) Increases total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia.

[00210] In some embodiments, antibodies comprise one of the following sets of VH and VL: (a) SEQ ID Nos: 146 and 145 (antibody h3.10C2.v1 Q100P); (b) SEQ ID Nos: 148 and 147 (antibody h3.10C2.v1 I58V/Q100P); and (c) SEQ ID Nos: 150 and 149 (antibody h3.10C2.v1 Q100P/V104L).

Antibody hPara.09.v2

[00211] In some embodiments, the antibody comprises the heavy and light chain CDRs of antibody Para.09.v2, in which the heavy chain CDRs are based on the Para.09 heavy chain and the light chain CDRs are based on the 3.27H7 Fab. In some embodiments, an antibody herein comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 (Kabat) or alternatively 19, 20, and 13 (Chothia), and/or the light chain CDRs of SEQ ID NOS: 14, 15, and 16. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 (Kabat) or alternatively 19, 20, and 13 (Chothia), and/or the light chain CDRs of SEQ ID NOS: 14, 15, and 16, and further comprises a heavy chain variable region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of

SEQ ID NO: 17. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 or alternatively 19, 20, and 13, and/or light chain CDRs of SEQ ID NOS: 14, 15, and 16, and further comprises a light chain variable region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 or alternatively 19, 20, and 13, and/or light chain CDRs of SEQ ID NOS: 14, 15, and 16, and further comprises a heavy chain variable region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 17, and a light chain variable region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 or alternatively 19, 20, and 13, and/or light chain CDRs of SEQ ID NOS: 14, 15, and 16, and further comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 or alternatively 19, 20, and 13, and/or light chain CDRs of SEQ ID NOS: 14, 15, and 16, and further comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 or alternatively 19, 20, and 13, and/or light chain CDRs of SEQ ID NOS: 14, 15, and 16, and further comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17, but with up to 5, such as 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions, in the heavy chain framework regions of SEQ ID NO: 17. In some embodiments, the antibody comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 or alternatively 19, 20, and 13, and/or light chain CDRs of SEQ ID NOS: 14, 15, and 16, and further comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18, but with up to 5, such as 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions, in the light chain framework regions of SEQ

ID NO: 18. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18, but with up to 5 amino acid substitutions, insertions, or deletions, such as 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions, in the framework regions of SEQ ID NO: 17 and/or SEQ ID NO: 18.

[00212] In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody further comprises a heavy chain and/or a light chain constant region.

[00213] In any of the embodiments herein, the antibody may be an antibody fragment, such as an Fv, single-chain Fv (scFv), Fab, Fab', or (Fab')₂. In other embodiments, the antibody may be a whole antibody (i.e., comprising heavy and light chain constant regions.) In other embodiments, the antibody may be an IgG, IgA, or IgM antibody. In some embodiments, the antibody may have a wild-type human IgG1 Fc region or a wild-type human IgG4 Fc region, a human IgG4 S228P Fc region, a human IgG4 S228P/M252Y/S254T/T256E Fc region, a human IgG1 N297G Fc region, a human IgG1 LALAPG (L234A/L235A/P329G) Fc region, or a human IgG1 N297G/M428L/N434S Fc region. If a murine IgG antibody, the antibody may be an mIgG1 or mIgG2 or mIgG2 LALAPG antibody. An antibody may, in some cases, comprise a full length heavy chain and/or a full length light chain. In some cases, the antibody may lack the C-terminal Lys or the C-terminal Lys and Gly residues of the heavy chain constant region. In other cases, the antibody contains one or both of those C-terminal residues. In some cases, the antibody may be bispecific or multispecific. In some cases, the antibody may be conjugated to another molecule, such as a label or drug either directly or through a linker. In some cases, the antibody has intact effector function. In some cases, the antibody has an Fc region with reduced effector function. In other cases, the antibody has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution.

[00214] In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144. In some embodiments, the

antibody comprises a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 and a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 but lacking the C-terminal lysine of SEQ ID NO: 144 or lacking the C-terminal glycine and lysine of SEQ ID NO: 144 and a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 144 and a light chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144, optionally without the C-terminal lysine or glycine-lysine, and a light chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 144 and a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody

comprises a heavy chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 144 and a light chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144, optionally without the C-terminal lysine or glycine-lysine, and a light chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence with 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions in comparison to the amino acid sequence of SEQ ID NO: 144 and a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176. In any of the above cases allowing for sequence variation in SEQ ID NO: 144 and/or SEQ ID NO: 176, in some embodiments such sequence variation is limited to the antibody framework and/or constant regions, such that the antibody also comprises heavy chain CDRs of SEQ ID NOS: 11, 12, and 13 or alternatively 19, 20, and 13, and/or light chain CDRs of SEQ ID NOS: 14, 15, and 16. In other embodiments, such sequence variation in SEQ ID NO: 144 and/or SEQ ID NO: 176 is limited to the antibody constant regions, such that the antibody also comprises SEQ ID NO: 17 and/or 18.

[00215] In some embodiments, the antibody may have certain properties described in more detail below.

[00216] For example, in some aspects, the antibody has one or more, two or more, three or more, four or more, five or more, or all of the following characteristics: (a) specifically binds to the stalk domain of TREM2; (b) does not bind to soluble TREM2 (sTREM2); and (c) specifically binds to human and cynomolgus TREM2 with a K_D of

less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR). In further aspects, the antibody may also (d) specifically bind to an epitope spanning the H157-S158 cleavage site of TREM2; (e) specifically bind to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94); and (f) show reduced binding affinity to a TREM2 stalk domain polypeptides individually comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). Accordingly, by way of examples, in some aspects, the antibody specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2 and does not bind to soluble TREM2. In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM. In some aspects, the antibody specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2 and/or specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94); and also does not bind to soluble TREM2. In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM. , at 37 °C by surface plasmon resonance (SPR). In some aspects, the antibody specifically binds to the stalk domain of TREM2; and does not bind to soluble TREM2. In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM. In some aspects, the antibody does not bind to soluble TREM2; and specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less

than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM, at 37 °C by surface plasmon resonance (SPR). In some cases, the antibody does not bind to soluble TREM2 and shows reduced binding affinity to a TREM2 stalk domain polypeptides individually comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM. In some cases, the antibody has intact effector function. In some cases, the antibody has an Fc region with reduced effector function. In other cases, the antibody has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution.

[00217] In some cases, the antibody also has a low off-target binding score (e.g. a score of < 1) in an off-target binding assay (performed as described in Example 10 herein). In some cases, the antibody may have a lower K_D for human TREM2 than an antibody comprising the heavy and light chain CDRs of 3.10C2.

[00218] In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2 and does not bind to soluble TREM2. In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2; does not bind to soluble TREM2. In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2; and does not bind to soluble TREM2; and also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM, at 37 °C by surface plasmon resonance (SPR). In some cases, the antibody has intact effector function. In some cases, the antibody has an Fc region with reduced effector function. In other cases, the antibody has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution.

[00219] In any of these cases, the antibody may further have one or more of the further properties (a) to (i) listed below.

[00220] Specifically, in some aspects, the antibody may also have one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the following characteristics: (a) Induces luciferase reporter activity in Jurkat-NFAT reporter cells expressing human TREM2; (b) Decreases levels of sTREM2 *in vivo* in plasma; (c) Inhibits shedding of sTREM2 in Jurkat-NFAT luciferase reporter cells expressing human TREM2; (d) Induces tyrosine phosphorylation in human MDM cells; (e) Induces SYK phosphorylation in human MDM cells; (f) Enhances survival of human iPSC-derived microglia in the absence of IL-34 and CSF-1; (g) Inhibits shedding of sTREM2 in human iPSC-derived microglia; (h) Induces SYK phosphorylation in human iPSC-derived microglia; and (i) Increases total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia. In some embodiments, the antibody may have higher luciferase reporter activity (e.g., a lower EC₅₀ in a Jurkat-NFAT reporter assay as described in the Examples herein) than an antibody comprising the heavy and light chain CDRs of 3.10C2. In some embodiments, the antibody may show greater inhibition of sTREM2 shedding in Jurkat-NFAT reporter cells (e.g., in an assay as described in the Examples) compared to an antibody comprising the heavy and light chain CDRs of 3.10C2.

hPara.09.v2 Variant Antibodies

[00221] In some embodiments, an antibody herein may comprise the heavy and light chain CDRs of hPara.09.v2 as well as the heavy chain framework regions of the hPara.09.v2 antibody, as described above and shown in Figs. 12A-B, but have additional modifications in the antibody light chain, e.g., as shown in Fig. 13A. For example, in some embodiments, certain light chain modifications may be made in the framework regions to improve expression yield as described in the Examples below.

[00222] In some such embodiments, the antibody comprises one of the following sets of VH and VL: (a) SEQ ID Nos: 133 and 132 (antibody hPara.09.v2 Q100P); (b) SEQ ID Nos: 135 and 134 (antibody hPara.09.v2 I58V/Q100P); (c) SEQ ID Nos: 137 and 136 (antibody hPara.09.v2 Q100P/V104L). In some embodiments, the antibody further comprises a heavy chain and/or a light chain constant region. In some embodiments, the antibody light chain comprises or consists of the amino acid sequence of SEQ ID NO: 176.

[00223] In any of the embodiments herein, the antibody may be an antibody fragment, such as an Fv, single-chain Fv (scFv), Fab, Fab', or (Fab')₂. In other embodiments, the antibody may be a whole antibody (i.e., comprising heavy and light chain constant regions.) In other embodiments, the antibody may be an IgG, IgA, or IgM antibody. In some embodiments, the antibody may have a wild-type human IgG1 Fc region or a wild-type human IgG4 Fc region, a human IgG4 S228P Fc region, a human IgG4 S228P/M252Y/S254T/T256E Fc region, a human IgG1 N297G Fc region, a human IgG1 LALAPG (L234A/L235A/P329G) Fc region, or a human IgG1 N297G/M428L/N434S Fc region. If a murine IgG antibody, the antibody may be an mIgG1 or mIgG2 or mIgG2 LALAPG antibody. An antibody may, in some cases, comprise a full length heavy chain and/or a full length light chain. In some cases, the antibody may lack the C-terminal Lys or the C-terminal Lys and Gly residues of the heavy chain constant region. In other cases, the antibody contains one or both of those C-terminal residues. In some cases, the antibody may be bispecific or multispecific. In some cases, the antibody may be conjugated to another molecule, such as a label or drug either directly or through a linker. In some cases, the antibody has intact effector function. In some cases, the antibody has an Fc region with reduced effector function. In other cases, the antibody has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution.

[00224] In some embodiments, the antibody may have certain properties described in more detail below. For example, in some aspects, the antibody has one or more, two or more, three or more, four or more, five or more, or all of the following characteristics: (a) specifically binds to the stalk domain of TREM2; (b) does not bind to soluble TREM2 (sTREM2); and (c) specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR). In further aspects, the antibody may also (d) specifically bind to an epitope spanning the H157-S158 cleavage site of TREM2; (e) specifically bind to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);

and (f) show reduced binding affinity to a TREM2 stalk domain polypeptides individually comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). Accordingly, by way of examples, in some aspects, the antibody specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2 and does not bind to soluble TREM2. In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM. In some aspects, the antibody specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2 and/or specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94); and also does not bind to soluble TREM2. In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM. , at 37 °C by surface plasmon resonance (SPR). In some aspects, the antibody specifically binds to the stalk domain of TREM2; and does not bind to soluble TREM2. In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM. In some aspects, the antibody does not bind to soluble TREM2; and specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM, at 37 °C by surface plasmon resonance (SPR). In some cases, the antibody does not bind to soluble TREM2 and shows reduced binding affinity to a TREM2 stalk domain polypeptides individually comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry). In some such cases, the antibody also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM,

less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM. In some cases, the antibody has intact effector function. In some cases, the antibody has an Fc region with reduced effector function. In other cases, the antibody has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution.

[00225] In some cases, the antibody also has a low off-target binding score (e.g. a score of < 1) in an off-target binding assay (performed as described in Example 10 herein). In some cases, the antibody may have a lower K_D for human TREM2 than an antibody comprising the heavy and light chain CDRs of 3.10C2. In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2 and does not bind to soluble TREM2. In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2; does not bind to soluble TREM2. In some aspects, the antibody is a TREM2 agonist that specifically binds to an epitope spanning the H157-S158 cleavage site of TREM2; and does not bind to soluble TREM2; and also specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, such as 10-50 pM or 10-25 pM, at 37 °C by surface plasmon resonance (SPR). In some cases, the antibody has intact effector function. In some cases, the antibody has an Fc region with reduced effector function. In other cases, the antibody has an Fc region that is effectorless. For example, in some cases the antibody comprises a hIgG1 Fc region with an N297G substitution.

[00226] In any of these cases, the antibody may further have one or more of the further properties (a) to (i) listed below.

[00227] In some aspects, the antibody may also have one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the following characteristics: (a) Induces luciferase reporter activity in Jurkat-NFAT reporter cells expressing human TREM2; (b) Decreases levels of sTREM2 *in vivo* in plasma; (c) Inhibits shedding of sTREM2 human TREM2 in Jurkat-NFAT luciferase reporter cells expressing human TREM2; (d) Induces tyrosine phosphorylation in human MDM cells; (e) Induces SYK phosphorylation in human MDM cells; (f) Enhances

survival of human iPSC-derived microglia in the absence of IL-34 and CSF-1; (g) Inhibits shedding of sTREM2 in human iPSC-derived microglia; (h) Induces SYK phosphorylation in human iPSC-derived microglia; and (i) Increases total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia. In some embodiments, the antibody may have higher luciferase reporter activity (e.g., a lower EC50 in a Jurkat-NFAT reporter assay as described in the Examples herein) than an antibody comprising the heavy and light chain CDRs of 3.10C2. In some embodiments, the antibody may show greater inhibition of sTREM2 shedding in Jurkat-NFAT reporter cells (e.g., in an assay as described in the Examples) compared to an antibody comprising the heavy and light chain CDRs of 3.10C2.

[00228] In some embodiments, antibodies comprise one of the following sets of VH and VL: (a) SEQ ID Nos: 133 and 132 (antibody hPara.09.v2 Q100P); (b) SEQ ID Nos: 135 and 134 (antibody hPara.09.v2 I58V/Q100P); (c) SEQ ID Nos: 137 and 136 (antibody hPara.09.v2 Q100P/V104L).

Nucleic Acids Encoding Antibodies

[00229] Nucleic acid molecules comprising polynucleotides that encode one or more chains of anti-TREM2 antibodies are also provided. In some embodiments, a nucleic acid molecule comprises a polynucleotide that encodes a heavy chain or a light chain of an anti-TREM2 antibody. In some embodiments, a nucleic acid molecule comprises both a polynucleotide that encodes a heavy chain and a polynucleotide that encodes a light chain, of an anti-TREM2 antibody. In some embodiments, a first nucleic acid molecule comprises a first polynucleotide that encodes a heavy chain and a second nucleic acid molecule comprises a second polynucleotide that encodes a light chain.

[00230] In some such embodiments, the heavy chain and the light chain are expressed from one nucleic acid molecule, or from two separate nucleic acid molecules, as two separate polypeptides. In some embodiments, such as when an antibody is an scFv, a single polynucleotide encodes a single polypeptide comprising both a heavy chain and a light chain linked together.

[00231] In some embodiments, a polynucleotide encoding a heavy chain or light chain of an anti-TREM2 antibody comprises a nucleotide sequence that encodes a leader sequence, which, when translated, is located at the N terminus of the heavy chain or light

chain. As discussed above, the leader sequence may be the native heavy or light chain leader sequence, or may be another heterologous leader sequence.

[00232] Nucleic acid molecules may be constructed using recombinant DNA techniques conventional in the art. In some embodiments, a nucleic acid molecule is an expression vector that is suitable for expression in a selected host cell.

Vectors and Host Cells and Methods of Production

[00233] Vectors comprising polynucleotides that encode anti-TREM2 heavy chains and/or anti-TREM2 light chains are provided. Vectors comprising polynucleotides that encode anti-TREM2 heavy chains and/or anti-TREM2 light chains are also provided. Such vectors include, but are not limited to, DNA vectors, phage vectors, viral vectors, retroviral vectors, etc. In some embodiments, a vector comprises a first polynucleotide sequence encoding a heavy chain and a second polynucleotide sequence encoding a light chain. In some embodiments, the heavy chain and light chain are expressed from the vector as two separate polypeptides. In some embodiments, the heavy chain and light chain are expressed as part of a single polypeptide, such as, for example, when the antibody is an scFv.

[00234] In some embodiments, a first vector comprises a polynucleotide that encodes a heavy chain and a second vector comprises a polynucleotide that encodes a light chain. In some embodiments, the first vector and second vector are transfected into host cells in similar amounts (such as similar molar amounts or similar mass amounts). In some embodiments, a mole- or mass-ratio of between 5:1 and 1:5 of the first vector and the second vector is transfected into host cells. In some embodiments, a mass ratio of between 1:1 and 1:5 for the vector encoding the heavy chain and the vector encoding the light chain is used. In some embodiments, a mass ratio of 1:2 for the vector encoding the heavy chain and the vector encoding the light chain is used.

[00235] In some embodiments, a vector is selected that is optimized for expression of polypeptides in CHO or CHO-derived cells, or in NSO cells. Exemplary such vectors are described, e.g., in Running Deer et al., *Biotechnol. Prog.* 20:880-889 (2004).

[00236] In some embodiments, a vector is chosen for *in vivo* expression of anti-TREM2 heavy chains and/or anti-TREM2 light chains in animals, including humans. In some such embodiments, expression of the polypeptide is under the control of a promoter

that functions in a tissue-specific manner. For example, liver-specific promoters are described, e.g., in PCT Publication No. WO 2006/076288

[00237] For recombinant production of an anti-TREM2 antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

[00238] Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, *see, e.g.*, U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (*See also* Charlton, *Methods in Molecular Biology*, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, describing expression of antibody fragments in *E. coli*.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[00239] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. *See* Gerngross, *Nat. Biotech.* 22:1409-1414 (2004), and Li et al., *Nat. Biotech.* 24:210-215 (2006).

[00240] Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of *Spodoptera frugiperda* cells.

[00241] Plant cell cultures can also be utilized as hosts. *See, e.g.*, US Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants).

[00242] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, *e.g.*, in Graham et al., *J. Gen Virol.* 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, *e.g.*, in Mather, *Biol. Reprod.* 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, *e.g.*, in Mather et al., *Annals N.Y. Acad. Sci.* 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR⁻ CHO cells (Urlaub et al., *Proc. Natl. Acad. Sci. USA* 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, *see, e.g.*, Yazaki and Wu, *Methods in Molecular Biology, Vol. 248* (B.K.C. Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).

[00243] Anti-TREM2 antibodies may be purified by any suitable method. Such methods include, but are not limited to, the use of affinity matrices or hydrophobic interaction chromatography. Suitable affinity ligands include the TREM2 ECD and ligands that bind antibody constant regions. For example, a Protein A, Protein G, Protein A/G, or an antibody affinity column may be used to bind the constant region and to purify an anti-TREM2 antibody. Hydrophobic interactive chromatography, for example, a butyl or phenyl column, may also be suitable for purifying some polypeptides. Many methods of purifying polypeptides are known in the art. In some embodiments, an anti-TREM2 antibody is produced in a cell-free system. Nonlimiting exemplary cell-free systems are described, *e.g.*, in Sitaraman et al., *Methods Mol. Biol.* 498: 229-44 (2009); Spirin, *Trends Biotechnol.* 22: 538-45 (2004); Endo et al., *Biotechnol. Adv.* 21: 695-713 (2003).

Methods of Pharmaceutical Use

[00244] The present disclosure also encompasses methods of using anti-TREM2 antibodies herein, for example, in pharmaceutical treatments. For example, the disclosure encompasses methods of treating a condition associated with TREM2 loss of function in

a subject. The disclosure also encompasses methods of reducing levels of sTREM2 in a subject.

[00245] In some cases, the condition is a neuroinflammatory or neurodegenerative disease. Examples include, for instance, Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Nasu-Hakola disease, Guillain-Barré Syndrome (GBS), lysosomal storage disease, sphingomyelinlipidosis (Neimann-Pick C), mucopolysaccharidosis II/IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, neuro-Behcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, stroke, transverse myelitis, traumatic brain injury, or spinal cord injury. In some cases, the condition is Alzheimer's disease. In some cases, the condition is MS.

[00246] For example, pathological hallmarks of Alzheimer's Disease (AD) include extracellular deposits of beta-amyloid peptides that form amyloid plaques and intracellular deposits of aggregated hyperphosphorylated tau called neurofibrillary tangles. These pathologies are followed by an increase in brain inflammation, including activated astrocytes and microglia, and neurodegeneration. Familial forms of AD may be caused by mutations in presenilin 1/2 and amyloid precursor protein genes. Transgenic mice expressing these human mutations as well as a mutation in the Tau protein show similar age-dependent increases in Abeta pathology, hyperphosphorylated Tau and neurodegeneration. Mutations causing a loss of TREM2 function result in irregular microglial compaction of plaque, elevated neuritic dystrophy surrounding the plaque, elevated abeta-induced tau pathology and neurodegeneration. Without wishing to be bound by theory, enhancing TREM2 activity may enhance microglia activity and facilitate the removal of toxic amyloid-beta peptides, by engulfment or compaction into less toxic amyloid plaques, thus treating AD.

[00247] Multiple sclerosis (MS) is a disease characterized by an autoimmune related demyelination in the CNS. In patients, the disease presents in episodes of symptoms such as ataxia, limb weakness, and optic neuritis among other neurological effects. Current treatments involve immune suppressing agents, and may have limited effectiveness, while no therapy effectively prevents or reverses the disease.

Remyelinating therapies have been proposed as an approach for treating and possibly

reversing MS. Compounds and therapies which promote oligodendrocyte differentiation from progenitors (OPCs) to mature, myelinating oligodendrocytes have been considered a possible route to a remyelinating therapy, as well as treatments which modify glial cells. Specifically, microglia are thought to have a role in clearing myelin debris, promoting new myelin to form. TREM2 loss of function leads to hypomyelinating leukodystrophy, and TREM2 knock-out mice have a profound impairment in remyelination and recovery in animal models of MS. Without wishing to be bound by theory, activation of the TREM2 pathway may accelerate remyelination, thus treating MS.

[00248] In various embodiments, anti-TREM2 antibodies may be administered *in vivo* by various routes, including, but not limited to, oral, intravenous, subcutaneous, parenteral, intranasal, intramuscular, intradermal, topical, transdermal, and intrathecal, or otherwise by implantation or inhalation. The subject compositions may be formulated into preparations in solid, semi-solid, liquid, or gaseous forms; including, but not limited to, tablets, capsules, powders, granules, ointments, solutions, suppositories, enemas, injections, inhalants, and aerosols. A nucleic acid molecule encoding an anti-TREM2 antibody may be administered, either directly or in a vector such as a viral vector. The appropriate formulation and route of administration may be selected according to the intended application.

[00249] In various embodiments, compositions comprising anti-TREM2 antibodies are provided in formulations with a wide variety of pharmaceutically acceptable carriers (see, e.g., Gennaro, *Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus*, 20th ed. (2003); Ansel et al., *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 7th ed., Lippencott Williams and Wilkins (2004); Kibbe et al., *Handbook of Pharmaceutical Excipients*, 3rd ed., Pharmaceutical Press (2000)). Various pharmaceutically acceptable carriers, which include vehicles, adjuvants, and diluents, are available. Moreover, various pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are also available. Non-limiting exemplary carriers include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.

[00250] In various embodiments, compositions comprising anti-TREM2 antibodies may be formulated for injection or infusion, by dissolving, suspending, or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids, or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives. In various embodiments, the compositions may be formulated for inhalation, for example, using pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen, and the like. The compositions may also be formulated, in various embodiments, into sustained release microcapsules, such as with biodegradable or non-biodegradable polymers. A non-limiting exemplary biodegradable formulation includes poly lactic acid-glycolic acid polymer. A non-limiting exemplary non-biodegradable formulation includes a polyglycerin fatty acid ester. Certain methods of making such formulations are described, for example, in EP 1 125 584 A1.

[00251] Pharmaceutical packs and kits comprising one or more containers, each containing one or more doses of an anti-TREM2 antibody are also provided. In some embodiments, a unit dosage is provided wherein the unit dosage contains a predetermined amount of a composition comprising an anti-TREM2 antibody, with or without one or more additional agents. In some embodiments, such a unit dosage is supplied in single-use prefilled syringe for injection. In various embodiments, the composition contained in the unit dosage may comprise saline, sucrose, or the like; a buffer, such as phosphate, or the like; and/or be formulated within a stable and effective pH range. Alternatively, in some embodiments, the composition may be provided as a lyophilized powder that may be reconstituted upon addition of an appropriate liquid, for example, sterile water. In some embodiments, the composition comprises one or more substances that inhibit protein aggregation, including, but not limited to, sucrose and arginine. In some embodiments, a composition of the invention comprises heparin and/or a proteoglycan.

EXAMPLES

Example 1: Preparation of Rat Anti-TREM2 Antibodies

A. Materials and methods

[00252] To generate anti-human TREM2 antibodies, Sprague Dawley rats (Charles River, Hollister, CA) or TREM2 knockout mice (Genentech, South San Francisco) were immunized with various antigen formats: human TREM2 extracellular domain (ECD) protein emulsified with Complete Freund's Adjuvant or Ribi; extracellular vesicles (EV) expressing human full length TREM2; or pDNA encoding full length human TREM2 delivered via gene gun or hydrodynamic tail vein (HTV) injection (Fig. 1).

[00253] Lymph nodes and spleens from immunized animals were harvested and B cells were isolated as follows. For rats, class switched B cells were enriched using a cocktail of biotinylated antibodies (CD4, CD8a, CD11b/c, CD161, HIS48, IgM) from BD Biosciences followed by magnetic separation (Miltenyi Biotec, San Diego, CA) using streptavidin beads. For mice, a pan B cell Isolation kit (Miltenyi Biotec, San Diego, CA) was used to enrich for B cells, followed by magnetic depletion of IgM-positive B cells (biotinylated anti-IgM II/41, BD Biosciences). IgM-depleted B cells were fused with Sp2ab myeloma cells (Abeome, Athens, GA) via electrofusion (Harvard Apparatus, Holliston, MA). After overnight recovery in Clonacell-HY Medium C (StemCell Technologies, Canada), cells were selected in HAT (hypoxanthine-aminopterin-thymidine) (Sigma-Aldrich). Fused hybridomas were then harvested and stained with anti-rat IgG-Alexa 488 (Jackson ImmunoResearch) for rat hybridomas, or anti-mouse IgG FITC (Bethyl Labs) for mouse hybridomas, and fluorescent conjugated human TREM2-Alexa Fluor 643 (Novus Biological). Single IgG⁺/human TREM2⁺ hybridoma cells were sorted into 96-well plates using a FACS Aria III sorter (BD, Franklin Lakes, NJ) and cultured for 7 days. Supernatants were screened by ELISA against human TREM2 antigen, and ELISA-positive clones were scaled-up. Purified IgG (Gamma Bind Plus, GE Healthcare, Pittsburgh, PA) from hybridoma supernatants was screened by FACS for cell surface binding using DOX-inducible human TREM2 expressing 293 cells and functional activity.

B. Results

[00254] A total of 1,650 hybridoma clones specifically bound immobilized human TREM2 in an ELISA format (Fig. 1). Of these, 947 bound in FACS to 293 cells expressing human TREM2 (Fig. 1). The variable regions of immunoglobulin genes of FACS-positive hybridoma clones were then sequenced.

[00255] A total of 229 unique clones were identified, with a majority coming from SD rats immunized with human TREM2 ECD (Fig. 1). The variable region sequences of unique FACS-positive anti-TREM2 clones were used for cloning as mouse IgG2a, effectorless mouse IgG2a with LALAPG (L234A/L235A/P329G, Eu numbering system), chimeric human IgG1, chimeric effectorless human IgG1 LALAPG (L234A/L235A/P329G) and chimeric effectorless human IgG1 N297G by gene synthesis (GeneWiz). Recombinant IgG were transiently expressed in CHO cells and purified by protein A and size exclusion chromatography. Selected clones were also cloned as chimeric human Fab fragments in CHO cells and purified by anti-CH1 affinity chromatography followed by size exclusion chromatography.

Example 2: Epitope Specificity of Anti-TREM2 Clones**A. Materials and methods**

[00256] Antibodies were screened for binding to peptides from the human TREM2 stalk (TREM2 residues 129-174). Peptides with overlapping sequences, ranging from TREM2 residues 129-175, were used to provide coverage for the entire stalk (Fig. 2A). The antibody epitopes were mapped to the stalk region of human TREM2 using enzyme-linked immunosorbent assay (ELISA). Overlapping biotinylated peptides were captured in ELISA plates coated with streptavidin. The binding of antibodies to peptides was detected with an anti-mouse IgG conjugated to horseradish peroxidase.

B. Results

[00257] Several antibody groups that bind to stalk peptide fragments of human TREM2 were found, with three rat anti-human antibodies generally binding to residues 151 to 161 of TREM2: antibodies 3.10C2, 3.18E5, and 3.50G1 in Fig. 2B (binding affinities in nM). In particular, these three antibodies bound to peptides of residues 146-169, 146-161, 149-168 or 151-165 of the hTREM2 stalk at least as well, if not better,

than to a peptide consisting of residues 129-175. These four peptides each encompass the region from residue 151 to residue 161 of the hTREM2 stalk and include the His157-Ser158 cleavage location on the hTREM2 stalk, which is also depicted in Figure 2A. Affinity of those antibodies for all of the other tested peptides was significantly reduced in comparison to affinity for the 129-175 peptide.

Example 3: Affinities of Rat Anti-TREM2 Antibodies

A. Materials and Methods

[00258] Forty-six rat anti-human antibodies were tested for binding affinity to the hTREM2 and cynomolgus TREM2 stalk. Antibody binding affinities for hTREM2 stalk and cynomolgus TREM2 stalk were measured by surface plasmon resonance (SPR) using a Biacore™ T200 apparatus. TREM2 stalk antigens (human or cynomolgus) were immobilized on anti-human IgG1 Fc Biacore™ chips and anti-TREM2 antibody clones were bound to immobilized TREM2 at 37 °C. Binding affinities, K_D (nM) were measured and recorded.

B. Results

[00259] The binding affinities of the forty-six tested antibodies against hTREM2 stalk were measured – the measured K_D values ranged from 1.13 μ M to 0.01 nM. Several antibodies were selected for binding measurements against cynomolgus TREM2 stalk. From the initial group of antibodies tested, five antibodies (3.10C2, 3.50G1, 3.18E5, 3.36F5, and 3.27H7) had particularly low K_D values for both human and cynomolgus TREM2 stalk regions. The binding affinities of antibodies 3.10C2, 3.50G1, 3.18E5, 3.36F5, and 3.27H7 for hTREM2 stalk were 0.24 nM, 0.61 nM, 0.26 nM, 10 nM, and 0.22 nM, respectively. The binding affinities of antibodies 3.10C2, 3.50G1, 3.18E5, 3.36F5, and 3.27H7 for cynomolgus TREM2 stalk were 0.25 nM, 0.57 nM, 0.30 nM, 12 nM, and 0.26 nM, respectively. These clones are independent clones in the same B cell clonal lineage and their sequences of the CDR and variable regions of 3.10C2, 3.50G1, 3.18E5, 3.36F5, and 3.27H7 are shown in Figs. 3A-B. Of those initial five antibodies, four had K_D values below 1 nM, specifically the 3.10C2, 3.50G1, 3.18E5, and 3.27H7. These four antibodies are referred to collectively below as the “3.10C2 group” of antibodies.

Example 4: Deep Sequencing of Rat Antibody Clones and Identification of Clone Para.09

[00260] Further studies were performed with a goal of identifying clones from an immunized rat antibody repertoire deep sequencing dataset that would have similar binding and activity properties as the 3.10C2, 3.50G1, 3.18E5, and 3.27H7 group of antibodies (collectively the “3.10C2 group”) and the 3.36F5 antibody clone, but with even higher affinity for TREM2.

A. Rationale and Introduction

[00261] It has been previously shown that, in rodent antibody repertoires, antibodies specific for an antigen that share the same V_H and V_L germline segments tend to share epitope specificity with a high frequency despite CDR H3 diversity (Hsiao *et al.*, *mAbs* 12:1, 1722541, doi:10.1080/19420862.2020.1722541 (2020)). Therefore, it was possible that additional antibodies from immunized rats with IGHV6-8 and IGKV2S11 germline segments but different CDR H3 sequences might recognize the same epitope as the 3.10C2 group of antibodies if these were TREM2-specific. Mining for clonally independent antibodies that bind antigen in a similar mode has been described for anti-HIV-1 gp120 antibodies from infected donors (Zhu *et al.*, *Proc. Natl. Acad. Sci. USA* 110:E4088-E4097, doi:10.1073/pnas.1306262110 (2013)). However, similar phylogenetic techniques as used for the HIV-1 antibodies were not available in the case of the 3.10C2 group of antibodies. There were at least three reasons for this: (1) the mutational load of the 3.10C2 group of antibodies was relatively low; (2) the important features of the 3.10C2 group of antibodies for antigen binding were not known; and (3) clonally independent antibodies in the same class as the 3.10C2 group were not known. The mining of cross-lineage, cross-donor antibodies by deep sequencing has been described only in the context of highly similar, long CDR H3 sequences that provide substantial sequence information for mining of specific clonal types from the repertoire (Zhu *et al.*, *Proc. Natl. Acad. Sci. USA* 110:E4088-E4097, doi:10.1073/pnas.1306262110 (2013)). In contrast, relatively limited information was available to mine the repertoire for clonally independent antibodies of the 3.10C2 group in this case, including a very short CDR H3 sequence that provides little specific sequence information for mining.

Thus, only V_H and V_L germline segment pairing information was available in the 3.10C2 group for mining, but this information lacked specificity for mining as many clones of different specificities in the repertoire, including specific for antigens other than TREM2, share the same germline segment pairings.

[00262] In addition, clone 3.36F5 has a very similar V_H as the 3.10C2 group of clones, with rat IGHV6-8 germline segment and Kabat CDR H3 sequence LDY (or TGLDY in the IMGT system) but has a different light chain, with germline segment IGKV2U18 (germline segment described in Goldstein *et al.*, *Commun. Biol.* 2:304, doi:10.1038/s42003-019-0551-y (2019)). (See Fig. 3B.) Therefore, light chains with similar IGKV segments may also substitute for the 3.10C2 group of clones to mine deep sequencing datasets. Lastly, because these clones do not descend from the same B cell, clonally independent V_H sequences that share the same specificity as the 3.10C2 group of clones could be derived from any TREM2-immunized rat that expresses the heavy chain IGHV6-8 germline segment and the light chain IGKV2S11, IGKV2U18 or similar germline segments.

[00263] A mining strategy for clones outside clonal lineages in deep sequencing datasets has been recently described (Richardson *et al.*, *mAbs* doi:10.1080/19420862.2020.1869409 (2021)). However, that method, unlike the one described here, relies on amino acid identities including CDR H3 and is limited to sequences with the same CDR H3 length (Richardson *et al.*, 2021). The search strategy used here ignores the CDR H3 sequence entirely, even allowing different CDR H3 lengths, in contradiction to the currently held view that CDR H3 is a major specificity determinant, implicit in the search strategy of Richardson *et al.*, which includes CDR H3 sequence in the identity calculation for clone selection. In addition, the method we describe here, unlike that Richardson *et al.*, does not explicitly require a given level of amino acid identity over any set of residues between clones, only V_H germline segment used, and in fact, seeks to identify clones with widely divergent CDR H3 sequences. Thus, mining by V_H germline segment, ignoring CDR H3 sequence properties, allows, in principle, a wider search for independent clones with the same epitope specificity than the method of Richardson *et al.* while obviating the need for information-rich sequence properties as implemented by Zhu *et al.*

B. Materials and methods

[00264] The V_H repertoire of 3 immunized rats was sequenced by paired-end Illumina sequencing using rat-specific primers for cDNA synthesis and PCR amplification. Briefly, bone marrow and spleen tissues from the same set of pooled 3 rats from which the 3.10C2 group clones were derived by hybridoma using lymph node tissues were used to extract total RNA and used in an RT-PCR step to amplify whole repertoire V_H segments with the rat V_H germline segment primers specific for the sequences encoding the first residues of the framework 1 region and constant region primers specific for rat IgG and IgA isotypes. Amplicons were submitted to paired-end sequencing in an Illumina HiSeq™ instrument. Sequence reads were assembled into full-length V_H sequences and parsed for germline segment and CDR boundaries using Absolve™ as previously described (Goldstein et al., *Commun. Biol.* 2:304, doi:10.1038/s42003-019-0551-y (2019)).

[00265] 29 clones from independent clonotypes with the IGHV6-8 germline segment and diverse CDR H3 sequences were selected and paired to different light chains of the 3.10C2 clonal group for expression of IgG fragments. DNA clones encoding full-length heavy and light chains of the selected variants were transfected into Expi293 cells in 1-ml scale and IgG was purified by protein A chromatography as previously described (Bos et al., *Biotechnol. Bioeng.* 112:1832-4, doi:10.1002/bit.25601 (2015); Luan et al., *Mabs* 10:624-35, doi:10.1080/19420862.2018.1445450 (2018)).

[00266] Clones were tested for binding to TREM2 stalk peptides in an ELISA format. The heavy chain CDR3 of each clone is shown in Fig. 4 (left column).

C. Results

[00267] Of the 29 selected clones, one clone, called Para.09, bound robustly to the human TREM2 stalk peptide (TREM2 residues 129-175) and to a TREM2 peptide fragment from residue 149 to 158 in ELISA when paired to light chains of the 3.10C2 group, similar to a 3.10C2 control (Fig. 4). The CDR H3 sequence of clone Para.09 is 1 residue longer than the CDR H3 of the 3.10C2 group and has a different IGHJ germline segment (IGHJ3 instead of IGHJ2), showing that Para.09 is not a clonal variant of the 3.10C2 group but rather an independently generated clonal lineage in the rat repertoire. In addition, Para.09 has 2 amino acid differences in CDR H3 relative to the 3.10C2 group

when ignoring the insertion (TG-LDY versus *TDILEY* for 3.10C2 and Para.09, respectively, insertion underlined and differences highlighted in boldface and italicized) (Fig. 3B). That is, only half (3 out of 6 in the IMGT system, 2 out of 4 in the Kabat system) of the residues of CDR H3 of Para.09 are the same in similar positions in clone 3.10C2. Highlighting the independent clonal origin of Para.09 relative to the 3.10C2 class of clones, Para.09 has a rat IGHJ3 germline segment in the heavy chain framework 4 region, whereas the 3.10C2 group of clones have a rat IGHJ2 germline segment.

[00268] In addition, CDR H3 sequence alone does not predict TREM2 binders. This is exemplified by clone Para.10, which does not bind TREM2 stalk or peptide fragment 149-158, the epitope bound by antibodies in the 3.10C2 group, when paired to any of the 3.10C2 group or germline light chains (Figs. 3A-B). This clone has a CDR H3 that is 1 residue longer than that in the 3.10C2 group (and the same length as Para.09 CDR H3) while differing from these in no other positions (TGL-DY versus TGLGDY for 3.10C2 and Para.10, respectively, insertion underlined). That is, there are no obvious sequence properties in the Para.09 CDR H3 region that makes this clone an obvious anti-TREM2 candidate. Finally, the frequency of 3.10C2 group and Para.09 lineage sequences in the deep sequencing datasets explains the reason for the unlikely finding of Para.09 clones by hybridoma: whereas there were 8,283 read counts for the 147 unique 3.10C2 group V_H sequences in the deep sequencing dataset, there were only 47 sequence reads for the 4 unique Para.09-related V_H clones. Given that with count frequencies of the 3.10C2 group V_H sequences only 4 of 174 hybridomas were in this group, the likelihood of identifying the low frequency Para.09 clones by hybridoma or similar techniques is presumed to be very low.

Example 5: Binding Affinity of Para.09 Fab Fragments

A. Materials and Methods

[00269] Antibody fragments comprising the heavy chain of clone Para.09 paired with light chains antibodies 3.10C2, 3.18E5, 3.27H7, and 3.50G1 (the “3.10C2 group”) were tested for affinity for human and cynomolgus TREM2 by SPR in a Biacore™ T200 apparatus. Briefly, clone variants were expressed as Fab fragments and purified by anti-CH1 affinity chromatography followed by size exclusion chromatography. TREM2-Fc

antigens were immobilized on anti-human IgG1 Fc Biacore™ chips and soluble Para.09 variant and 3.10C2 clone Fab fragments were bound to immobilized TREM2 at 37°C.

B. Results

[00270] All Para.09 clone variants showed significantly higher affinity than a Fab comprising the heavy and light chain variable regions of antibody 3.10C2, irrespective of light chain used and despite the high similarity of CDR H1 and H2 in Para.09 relative to 3.10C2 (Table 1). This indicates that CDR H3 is critical for the higher binding affinity. The higher affinities were reflected by both higher association (k_a) and lower dissociation (k_d) rates in binding kinetics. Results are shown in Table 1 below.

Table 1: Affinities of Fab fragments of Para.09 clones with different light chains for human and cynomolgus TREM2 at 37°C.						
Fab fragment (Light chain)	Human TREM2			Cynomolgus TREM2		
	K_D (M)	k_a (1/Ms)	k_d (1/s)	K_D (M)	k_a (1/Ms)	k_d (1/s)
3.10C2 (3.10C2)	2.0E-10	8.5E+05	1.7E-04	2.2E-10	6.8E+05	1.5E-04
Para.09 (3.10C2)	3.8E-12	7.1E+06	2.7E-05	1.6E-12	4.8E+06	7.8E-06
Para.09 (3.18E5)	5.0E-12	5.6E+06	2.8E-05	2.4E-12	3.8E+06	8.9E-06
Para.09 (3.27H7)	4.2E-12	6.3E+06	2.7E-05	2.5E-12	4.8E+06	1.2E-05
Para.09 (3.50G1)	1.1E-12	5.1E+06	5.8E-06	2.0E-12	3.9E+06	7.9E-06

Example 6: Mapping of Residues in the TREM2 Stalk that Interact with the Antibodies

A. Materials and methods

[00271] While the epitope of Para.09 was expected to reside in the same region as antibodies in the 3.10C2 group, based on how the antibody was generated, more detailed studies were conducted to assess the importance of individual residues on binding. Epitope mapping of clone Para.09, antibody 3.10C2, and other antibodies of the 3.10C2 group such as 3.50G1, was carried out by testing the binding to synthetic TREM2 peptides with single alanine point mutations of residues 149 to 161 or an alanine to glycine mutation at position 153 (Fig. 5). Binding to the synthetic peptides was tested by biolayer interferometry (BLI) in an Octet Red instrument, immobilizing synthetic peptides in streptavidin-coated sensor tips and binding the peptides to free soluble Fab fragments, to avoid avidity effects that obscure effects on binding. This was necessary

because the effect of single mutations on antibody binding is not apparent due to their high affinity, especially Para.09, which allows robust binding to mutant peptides even with a lowered affinity to the mutants. Thus, reduced binding or faster dissociation of Fab fragments was used as a readout for the impact of the mutations on antibody binding.

B. Results

[00272] The overlapping peptide mapping provided an approximate span for the epitope of 3.10C2, 3.18E5 and 3.50G1 from ranging from residue Glu-151 to the interval between residues Ile-159 to Arg-161, included (Figs. 2A-B). The further mapping of 3.10C2, 3.50G1 and Para.09 by mutational scanning as described in this Example showed that the residues with side-chains important for binding are located within a range from Asp-152 to Ile-159, included, consistent with the binding to overlapping peptides. As shown in Fig. 5, antibodies 3.10C2 and 3.50G1, both in the 3.10C2 group, had similar binding profiles, with the synthetic peptides comprising alanine mutations at positions 152, 154, 157, 158 and 159, spanning the TREM2 cleavage site, each impacting binding of the Fab fragment to the peptide. Specifically, important TREM2 residue side-chains for binding include at least Asp-152, His-157 and Ile-159 for each of 3.10C2, 3.50G1 and Para.09 antibodies. Examination of crystal structures of huPara.09.v2 Q100P and hu3.10C2.v1 Q100P in complex with a peptide with residues 148 to 165 of TREM2 (resolution = 2Å) additionally showed that the main contacts of TREM2 with the two antibodies are mediated by residues Asp-152, His-154, Val-155, Glu-156, His-157 and Ile-159 (residues identified by scanning mutagenesis are underlined). Antibody 3.50G1 was also impacted by the E156A and S160A mutations whereas 3.10C2 was not. Another antibody clone according to the present disclosure, 3.47B1, had a more restricted set of mutations impacting binding to TREM2, with only H157A and I159A having detectable effects on binding (Fig. 5). Antibody Para.09, comprising the Para.09 heavy chain variable region paired with the light chain variable region of antibody 3.27H7 (thus, also called Para.09-L27H7 herein), had a similar pattern as 3.10C2 except that no impact on binding was observed for mutations H154A and S158A (Fig. 5). Further examination of crystal structures showed that 3.10C2 and Para.09 are highly similar in the complex structures, with differences in the angles and number of contacts and the depth of

hydrophobic pockets likely brought about by the different CDR H3 lengths of both antibodies that may account for observed differences.

[00273] Several previously described anti-TREM2 antibodies were also assessed for binding to the stalk region of TREM2 using mutational scanning. For antibodies 14D3 and 14D8 (described, e.g., in WO2018015573), the A153G mutation impacted binding while the D152A and S158A mutations did not (Fig. 5), indicating differences in epitope specificity between the 3.10C2 group and Para.09 relative to the 14D3/14D8 antibodies. The previously described 9F5 and AL2p-31 antibodies (described in WO2017062672 and/or WO201928292), the latter being a humanized and affinity-matured version of 9F5, had a distinct pattern of sensitivity to mutations compared to the 3.10C2, 3.50G1, and Para.09-L27H7 antibodies, extending from residue 150 to residue 156 or 157 just before the cleavage site (Fig. 5). In contrast to 3.10C2, 3.50G1, and Para.09-L27H7, alanine mutations from residues 158 to 161 did not impact the binding of 9F5 and AL2p-31 Fabs. Thus, these previously described antibodies appear distinct in that they do not interact with residues on either side of the cleavage site but rather only with residues found in sTREM2 upon cleavage.

Example 7: Humanization of Antibody 3.10C2

A. Materials and methods

[00274] Antibody 3.10C2 was humanized in VK2 and VH3 frameworks by CDR grafting. Briefly, CDR regions of the rat antibodies were grafted into light chain IGKV2-28*01 and heavy chain IGKV3-73*01 frameworks, the closest human germlines of these antibodies (Figs. 6A-B). CDR regions included, for the light chain, Kabat positions 24-34 (CDR L1), 50-56 (CDR L2) and 89-97 (CDR L3), and, for the heavy chain, Kabat positions 26-35 (CDR H1), 50-65 (CDR H2) and 93-102 (CDR H3). Rat framework residues known as “Vernier” positions and in the domain interface that differed between the rat antibodies and human germlines were added to the CDR grafts to rescue binding to antigen, as it is normally done in CDR graft humanizations (see for example US Patent No. 8,426,147). These included in this case light chain residues 2, 4 and 68 and heavy chain framework residues 24, 48, 49, 76 and 78 (Figs. 6A-B). Variants with different sets

of human and mouse framework residues were expressed as human IgG1 in Expi293 cells and purified by Protein A chromatography.

[00275] The humanized heavy chain variants were tested for affinity by combining the heavy chain variants with the 3.10C2-L1 light chain. These variants were expressed as Fab fragments, purified by protein A chromatography, and tested for affinity for TREM2-Fc coated on a protein A chip with a Biacore™ T200 apparatus.

B. Results

[00276] Purification yields of the humanized variants with the 3.10C2-L1 light chain variant with all rat framework Vernier residues were consistently low (Fig. 7A). Another light chain variant, 3.10C2-L5, with rat framework residue Thr-2 and human residues Met-4 and Gly-68 also had consistently low yields in Expi293 cells (Fig. 7A).

[00277] Two humanized variants, 3.10C2-H3/3.10C2-L1 and 3.10C2-H5/3.10C2-L1 Fab fragments had dissociation rates comparable to the rat 3.10C2 Fab fragment but with significantly reduced association rates (Table 2). The other variants had significantly lower dissociation rates (Table 2).

Table 2: Screening of humanized 3.10C2 heavy chain variants at 37°C			
Rat framework residues	Fab variant	k_a (M⁻¹s⁻¹)	k_d (s⁻¹)
N/A	Rat 3.10C2	7.2E+05	1.9E-04
T24, A49, T76, I78	H3	3.7E+04	5.6E-04
T24, I48, A49, I78	H5	1.7E+05	8.0E-04
T24, A49	H7	1.2E+06	1.8E-02
T24, I78	H2	5.2E+05	5.9E-03
I48, I78	H4	1.2E+06	2.4E-02
T24, A49, I78	H6	2.1E+05	1.3E-03

[00278] The low expression of humanized variants combined with the unexpected low association rate of Fab variants tested in solution suggested a defect in expression and product quality. Replacing Pro-100 (rat residue) with Gln-100 (human residue) in the light chain, a Framework 4 position not typically included in humanization, in light chains L9 and L10 (corresponding to light chains 1 and 5 with Pro-100, respectively)

restored expression of IgG in the context of several humanized heavy chain variants (Fig. 7A)-yet retained an elution peak corresponding to heavy chain (HH) dimers.

[00279] The results with the light chain Pro-100 mutants suggested that the poor expression was due to a defect in the light chain. We confirmed this by expressing hybrid Fab fragments comprised of the 3.10C2-H1 heavy chain (humanized variant with framework positions 24, 48, 49, 76 and 78 as the 3.10C2 rat residues) combined either with the humanized 3.10C2-L1 or rat 3.10C2 light chains. The 3.10C2-H1/3.10C2-L1 humanized variant expressed poorly whereas the hybrid Fab fragment with the 3.10C2-H1 heavy chain and the rat 3.10C2 light chain expressed robustly (Fig. 7B), confirming that the light chain of the humanized 3.10C2 has a defect in expression. We investigated if other light chains of the 3.10C2 antibody group would be better suited for humanization and expression.

[00280] We tested whether a humanized light chain variant of anti-TREM2 antibody 3.27H7, a clonal variant of 3.10C2, paired with the humanized 3.10C2 heavy chains would lead to better expression and product quality of humanized variants. The 3.27H7 light chain was humanized in the same framework as the 3.10C2 light chain, including light chain framework residues 2, 4, 58 and 68 in the grafts (Figs. 8A-B). Humanized 3.10C2 heavy chain variants were combined with humanized 3.27H7 light chain variants to produce human IgG1 with the N297G mutation.

[00281] Four humanized 3.10C2/3.27H7 hybrid variants were expressed and purified. The 3.10C2-H1/3.27H7-L1 clone expressed well, at 246 mg/L in transiently transfected CHO cells, after purification by protein A chromatography and showed a monodisperse peak with 99.5% of the material.

[00282] The variants 3.10C2-H3/3.27H7-L1 IgG and 3.10C2-H3/3.27H7-L6 IgG also expressed well in CHO cells, at 364 and 408 mg/L. However, some heavy chain – heavy chain (HH) dimer was detectable by mass spectrometry in the purified samples.

[00283] Variant 3.10C2-H1/3.27H7-L6 IgG expressed well in CHO cells, at 356 mg/L, showed a monodisperse peak by size exclusion chromatography and no detectable HH dimer by mass spectrometry under non-reducing conditions. This variant was re-named as h3.10C2.v1 and its sequences are shown in Figs. 9A-B.

[00284] Affinity of h3.10C2.v1 (Figs. 9A-B) for human and cynomolgus TREM2 was determined by SPR in a Biacore™ T200 apparatus in two formats, both at 37°C. In one format TREM2-Fc was immobilized on protein A chips and soluble anti-TREM2 Fab fragments used as ligands. In the second format, anti-TREM2 IgG was immobilized on anti-CH1 Biacore™ chips and used soluble monomeric TREM2 as ligand. The affinity of humanized antibody h3.10C2.v1 for hTREM2 ranged from 390 to 420 pM whereas the affinity for cynomolgus monkey TREM2 was a similar 430 pM (Table 3). Thus, the humanized anti-TREM2 h3.10C2.v1 was found to express well and retain high affinity for both human and cynomolgus TREM2.

Example 8: Affinity Maturation of Antibody 3.10C2 Heavy Chain by Saturation Mutagenesis

A. Materials and methods

[00285] A library of mutants based on the 3.10C2 antibody heavy chain was constructed by overlap recombinant PCR with the goal of further improving antibody affinity. The DNA fragments encoding heavy and light chains were mixed, one mix for each mutant, and used to transfect Expi293 cells in 1 ml scale and purified by protein A chromatography as previously described (Bos et al., *Biotechnol. Bioeng.* (2015); Luan et al., *Mabs* (2018)).

[00286] The resulting library consists of individual IgG clones, each with one mutation per molecule in the heavy chain variable regions. Clones were screened for off-rate (dissociation rate) by SPR in a Biacore™ 8K instrument using anti-human Fab chips to capture mutant IgGs and soluble monomeric TREM2 as ligand.

B. Results

[00287] Only 2 of several hundred mutant clones generated, comprising mutations T93E and T93H, had a significant but relatively small (1.4 to 2-fold) reduction in off-rate relative to the parental 3.10C2 clone (Fig. 10). Interestingly, mutations G94D and D101E, the respective CDR H3 residues of Para.09 relative to the same positions in antibody 3.10C2, either diminished the affinity (G94D) or abolished (D101E) binding of 3.10C2 for TREM2 (Fig. 10), indicating that the CDR H3 of Para.09 is not structurally equivalent to the CDR H3 of 3.10C2. In addition, the scanning mutagenesis (Fig. 10) indicated that

clone 3.10C2 affinity was nearly at a maximum and cannot be easily improved by mutagenesis of heavy chain CDRs. Thus, the substantially higher affinity achieved with clone Para.09 against the same epitope as the 3.10C2 group required substantial changes in CDR H3, including an insertion, that were not easily accessible by traditional affinity optimization methods which explore variations of the same structural CDR H3 sequence and but not structurally distinct solutions in CDR H3.

Example 9: Humanization of Antibody Para.09

A. Materials and methods

[00288] Antibody Para.09, comprising the Para.09 heavy chain variable region and the 3.27H7 light chain variable region (also called Para.09-27H7) was humanized in VK2 and VH3 frameworks by CDR grafting using the same frameworks as for antibody 3.10C2. Briefly, CDR regions of the rat Para.09 VH sequence were grafted into the heavy chain IGKV3-73*01 framework, the closest human germlines of this antibody (Fig. 9B). The light chain for Para.09 humanization used the same humanized light chain variants of antibody 3.27H7 described above (Fig. 9A). Rat framework residues known as “Vernier” positions and in the domain interface that differed between the rat antibodies and human germlines were added to the CDR grafts to rescue binding to antigen, as described in Example 7 for the 3.10C2 antibody humanization. A variant called Para.09-H1/3.27H7-L1, with all the framework Vernier positions was expressed as a human IgG1 with the N297G mutation in CHO cells.

B. Results

[00289] Purification yield of the humanized Para.09-H1/3.27H7-L1 was low compared to the chimeric antibodies with either mouse IgG2a or human IgG1 constant regions (Fig. 11). However, expression of humanized Para.09-H1 heavy chain paired to 3.27H7-L6, the same light chain as in h3.10C2.v1, in CHO cells yielded high levels of IgG (314 mg/L of culture), no HH dimers and relatively few other side-products of IgG assembly. Further analysis of heavy chain variants with fewer rat framework residues led to the identification of Para.09-H5 as the variant with the fewest rat residues that, when combined to light chain 3.27H7-L6, yielded high levels of IgG expression in CHO cells (544 mg/L of culture) without detectable HH dimers. This variant was called hPara.09.v2,

and its sequences are shown in Figs. 12A-B. The monovalent affinities of this variant, re-named hPara.09.v2 (Figs. 12A-B), for TREM2, determined as described above for the h3.10C2.v1 IgG and Fab fragments, ranged from 11 to 21 pM for hTREM2 and 18 to 22 pM for cynomolgus monkey TREM2 (Table 3).

Table 3: Binding affinities of hPara.09.v2 and h3.10C2.v1 for human TREM2 and cynomolgus TREM2

	Ab type	Ab Format	Human TREM2			Cynomolgus TREM2		
			K_D (pM)	k_a (1/Ms)	k_d (1/s)	K_D (pM)	k_a (1/Ms)	k_d (1/s)
hPara.09.v2	Humanized	Fab	21	3.0×10^6	6.1×10^{-5}	22	2.9×10^6	6.3×10^{-5}
h3.10C2.v1			390	1.5×10^6	5.7×10^{-4}	430	1.4×10^6	6.2×10^{-4}
hPara.09.v2		IgG	16	2.3×10^6	3.5×10^{-5}			
h3.10C2.v1			420	8.4×10^5	3.5×10^{-4}			
Para.09	Rat	Fab	15	2.3×10^6	3.5×10^{-5}	18	2.3×10^6	4.1×10^{-5}
3.10C2			190	9.1×10^5	1.8×10^{-4}	220	9.1×10^5	2.0×10^{-4}
Para.09		IgG	11	2.0×10^6	2.1×10^{-5}			
3.10C2			120	7.8×10^5	9.6×10^{-5}			

[00290] In summary, TREM2 binding epitopes of a series of rat anti-TREM2 antibodies were determined and binding affinities were measured. See Examples 1-6. Candidate antibodies were engineered for improved TREM2 affinity and expression yield, and humanized. See Examples 7-9. Antibodies identified included: (1) rat Para.09 (which comprises a 3.27H7 light chain and a Para.09 heavy chain; i.e., Para.09-L27H7; sequences are shown in Figs. 3A-B), (2) humanized Para.09.v2 (i.e., hPara.09.v2; sequences are shown in Figs. 12A-B), (3) rat 3.10C2 (sequences are shown in Figs. 6A-B), (4) humanized 3.10C2.v1 (i.e., h3.10C2.v1; sequences are shown in Figs. 9A-B).

Example 10: Determination of Off-target Binding

A. Materials and methods

[00291] The potential for the rat and humanized antibodies to bind to “off-targets” (i.e., targets other than the intended TREM2) was tested with an ELISA assay using baculovirus particles as antigen (BV ELISA; Hötzel et al., *Landes Bioscience* dx.doi.org/10.4161/mabs.22189 (2012)). Normalization was performed by dividing the ELISA absorbance reading of antibody samples by the absorbance reading of a blank

well without test antibody as previously described. (*Id.*) Control antibodies previously shown to have high (score > 5), medium (score around 5) and low (non-detectable, score below 1) off-target binding in this assay were tested in parallel. Four antibodies were tested, chimeric clones with rat variable regions and human IgG1 constant regions and humanized variants h3.10C2.v1 and hPara.09.v2 with human IgG1 constant regions with a N297G mutation.

B. Results

[00292] Chimeric rat antibodies with human IgG1 constant regions had very low reactivity in the assay, with scores below 1 (Fig. 15). Similarly, normalized BV ELISA scores of humanized anti-TREM2 antibodies h3.10C2.v1 and hPara.09.v2, both as human IgG1 N297G, were below 1 (Fig. 15), indicating no detectable propensity for off-target binding. Thus, the humanized h3.10C2.v1 and hPara.09.v2 antibodies have high affinity of binding for TREM2, in the mid to low-picomolar range, while retaining favorable, low or non-detectable off-target binding potential.

Example 11: Determination of Binding to Soluble TREM2

A. Materials and methods

[00293] A human TREM2 ELISA assay was used to measure binding of more than forty antibodies to soluble TREM2 (sTREM2) as follows: test anti-hTREM2 antibodies were coated onto plate wells as capture reagents and a biotinylated IgV-reactive monoclonal antibody, 3.17A9, was used as the detection reagent. Antibody 1.16B8 was used as a control antibody to establish the standard for sTREM2 binding. Plates coated with test or control antibody were incubated with diluted culture supernatant from bone marrow-derived macrophage (BMDM) cultures from transgenic mice expressing hTREM2. sTREM2 is constitutively produced by the BMDM cultures expressing hTREM2 and shed into the culture supernatant. Measurements were recorded at 450 nm for detection and 570 nm for background. The 3.17A9/1.16B8 antibody pair was selected over reagents provided in the R&D Systems kit as the commercial reagents were not compatible with sTREM2 detection of some of the antibodies tested. Control antibody 1.16B8 light chain sequence is shown in SEQ ID NO: 170, and its heavy chain sequence

is shown in SEQ ID NO: 171. Detection antibody 3.17A9 light chain sequence is shown in SEQ ID NO: 168, and heavy chain sequence shown in SEQ ID No: 169.

B. Results

[00294] Fig. 16 shows values for sTREM2 binding for antibodies. Binding was normalized to the control (CTL) antibody 1.16B8, which was set to 1. Normalized sTREM2 binding is shown for: rat Para.09 – LC 3.27H7 mIgG2a LALAPG (Para09), rat 3.10C2 mIgG2a LALAPG (3.10C2), rat 3.18E5 mIgG2a LALAPG (3.18E5), rat 3.50G1 mIgG2a LALAPG (3.50G1), rat 3.27H7 mIgG2a LALAPG (3.27H7), rat 3.36F5 mIgG2a LALAPG (3.36F5), A.9F5, AL2p-12, AL2p-31, AL2p-58, BM.3D3, BM.42E8, BM.RS9, BM.14D3, and BM.14D8. The tested antibodies rat Para.09 – LC 3.27H7 mIgG2a LALAPG (Para09), rat 3.10C2 mIgG2a LALAPG (3.10C2), rat 3.18E5 mIgG2a LALAPG (3.18E5), rat 3.50G1 mIgG2a LALAPG (3.50G1), rat 3.27H7 mIgG2a LALAPG (3.27H7), rat 3.36F5 mIgG2a LALAPG (3.36F5) comprise a mIgG2a LALAPG heavy chain constant region. Of the antibodies tested, only 3.10C2, Para.09 and clonally related antibodies 3.18E5, 3.50G1, 3.27H7, and 3.36F5 did not show any binding to sTREM2 (see Fig. 16, showing normalized sTREM2 binding of near zero for those antibodies in contrast to the 1.116B8 control). The humanized antibody Para.09.v2 antibody with a hIgG1 N297G constant region was also tested for sTREM2 binding and, like rat Para.09 with mIgG2 LALAPG, did not show any binding to sTREM2.

[00295] Additionally, nine antibodies previously described in literature as binding to stalk hTREM2 were tested in this experiment, including A.9F5 (also called 9F5), AL2p-12, AL2p-31, AL2p-58, BM.3D3, BM.42E8, BM.RS9, BM.14D3, and BM.14D8, described, for example, in WO2018015573, WO201955841, WO2017062672 and/or WO201928292. Unlike the 3.10C2, Para.09, 3.18E5, 3.50G1, 3.27H7, and 3.36F5 antibodies, the nine previously described antibodies tested here bound to sTREM2 in the assay (see Fig. 16, showing normalized sTREM2 binding of 0.5 to 1.5 for those antibodies). This result is surprising when considered together with the binding profiles of the antibodies tested, as the tested antibodies have epitopes in the TREM2 stalk region, and the result may reflect the unique epitopes of the 3.10C2, Para.09, 3.18E5, 3.50G1, 3.27H7, and 3.36F5 antibodies in comparison to the previously described antibodies. (See, e.g., Fig. 5.)

[00296] The peptide mapping and mutational scanning results described in earlier Examples may offer a basis for the differences in binding to soluble TREM2 observed between 3.10C2/Para.09/3.50G1 and antibody 9F5 and its derivatives. The epitope for Para.09, 3.10C2 and 3.50G1 straddles the ADAM10 cleavage site between His-157 and Ser-158, with important contact sites on both sides of the cleavage site as determined by mutational scanning and structural analysis. (See Fig. 5.) In contrast, as noted in Example 6 above, the epitope for A.9F5 (9F9 in Fig. 5) and its derivative AL2p-31 is located entirely on the N-terminal side of the TREM2 cleavage site. (See Fig. 5.) This difference in TREM2 contact points may account for the observed difference in binding to sTREM2 resulting in these previously described antibodies binding to soluble TREM2.

[00297] Surprisingly, however, antibodies 14D3 and 14D8 have a pattern of binding to alanine mutant peptides that appears similar to antibodies 3.10C2, 3.50G1 and Para.09 (Fig. 5) but still show robust binding to sTREM2, in a monovalent and physiologically relevant manner (Fig. 16). This was very surprising as the 3.10C2 and Para.09, with their very high affinities, might be expected to retain binding for the partial epitope in soluble TREM2 while the lower affinity (3 to 5 nM) 14D3 and 14D8 antibodies might more easily lose binding to these partial epitopes. This shows that the binding profile described in earlier Examples may not account for all interactions between anti-TREM2 antibodies and TREM2 necessary for anti-TREM2 antibodies to discriminate between full-length, membrane-bound TREM2 and soluble TREM2 forms, further establishing the uniqueness of the antibodies of the present disclosure.

[00298] Thus, as these results show, antibodies having the binding profile of 3.10C2, Para.09, 3.18E5, and 3.50G1 antibodies are unique. These antibodies effectively bind to TREM2 stalk region while not binding to soluble TREM2. The specificity of these antibodies may have several potential benefits, including allowing soluble TREM2 in the periphery and brain after *in vivo* dosing to remain free of the dosed antibodies. The high affinity of these antibodies for their epitope spanning the cleavage site of intact TREM2 and their lack of binding to cleaved, soluble TREM2 could be beneficial *in vivo* in any of several ways – ranging from allowing more of the dosed anti-TREM2 antibody to reach the desired target of TREM2 on the surface of cells, to reducing the amount of sTREM2 that is shed from the cell surface.

Example 12: Anti-TREM2 Antibodies Induce TREM2-dependent and NFAT-driven Luciferase Activities

A. Materials and methods

[00299] Jurkat-based luciferase reporter cell lines were used to test the ability of full length anti-hTREM2 antibodies to induce human TREM2-related signaling. TREM2 activation and its interaction at the cellular membrane with DAP12 (DNAX-activating protein of 12 kiloDaltons) may induce phosphorylation of Syk kinase (spleen tyrosine kinase, whose phosphorylated form is designated pSYK or phospho-SYK) and other cell signaling events in the cytoplasm, ultimately resulting in activation of nuclear factor of activated T cells (NFAT)-controlled gene expression. Thus, both phosphorylation of Syk kinase and NFAT-controlled gene expression may be used to determine the effect of antibodies on TREM2 activity and whether the antibodies agonize TREM2. In this assay, Jurkat cells were engineered to express a luciferase reporter under the control of an NFAT response element, and also to co-express human TREM2 and DAP12, in order to test whether addition of antibodies would induce expression of the reporter gene due to activation of NFAT.

[00300] A parental Jurkat luciferase reporter cell line (human T lymphocyte; Signosis) was engineered to stably express firefly luciferase reporter gene under the control of NFAT response element. The parental Jurkat luciferase reporter cell line was then transduced using a MSCV-based retroviral vector to co-express TREM2 (wildtype or mutants) and DAP12, to generate Jurkat-NFAT luciferase TREM2 reporter cell lines.

[00301] Jurkat reporter assays were used to test for agonistic effects of anti-human TREM2 antibodies compared to an isotype control antibody. Each antibody and isotype control were added in soluble form at 10 ug/mL to the Jurkat-NFAT luciferase reporter cells and incubated at 37 °C for 24 hours. Luciferase activity was measured by adding Bright-Glo™ substrate (Promega Catalog No. E2610). After a 3-minute incubation at room temperature, luminescence measurements were recorded using the M1000 program on Tecan plate reader.

[00302] To determine time-dependent reporter activities of anti-human TREM2 antibodies, Jurkat-NFAT luciferase reporter cells were cultured in the presence of anti-

TREM2 antibodies each at 10 µg/mL for 3, 6 or 24 hours prior to the addition of Bright-Glo™ substrate for measurement of luciferase activities.

B. Results

[00303] Fifty-six rat anti-human TREM2 antibodies (in the form of recombinant mIgG2a), identified in the screens of Example 1, were screened in a Jurkat reporter assay. Out of these 56, only 8 antibodies, including the four “3.10C2 group” antibodies: 3.10C2, 3.18E5, 3.27H7 and 3.50G1, induced luciferase reporter activities in Luc RLU (Luciferase relative light units) compared with isotype control, suggesting that these anti-TREM2 antibodies can mimic natural ligand activities in the Jurkat-NFAT luciferase reporter cells (Fig. 17). Of those 8 antibodies, the four “3.10C2 group” antibodies: 3.10C2, 3.18E5, 3.27H7 and 3.50G1, demonstrated comparably strong agonism while four other tested antibodies showed only modest agonistic activities (Fig. 17). The remaining 48 tested antibodies had Luc RLU values that were less than the isotype control. These data indicate that the 3.10C2 group antibodies, which bind specifically to a particular epitope at positions 151-165 of the TREM2 stalk have relatively strong agonist activity, in comparison to antibodies binding outside of that region of the stalk.

[00304] The same 56 antibodies were also tested in a time course assay using Jurkat-NFAT reporter cells. Of the tested antibodies, the “3.10C2 group” antibodies 3.10C2, 3.18E5, 3.27H7, and 3.50G1 also demonstrated strong time-dependent agonist activity (Luc RLU fold change) compared with isotype.

Example 13: Anti-TREM2 Antibodies in mIgG2a LALAPG or hIgG1 N297G

Format Induce Luciferase Activity in Jurkat Reporter Cells

A. Materials and methods

[00305] The rat anti-human antibodies Para.09 and 3.10C2 were engineered to comprise a murine IgG2a LALAPG Fc region (to reduce effector function of the Fc) and further tested for agonist activity in Jurkat-NFAT luciferase reporter cells. The humanized antibodies Para.09.v2 and 3.10C2 were similarly engineered in human IgG1 N297G format to reduce effector function and were also tested. Jurkat-based luciferase reporter assays were performed as described above in Example 12. To test dose-dependent activities of anti-human TREM2 antibodies, Jurkat-NFAT luciferase reporter

cells were cultured in the presence of serially diluted anti-human TREM2 antibodies for 24 hours.

[00306] Anti-hTREM2 antibody activity against common hTREM2 mutations was also assessed: Jurkat-NFAT luciferase reporter cell lines were constructed that express three hTREM2 mutants: R47H, R62H, and H157Y, respectively. Presence of these mutants may correlate with increased risk of Alzheimer's disease.

[00307] Supernatant samples were collected for TREM2 shedding analysis prior to the addition of Bright-Glo™ substrate (Promega Catalog No. E2610) for the measurement of luciferase-driven luminescence.

B. Results

[00308] Both rat and humanized antibodies demonstrated agonist activities at 24 hours as shown by induction of luciferase reporter activity. See Fig. 18A (rat antibodies) and Fig. 18B (humanized antibodies). These data further demonstrate that both rat and humanized Para.09 and 3.10C2 antibodies have agonist activities, and that such activities are not related to antibody effector functions.

[00309] The four "3.10C2 group" antibodies (in mIgG2a LALAPG format) 3.10C2, 3.18E5, 3.27H7 and 3.50G1 also induced luciferase activity in the Jurkat-NFAT reporter cells engineered to express three hTREM2 mutants, R47H (Fig. 19A), R62H (Fig. 19B), and H157Y (Fig. 19C), respectively. These results demonstrate that the anti-hTREM2 antibodies have agonist activity against both wild-type hTREM2 and against these hTREM2 mutations, and therefore, that they may be useful in patients with these mutant TREM2 proteins.

Example 14: Anti-TREM2 Antibodies in mIgG2a LALAPG or hIgG1 N297G

Format Block TREM2 Shedding in Jurkat Reporter Cells

A. Materials and methods

[00310] TREM2 shedding, releasing soluble TREM2, may occur in Alzheimer's disease patients decades before disease onset. Soluble TREM2 binding to amyloid plaques may in turn interrupt neuron-protective plaque compaction by microglia. Thus, both rat and humanized Para.09 and 3.10C2 antibodies herein were tested in the Jurkat-NFAT luciferase reporter cells described in Example 12 and 13 to determine if they can

also inhibit TREM2 shedding. To determine TREM2 shedding inhibition activities of soluble anti-human TREM2 antibodies in Jurkat-NFAT luciferase reporter cells, supernatants were harvested from the reporter assay plates at 24 hours and sTREM2 was measured using ELISA assay as described above in Example 11.

[00311] The activities of humanized Para.09 variants, hPara.09 v2, hPara.09 v2.Q100P/V104L and hPara.09.v2 Q100P, in the Jurkat-NFAT reporter and TREM2 shedding inhibition assays were next compared to the activities of the humanized 3.10C2.v1 antibody. Jurkat-NFAT luciferase reporter cells were cultured in the presence of serially diluted humanized antibodies for 24 hours, and tested as described above.

B. Results

[00312] In the ELISA assay, Para.09 in mIgG2a LALAPG form demonstrated strongest TREM2 shedding inhibition activity compared to other tested antibodies in the same format. The humanized antibody hPara.09.v2 in hIgG1 N297G format demonstrated stronger TREM2 shedding inhibition than the humanized antibody h3.10C2 v1 in hIgG1 N297G format (See Fig. 20B). Inhibition of sTREM2 shedding by the rat antibodies is shown in contrast to another antibody (1.20A2 mIgG2a LALAPG), which shows little shedding inhibition in the assay. (See Fig. 20A).

[00313] Variants hPara.09 v2.Q100P/V104L and hPara.09.v2 Q100P, are identical to hPara.09v2 except for the Q100P/V104L and Q100P mutations, respectively (Figs. 13A-B). As shown in Figs. 20C-D, hPara.09 v2, hPara.09 v2.Q100P/V104L and hPara.09.v2 Q100P in hIgG1 N297G format demonstrated comparable activities. In addition, consistent with results shown in Example 13, the activities of those three Para.09 humanized antibodies were higher than that of the humanized 3.10C2.v1 antibody.

[00314] The measured potency of TREM2 antibodies in the Jurkat NFAT luciferase reporter cells (EC₅₀) and TREM2 shedding inhibition (IC₅₀) are summarized below in Table 4.

Table 4: Potency of TREM2 antibodies (EC₅₀) and TREM2 shedding inhibition (IC₅₀)

Anti-human TREM2 Abs	EC ₅₀ , ng/mL	IC ₅₀ , ng/mL
hPara.09.v2	24.52	161.50
hPara.09.v2 Q100P/V104L	23.23	113.90
hPara.09.v2 Q100P	17.80	123.40
3.10C2.v1 hIgG1 N297G	76.00	975.00
Rat para.09 mIgG2a LALAPG	40.00	NA
Rat 3.10C2 mIgG1a LALAPG	279.60	NA
Rat 1.20A2 mIgG2a LALAPG	NA	7915.00

(NA = not available)

Example 15: Soluble Anti-TREM2 Antibodies Block TREM2 Shedding in Human iPSC-derived Microglia

A. Materials and methods

[00315] Since TREM2 is expressed *in vivo* in microglia cells, inhibition of TREM2 shedding was next tested in human iPSC-derived microglia cells. To determine TREM2 shedding inhibition by anti-human TREM2 antibodies in human iPSC-derived microglia (Cellular Dynamics), the iPSC-microglia were cultured with maintenance media (Cellular Dynamics) in the presence of soluble anti-TREM2 mIgG2a LALAPG antibodies at 10ug/mL. ADAM10 protease inhibitor GI254023X (Sigma-Aldrich) was used as a positive control for blocking sTREM2 cleavage and shedding. The culture supernatant samples were harvested at day 3 for ELISA assay using the R&D assay kit.

B. Results

[00316] Rat anti-human TREM2 antibodies 3.10C2, 3.18E5, 3.27H7 and 3.50G1 reduced sTREM2 at comparable levels to GI254023X, a potent and selective metalloproteinase inhibitor for the α -secretase ADAM10, while previously described antibody 9F5 inhibited TREM2 shedding to lesser extent (Fig. 21). These data suggest that TREM2 shedding is blocked by the 3.10C2, 3.18E5, 3.27H7 and 3.50G1 agonistic anti-TREM2 antibodies and cell membrane-bound TREM2 may also be stabilized by these same antibodies. These data also confirm the data from the Jurkat-NFAT cells in a cell type that expresses TREM2 *in vivo*.

Example 16: Phospho-tyrosine and pSYK Activation Following TREM2 Stimulation in Primary Human Monocyte-derived Macrophages (MDMs)

[00317] As noted above, binding of TREM2 to DAP12 at the cell membrane leads to activation of TREM2-related cell signaling in part through the phosphorylation of Syk kinase (SYK), to form pSYK. Thus, the effects of anti-TREM2 antibodies on SYK phosphorylation, as well as on pan tyrosine phosphorylation, were determined in a human macrophage model system, in order to further assess agonist activity of the antibodies. To ensure that changes in phosphorylation are due to TREM2 activity, tests were also run in the context of TREM2 deletion. Antibodies were tested in human IgG1 N297G format to reduce antibody effector activity.

A. Materials and methods

1. Isolation and culture of human monocyte derived macrophages

[00318] Human peripheral blood mononuclear cells (PBMCs) were isolated from consenting healthy donor buffy coats using Ficoll® Paque Plus (Sigma Aldrich). Next, CD14⁺C16⁻ monocytes were isolated from PBMCs using the classical monocyte isolation kit (Miltenyi Biotec) per kit instructions. Flow through was collected and spun down at 300 x g for 10 min, then resuspended in growth medium. Cells were diluted to a final concentration of 10 % DMSO, frozen, and stored in liquid nitrogen for future use. For each experiment, aliquots from multiple donors were thawed and monocyte derived macrophages (hMDMs) were differentiated in culture for 5 to 7 days in high glucose DMEM containing 10% heat-inactivated serum and 50 ng/mL recombinant human M-CSF (Peprotech) with partial media changes every other day.

[00319] To form guide RNA duplexes targeting TREM2, Alt-R CRISPR-Cas9 crRNA (Integrated DNA Technologies) based on sequences TTGTAGATTCCGCAGCGTAA or AATGGTGAGAGTGCCACCCA or TACCAGTGCCAGAGCCTCCA (SEQ ID Nos: 173, 174, and 175, respectively) were dissolved to 100 uM in Duplex buffer (Integrated DNA Technologies) and mixed at a 1 to 1 molar ratio with Alt-R tracrRNA dissolved at 100 uM in Duplex buffer. The crRNA and tracrRNA mixtures were hybridized by incubation at 95°C for 5 min, followed by 15 min incubation at room temperature and storage at -20°C. Ribonucleoprotein complexes

were formed by mixing crRNA/tracrRNA duplexes with 5 µg Alt-RS.p. HiFi Cas9 Nuclease V3 (Integrated DNA Technologies) at a 3 to 1 molar ratio and incubating at room temperature for at least 15 min. The two ribonucleoprotein complexes for the two separate guide RNA sequences were combined at a 1 to 1 ratio, and both guide RNAs were transfected into hMDMs.

[00320] To generate TREM2-deficient cell pools, hMDMs were collected 16-24 hours after thawing, centrifuged 500 x g for 5 min, and resuspended in P3 primary nucleofection solution (Lonza) to a concentration of $2-4 \times 10^6$ cells per 20 µL reaction. Each 20 µL reaction was mixed with a total of 10 µg of Cas9 complexed with the three TREM2-targeting guide RNAs and immediately transferred to supplied nucleofector cassette strips (Lonza). The strip was loaded into the Lonza 4D-nucleofector (4D-Nucleofector Core Unit: Lonza, AAF-1002B; 4D Nucleofector X Unit: AAF-1002X) and electroporated using the CM-137 pulse program. Cells were recovered, diluted into growth medium to 10^6 cells per mL and plated for 5-7 days. Efficient knockout (>90%) was confirmed by TIDE analysis and FACS.

2. Measurement of pan tyrosine and SYK phosphorylation

[00321] For all experiments, hMDMs were switched into low glucose media and deprived of M-CSF and serum for 24 hours prior to addition of anti-TREM2 antibodies. hMDMs were incubated for 10 or 20 minutes at 37 °C with antibodies. Following antibody stimulation, culture media was removed and cells were lysed in RIPA buffer containing cOmplete mini protease inhibitor (Roche) and phosSTOP (Roche) phosphatase inhibitors. After protein lysates were collected, samples were used to measure both pan phospho-Tyrosine (pY) and phospho-SYK activity. For pY expression, samples were run on a Western blot and membranes were incubated overnight at 4°C with P-Y-1000 (1:1000, Cell Signaling Technology) and anti-beta actin (1:1000, Sigma Aldrich). Secondary fluorescent antibodies were added the next day for 1 hour in the dark at room temp and imaged using the Odyssey infrared imaging platform (1:10,000, LI-COR). Band intensities were calculated in ImageStudio Lite (LI-COR) and all samples were normalized to loading controls before normalization to isotype control.

[00322] Total SYK and phospho-SYK were measured using the respective AlphaLISA® SureFire® Ultra™ assays (PerkinElmer) per kit instructions. Briefly, protein lysates were incubated with Acceptor beads for 1 hour followed by a subsequent 1-hour incubation with Streptavidin-coated donor beads in the dark. After which, plates were imaged using the compatible Synergy™ Neo2 plate reader (BioTek). For phospho-SYK quantifications, samples first were normalized to total SYK then to isotype control antibody.

B. Results

[00323] In Fig. 22A, pan phospho-tyrosine activity was assessed on Western blots. Relative to isotype control, hPara.09.v2 N297G treatment demonstrated a significant increase in pY at 20 minutes after stimulation. In Fig. 22B, phospho-SYK levels were measured with the alphaLISA® assay kit, and all samples were normalized to total SYK levels. Significant increases in pSYK were observed from both hPara09.v2 and h3.10C2.v1 antibodies at 20 minutes. No increase in pSYK was observed in TREM2-deficient cells (cells transfected with a Cas9 ribonucleoprotein complex including guide RNA targeting TREM2, or gTREM2) 20 min after antibody treatment. Mean $\pm$ SEM, n=6 from 5 separate biological specimens, or n = 2 from 2 separate biological specimens for gTREM2 **p<0.01 ***p<0.001 (one-way ANOVA with Dunnett's test comparing to isotype control condition). As shown in Fig. 22C, stimulation with humanized antibodies hPara.09.v2 N297G and hPara.09.v2 Q100P/V104L N297G increased phospho-SYK levels in primary hMDM.

Example 17: Anti-TREM2 Antibody Para.09 Promotes Human iPSC Microglia Survival

[00324] As TREM2 is expressed in the brain in microglia cells, further experiments were performed in a human iPSC-derived microglia cell model system to determine effects of antibodies on microglia survival, sTREM2 shedding, SYK phosphorylation, and formation and compaction of A β plaques.

A. Materials and methods

1. iPSC microglia survival assay (EC₅₀ experiments)

i. Antibody coating

[00325] For coating of 384 well plates (Cell Carrier Ultra, Perkin Elmer), stock solutions of 1 mg/mL of the N297G and LALAPG variants of h3.10C2.v1 and hPara.09.v2.N297G were prepared in cold DMEM/F12 (Gibco). Stock solutions were mixed and used for serial dilutions in 96 well reagent master blocks (Greiner Bio-One). Coating solutions were transferred to 384 well plates by repeat dispensing (n = 4 to 6) of 25 µL/well using a pipetting robot (Assist Plus, Integra) equipped with an automatic multichannel pipette (Voyager 125 µL, Integra). To minimize evaporation and edge effects, outer wells were filled with DPBS (Sigma-Aldrich). After brief centrifugation, plates were incubated over night at 37°C, 5% CO₂, and 95% humidity.

ii. iPSC microglia culture media preparation

[00326] Base media used was basal medium (BrainPhys Basal, StemCell Technologies) containing B27 supplement (Gibco), N2 supplement (Gibco), 1 mM Creatin (Sigma), 200 nM L-ascorbic acid 2-phosphate sesquimagnesium (Sigma), 20 ng/mL recombinant BDNF (Peprotech), 20 ng/mL recombinant human GDNF (Peprotech), 1 µg/mL laminin mouse protein (Gibco), 0.5 mM Glutamax™ (Gibco), 50 U/mL Penicillin-Streptomycin (Gibco), 0.1 mg/mL Normocin™ (InvivoGen), 5 ng/mL recombinant human TGF-β1 (Peprotech, HEK293 derived), 1.5 ng/mL ovine wool cholesterol (Avanti), 0.1 ng/mL oleic acid (Cayman Chemicals), 0.001 ng/mL 11(Z)-eicosenoic acid (Cayman Chemicals), 460 µM 1-Thioglycerol (Sigma-Aldrich), 10 µg/mL Insulin, 5.5 µg/mL Transferrin, 6.7 ng/mL sodium selenite (ITS-G, Gibco), 5.4 µg/mL human insulin solution (Sigma). BDNF, GDNF, TGF-β1, IL-34 and M-CSF were reconstituted in 0.1% BSA. Ovine wool cholesterol, oleic acid and 11(Z)-eicosenoic acid were freshly prepared in ethanol every month. To obtain complete microglia culture medium, reduced microglia medium was supplemented with 100 ng/mL recombinant humane IL-34 (Peprotech) and 25 ng/mL recombinant human M-CSF (Peprotech). For preparation of minimal microglia culture medium, base medium was supplemented with 25 ng/mL recombinant humane IL-34 (Peprotech) and 0.313 ng/mL recombinant human M-CSF (Peprotech).

iii. iPSC microglia cell thawing, seeding, and culture

[00327] Human wild-type or TREM2KO iPSC-derived microglia (iCell Microglia, Fujifilm Cellular Dynamics, Inc.) were thawed in complete microglia medium. After counting, cells were centrifuged and resuspended in minimal microglia culture medium. For cell survival assays, coating solutions of previously coated 384 well plates (Cell Carrier Ultra, Perkin Elmer) were aspirated and cells were seeded with 8,000 cells/well in 50 μ L of respective media. Plates were briefly centrifuged and cells were cultured for 3 days at 37°C, 5% CO₂, and 95% humidity.

iv. Collection of supernatant and fixation of cells

[00328] After 3 days of culture, supernatants of cells were collected by a pipetting robot (Assist Plus, Integra) equipped with an automatic multichannel pipette (Voyager 125 μ L, Integra). Aspiration speed was set to 2 μ L/sec and pipetting height was kept at 1-1.2 mm above plate bottom to avoid disturbance of the cell layer. 30 μ L/well was transferred to 384 deep well microplate (Greiner Bio-One). Right after supernatant collection, cells were fixed in 4% PFA (Electron Microscopy Science), 4% sucrose (Sigma-Aldrich) in DPBS (Sigma-Aldrich) for 1 hour at room temperature. After fixation, cells were washed twice with DPBS (Sigma-Aldrich).

2. Immunostaining

[00329] Prior to immunostaining, cells were incubated with blocking buffer containing 2% normal donkey serum (JacksonImmuno Research), 1% BSA (JacksonImmuno Research) and 0.1% Triton X-100 (Sigma-Aldrich) in DPBS (Sigma-Aldrich) for 1 hour at room temperature. Primary rabbit-anti-Iba1 polyclonal antibody (1:500, Wako) was diluted in blocking solution, incubated for 1 hour at room temperature and cells were washed three times with blocking buffer. Secondary Cy3 donkey-anti-rabbit (1:600, JacksonImmuno Research), Alexa Fluor™ 488 Phalloidin (1:1000, Invitrogen) and Hoechst 33342 (1:10000, Invitrogen) were prepared in blocking buffer and incubated for another hour at room temperature. After secondary staining, cells were washed 6 times by repeat addition and aspiration of DPBS (Sigma-Aldrich) and stored in the dark until imaging.

3. Imaging

[00330] Microplates containing stained microglia were imaged on automated high content imager (Opera Phenix® High Content Screening System, Perkin Elmer) equipped with a 20x water immersion objective. Tile scans (3 x 3 tiles) of all wells were acquired in spinning disk confocal mode (image size 1080 x 1080 pixels, pixel size 0.598 μm), resulting in an effective field of view of 2.88 mm^2 (~27% of each well). Each position was imaged in three fluorescent channels. Excitation of nuclear dye Hoechst 33342 was performed at 405 nm and the main emitted signal was detected at 456 nm. Actin was detected at 522 nm by excitation of Alexa Fluor™ 488 Phalloidin at 488 nm. Iba1 was visualized by excitation of Cy3 at 561 nm, mainly emitting at 599 nm.

4. iPSC microglia A β plaque formation assay

[00331] To test the effect of plate-bound anti-TREM2 antibodies in formation and compaction of an A β plaque, an *in vitro* human iPSC-MG plaque formation assay using synthetic A β oligomers to mimic the increased level of A β oligomers found in the AD brain was conducted. iPSC microglia were cultured as described in Section 1 of this example in the presence of control antibody (gD hIgG1 N297G), or anti-TREM2 antibodies at increasing concentration in the presence of A β oligomers, without IL-34 and CSF-1. A β oligomers were generated by incubating reconstituted A β monomer (1-42) (Anaspec) to 100 μM in BrainPhys™ basal media in 4°C for 24 hours. A β oligomers were applied to cells right after plating at final concentration of 2.5 μM . Cells were incubated for 2 days and then fixed and stained for A β , Methoxy-X04 (amyloid plaque dye), and IBA1. Microplates containing stained microglia were imaged on automated high content imager (IN CELL 6000, General Electric) equipped with a 20x air objective. Tile scans (3 x 3 tiles) of all wells were acquired. Each position was imaged in four fluorescent channels. Excitation of A β plaque binding dye Methoxy-X04 was performed at 405 nm and the main emitted signal was detected at 456 nm. Actin was detected at 522 nm by excitation of Alexa Fluor™ 488 Phalloidin at 488 nm. Iba1 was visualized by excitation of Cy3 at 561 nm, mainly emitting at 599 nm. A β was visualized by Anti-6E10 antibody using an excitation wavelength of 647 nM.

5. AlphaLISA® assay

[00332] 48 or 96 well cell culture microplates of different formats were coated with 200 µg/mL antibody in DMEM/F12 (Gibco). 96 well plates (Greiner Bio-One) were coated with 50 µL/well and 48 well plates (Greiner Bio-One) were coated with 150 µL/well and incubated over night at 37°C, 5% CO₂, 95% humidity. iPSC microglia were plated and culture as described in Section 1 of this example.

6. Lysate preparation

[00333] After 3 days of culturing, samples for measurements of phosphorylation on Tyr525/526 and total levels of endogenous SYK were obtained by cell lysis with lysis buffer (lysis buffer ultra, Perkin Elmer). Used culture medium was removed and freshly prepared 1x lysis buffer was added to microplates (100 µL for 48 well, 60 µL for 96 well). Plates were agitated on a plate shaker (350 rpm) for 10 minutes at room temperature. Concentrated samples were generated by successive carryover of lysates to non-lysed replicate wells of the same culture condition (N= 3 to 4, n = 2 to 3). Plates were agitated again for 10 minutes at room temperature and concentrated lysates were transferred to 96 well deep well plate (Greiner Bio-One) and frozen at -80°C.

7. Luminex assay

[00334] Multiplex protein quantification from collected microglia culture supernatants was performed using Luminex multianalyte profiling technology (Inflammation 20-Plex Human ProcartaPlex™ Panel). The assay kit was used according to manufacturer's protocol. To obtain sufficient sample volume, supernatants of multiple wells of the same conditions were pooled and pooled samples were analyzed in duplicates. Assay plates were read on Luminex™ MAGPIX™ Instrument System (Invitrogen).

8. SYK phosphorylation assay

[00335] To determine whether anti-TREM2 antibodies induced SYK phosphorylation, wild-type iPSC-MG were cultured in 48 well plates in culture media without IL-34 and CSF-1 and in the presence of plate-bound antibody: control (gD hIgG1 N297G), anti-TREM2 hPara.09.V2 hIgG1 N297G, or variant hPara.Q100P.V104L hIgG1 N297G antibody. Cells were plated for indicated time points (1 hour, 4 hours, 24 hours), then were lysed and analyzed with AlphaLISA® assay for pSYK and total SYK. The

ratio was further normalized at each time point to the ratio measured using anti-gD control antibody. For each condition, there were n=4 wells. The ratio of phospho-SYK to total SYK in protein lysate from the treated cells was measured by ELISA.

B. Results

1. Anti-TREM2 antibodies promote human iPSC-MG survival

[00336] We tested whether anti-TREM2 antibodies 3.10C2v1 and hPara09.v2 (in an IgG1 N297G background) promote human iPSC derived microglia (iPSC-MG) survival by culturing iPSC-MG without IL-34 and CSF-1, which are normally required for microglia survival, compared to control anti-gD antibody. (Fig. 23A). With the control antibody, most microglia died after 3 days of culture without IL-34 and CSF-1. In contrast, 3.10C2v1 and hPara09.v2 promoted iPSC-MG survival in a dose-dependent manner. To validate that the survival effect is mediated through TREM2 signaling, antibodies were also tested in TREM2 knock-out (KO) iPSC microglia. Antibodies 3.10C2v1 and hPara09.v2 did not promote TREM2-KO iPSC microglia survival. Therefore, anti-TREM2 agonist antibodies 3.10C2v1 and hPara09.v2 promoted iPSC-MG survival in a TREM2 dependent manner.

[00337] The human iPSC-MG survival assay was used to screen anti-TREM2 antibodies from the screens of Example 1 that showed binding to different regions of hTREM2, using 2-4 antibody clones with the highest affinity from each of 6 epitope bins (Fig. 23B). Antibodies in the epitope bin corresponding to the 3.10C2 group showed the highest survival activity even at 1 ng and 10 ng. Thus, 3.10C2 group antibodies showed the highest agonist activity in promoting iPSC-MG microglia survival.

2. Anti-TREM2 antibodies induce pSYK-dependent survival in iPSC-MG

[00338] TREM2 signals through its association with DAP12, which recruits SYK through its cytosolic immunoreceptor tyrosine-based activation motifs (ITAMs). SYK, therefore is a downstream effector of TREM2 signaling. As shown in Fig. 23C, compared to the control anti-gD antibody, both hPara.09.V2 hIgG1 N297G and variant hPara.Q100P.V104L hIgG1 N297G antibodies showed a 2-fold elevation of phospho-SYK at 1 hour of incubation, and more than 10-fold induction at 4 hours (Error bar +/- SEM. * P<0.05, ** P<0.01, ****< 0.0001, using a 2 way ANOVA). Phospho-SYK levels returned to control level at 24 hours. Consistent with results shown above for

human MDM cells, both antibodies elicited increased TREM2 signaling via SYK kinase in iPSC-derived microglia.

[00339] To test if TREM2 activation mediated survival requires SYK kinase activity, human iPSC-MG were incubated with anti-TREM2 antibody hPara.09.V2 hIgG1 N297G in the presence of a SYK inhibitor PRT-060318 (PRT318) at 250nM (Fig. 23D). In the presence of the SYK inhibitor, hPara.09.V2 hIgG1 N297G did not promote iPSC-MG survival, indicating that the TREM2 mediated survival function requires SYK activity.

[00340] The iPSC-MG assay was further used to determine the EC₅₀ of anti-TREM2 antibody clones. As shown in Fig. 23E, the tested anti-TREM2 antibodies promoted iPSC-MG survival in the sub-nanomolar range.

[00341] These data further confirmed that the antibodies potently activate TREM2 signaling through phosphorylation of SYK in macrophage and microglia models.

3. Anti-TREM2 antibodies and TREM2's neuroprotective function against Alzheimer's disease

[00342] Several prior studies have indicated that TREM2 activity regulates microglial packing of A β into a dense plaque, and this may confer an important neuroprotective activity in Alzheimer's disease (AD). (Ulrich et al., *ACS Chem Neurosci* doi: 10.1021/acscchemneuro.5b00313 (2016); Yeh FL et al., *Trends Mol Med* doi: 10.1016/j.molmed.2017.03.008 (2017); Bohlen CJ et al., *Ann Rev Genet* doi: 10.1146/annurev-genet-112618-043515 (2019); Wang Y et al., *J Exp Med* doi: 10.1084/jem.20151948 (2016); Meilandt WJ et al., *J Neurosci* doi: 10.1523/JNEUROSCI.1871-19.2019 (2020).)

[00343] Fig. 24A shows staining of cells treated with either control anti-gD antibody or hPara09.Q100P with markers for A β (Abeta), amyloid plaques (X04), and IBA1 individually, and in combination (merged). Adding A β oligomers to human iPSC derived microglia culture for 2 days led to robust A β plaque-like structure formation and formation of A β aggregates (Fig. 24A A β panel at left). The amyloid specific binding dye Methoxy-X04 binds to a specific confirmation of A β peptide found in the amyloid plaques (Klunk WE et al., *Neuropathol Exp Neurol* doi: 10.1093/jnen/61.9.797 (2002)).

X04 staining was used to confirm that observed aggregates were amyloid plaques formed by the microglia. (Fig. 24A, X04 panel at center.) The IBA1 marker labels microglia. In Fig. 24A, the IBA1 panel at right shows more intense IBA1 staining in the presence of the hPara09.Q100P hIgG1 N279G antibody.

[00344] Increases in A β and X04 staining intensity each reflect the formation and compaction of amyloid plaques. Compared to control antibody, hPara09.Q100P hIgG1 N279G enhanced the formation of A β aggregates in human iPSC microglia (Fig. 24A). A β aggregates in cells treated with the control antibodies were more diffuse, whereas the A β aggregates formed in the presence of the anti-TREM2 hPara09.Q100P hIgG1 N279G antibody were brighter and much more compacted and round (Fig. 24A, A β panel). The increased A β staining indicated that there are more A β peptides compacted into the same area of A β aggregates in response to anti-TREM2 hPara09.Q100P hIgG1 N279G antibody. Consistent with the A β staining, there was also more intense X04 staining in the A β aggregates in the presence of anti-TREM2, indicating more dye was bound to the specific amyloid plaque-like structures (Fig. 24A, X04 panel). More microglia were detected surrounding the amyloid plaques in the presence of anti-TREM2 compared to control (Fig. 24A, Merged panel).

[00345] Several humanized anti-TREM2 antibodies were tested in this assay in addition to hPara09.Q100P hIgG1 N279G. To quantify total amyloid plaque formation, total X04 intensity was measured and normalized to a no antibody control. N=4 wells per condition. Error bar +/- SEM. There was up to a 5-fold increase of amyloid plaque-like structures in the presence of the anti-TREM2 antibodies. (Fig. 24B). To measure amyloid plaque compaction, the average intensity of plaque dye X04 staining within each of the A β aggregate area was measured. Fig. 24C shows average X04 iPSC-MG plaque intensity at increasing antibody concentrations. EC₅₀ values are provided in nM for each antibody in the table below the curve. As shown in Fig. 24C, anti-TREM2 antibodies increased the average X04 intensity up to 3-fold.

[00346] Thus, treatment with anti-TREM2 antibodies of the present disclosure demonstrated up to 10-fold increase of phospho-SYK ratio, indicative of TREM2 signal activation, and led to a 5-8 fold increase of microglia survival in the absence of the

required microglial growth factors IL-34 and CSF-1. In the presence of A β oligomers modeling the AD pathological brain environment, the anti-TREM2 antibodies also increased A β plaque formation and compaction by 3-5 fold, as measured by increases in total A β plaque intensity and average X04 plaque intensity. This increased microglia survival might allow more microglia to act on A β oligomers and package them into amyloid plaques. Therefore, the antibodies may offer neuroprotection in vivo by activating TREM2 signaling in human microglia, functionally increasing microglia survival, and promoting A β compaction into amyloid plaques.

Example 18A: Systemic Administration of 3.10C2 and Para.09 in Mice Decreased in vivo Soluble TREM2 Levels

A. Materials and methods

[00347] Transgenic mice expressing human TREM2 in a PS2APP mouse TREM2 knock-out (KO) background were dosed with 3.10C2, Para.09 (rat Para.09-LC 3.27H7), or a control gp120 IgG antibody by intraperitoneal (i.p.) administration. Each antibody comprised a mIgG2a LALAPG backbone. The doses administered were 20 mg/kg and 80 mg/kg on day 0, and plasma and brain samples were collected on day 3.

[00348] The mice were 7 to 8 months old. Mice were anesthetized with Avertin and blood was collected by cardiac puncture. Mouse brains were perfused with cold phosphate buffer saline (PBS), removed and split down the midline. One hemisphere was drop fixed in 4% PFA for 48 hours then transferred to PBS then 30% sucrose for cryopreservation. Coronal sections (35 μ m) were made on a sliding microtome. From the other hemibrain, the hippocampus and cortex were isolated and quickly frozen. Cortical tissue was homogenized in 10 volumes of TBS (50 mM Tris pH 7.5, 150 mM NaCl) containing protease inhibitor cocktail (Roche Catalog No. 4693159001) and PhosSTOP™ (Roche Catalog No. 4906837001); 1 ml lysis buffer was used for every 100 mg tissue. Subsequently, one 3-mm stainless steel bead (Qiagen) was added into each tube and samples were homogenized with the Qiagen TissueLyser™ II at 30 Hz for 3 min. The homogenized samples were then cleared by centrifugation at 20,000 x-g for 20 min at 4 °C. Supernatants were transferred to new tubes and stored at -80 °C.

[00349] The Human TREM2 ELISA assay by R&D Systems (Catalog No. DY1828-05) was used to test for sTREM2 in plasma and brain lysates. The human sTREM2 capture antibody (AF1828) that was provided in the assay kit was diluted in PBS and immobilized in 96 well plates. After blocking and washing the plate diluted sample and standards were added and incubated for 2 hours at room temperature. After washing, the human sTREM2 detection antibody was diluted and incubated for another 2 hrs. The plate was once again washed and incubated with Streptavidin-HRP for 20 min followed by a substrate solution incubation of 20 min at room temperature. After stopping the reaction, the plate was read using two filters, 450 nm for detection and 570 nm for background. Concentrations were determined on a standard curve obtained by plotting optical density versus concentration.

B. Results

[00350] Administration of the 3.10C2.mIgG2a LALAPG and Para.09. mIgG2a LALAPG antibodies caused a dose-dependent decrease in soluble TREM2 levels in both plasma (Fig. 25A) and brain homogenate (Fig. 25B) samples, relative to levels of soluble TREM2 measured after administration of a control antibody (gp120). A decrease in sTREM2 may indicate that the antibodies block shedding or alternatively that they may induce internalization of the receptor upon activation. The decrease in sTREM2 suggests that the therapeutic antibodies can engage with the target *in vivo* in the periphery and in the brain.

Example 18B: Para09 Administration Results in a Decrease in *in vivo* Plasma Soluble TREM2 Levels, Contrary to the Effect Seen with a Comparator anti-TREM2 Antibody

A. Materials and methods

[00351] Transgenic mice (5-6 months old) expressing human TREM2 in a PS2APP mouse TREM2 knock-out (KO) background were dosed with Para.09 (rat Para.09-LC 3.27H7), a comparator antibody AL2p58, or a control gp120 IgG antibody by i.p. administration. Each antibody comprised a mIgG2a LALAPG backbone. The doses administered were: Para09 – 100 mg/kg, 200 mg/kg; AL2p58 – 20 mg/kg, 100 mg/kg, 200

mg/kg; gp120 isotype control – 200 mg/kg. Terminal plasma was collected on day 3 or day 7.

[00352] Animal handling, tissue collection and processing, and human TREM2 ELISA assay by R&D Systems were performed as described in Example 18A. Mice were anesthetized with Avertin and blood was collected by cardiac puncture. The Human TREM2 ELISA assay by R&D Systems (Catalog No. DY1828-05) was used to test for sTREM2 in plasma lysates. The human sTREM2 capture antibody that was provided in the assay kit was diluted in PBS and immobilized in 96 well plates. After blocking and washing the plate diluted sample and standards were added and incubated for 2 hours at room temperature. After washing, the human sTREM2 detection antibody was diluted and incubated for another 2 hrs. The plate was once again washed and incubated with Streptavidin-HRP for 20 min followed by a substrate solution incubation of 20 min at room temperature. After stopping the reaction, the plate was read using two filters, 450 nm for detection and 570 nm for background. Concentrations were determined on a standard curve obtained by plotting optical density versus concentration.

B. Results

[00353] Administration of Para.09 mIgG2a LALAPG antibodies caused a substantial and dose-dependent decrease of 70%-85% in soluble TREM2 levels in plasma (Fig. 25C) samples. In contrast, the comparator anti-TREM2 antibody, which has been described as binding to the stalk region of TREM2, AL2p58 (see WO2019028292), and is shown in earlier Examples to bind to sTREM2, showed a marked increase in plasma sTREM2 levels of more than 2 fold relative to sTREM2 levels seen with the control antibody. This increase in plasma sTREM2 levels in animals treated with AL2p58 persisted for at least 7 days post-treatment, as shown in Fig 25C. Thus, administration of Para09 reduced sTREM2 levels in plasma whereas administration of the comparator antibody had the opposite effect of causing a prolonged and substantial increase in plasma sTREM2 levels *in vivo*, which may be an undesirable side effect of binding to sTREM2.

Experiment 18C: Single Dose Intravenous Injection of h3.10C2.v1 and hPara.09.v2 Antibodies in Cynomolgus Monkeys Decreased Soluble TREM2 Levels *in vivo*

A. Materials and methods

[00354] Native female cynomolgus monkeys approximately 2-3 years old were dosed intravenously with h3.10C2.v1.huIgG1.N297G, hPara.09.v2.hIgG.N297G, or a control antibody (anti-gD.hIgG1.N297G) at 50 or 200 mg/kg on day 1. Cynomolgus monkeys were surgically implanted with an intrathecal catheter in the lumbar spine for CSF sample collection. Blood samples were collected from conscious animals via a peripheral vein. Animals were euthanized and gross necropsy performed to collect brain samples. Brain punctures at 30-50 mg were collected from the cerebellum, cerebral cortex, and hippocampus. CSF and plasma samples were collected on day -7, 0, 1 and 2 for the cohorts that had a duration of 2 days post dose and on day -7, 0, 1, 2, 4, 7, 10, 14, 21, and 28 for the cohorts that had a duration of 28 days post dose. The samples collected on day -7 and 0 prior to treatment were averaged to determine baseline soluble TREM2 (sTREM2) concentration. Brain samples were collected from animals euthanized on study days 3 and 29.

[00355] A commercial human TREM2 ELISA kit (Origene EA102484) was used to determine soluble TREM2 levels in cynomolgus CSF, plasma, and brain lysate. The 96-well plates were precoated with anti-TREM2 capture antibody. 100 μ L of standard, controls or samples were added to each well and incubated at 37 °C for 90 minutes. The contents of the wells were removed by aspiration and 100 μ L of diluted biotinylated detection antibody was added into each well. After 1 hr incubation at 37 °C, the plates were washed 3 times with wash buffer. 100 μ L/well of avidin-peroxidase secondary detection reagent was added to the plates and plates were further incubated at 37 °C for 30 minutes. After washing the plates 5 times, 90 μ L/well of color developing reagent was added and the plates were incubated for 15-25 minutes. 100 μ L/well of stop solution was added to stop the color development. Absorbance was measured at 450 nm against a reference wavelength of 650 nm. The concentration of the samples was extrapolated from a 4-parameter fit of the standard curve. The reportable assay range is 0.0313-2.0 ng/mL

with a lower limit quantification of 156 pg/mL for CSF, 313 pg/mL for plasma, and 94 pg/mL for brain lysate.

B. Results

[00356] A general trend of decreased sTREM2 was observed for most samples in h3.10C2.v1.huIgG1.N297G and hPara.09.v2.hIgG.N297G groups compared to the control group (Figs. 26A-26C). The greatest decrease was observed in plasma ($\geq 50\%$ for treatment groups relative to control group), then CSF, then brain. Treatment with h3.10C2.v1.huIgG1.N297G or hPara.09.v2.hIgG.N297G appeared to show a dose dependent response in CSF and brain. hPara.09.v2.hIgG.N297G showed the largest decrease in brain and CSF sTREM2 compared to h3.10C2.v1.huIgG1.N297G. For the 50 mg/kg groups that ran for 28 days, decrease in sTREM2 was observed in brain, CSF, and plasma especially at ten days (Figs. 26D-26F).

[00357] The decrease of sTREM2 suggests that the therapeutic antibodies can engage with the intact TREM2 target *in vivo* in the brain and CSF, and also lead to prolonged reduction of sTREM2 in the periphery.

Example 19: TREM2 Activating Antibodies Increase Cell Proliferation *In Vivo*

A. Material and methods

[00358] Free floating coronal sections (35 μm , two per animal) were washed in PBS twice for 5 minutes followed by PBS-Triton X100 (0.1%) twice for 10 minutes. Sections were then incubated in Dako Target Retrieval Solution (Roche Catalog No. S236784-2) for 10 minutes at 105C, washed in PBS then blocked in 5% bovine serum albumin (BSA) 0.3% Triton X100 in PBS for 2 to 3 hours at room temperature. Primary antibody (mouse monoclonal Ki67; BD Pharmigen Catalog No. 556003) was diluted 1:100 and incubated at 4°C overnight, donkey anti-mouse Alexa555 secondary antibody was incubated at RT for 2 hours. Sections were mounted onto Superfrost™ plus (Fisherbrand) glass slides and cover-slipped with Prolong™ Gold plus DAPI antifade mounting media. Image acquisition of immunofluorescent slides was performed at 200x magnification using the NanoZoomer® S60 or XR (Hamamatsu Corp, San Jose, CA) digital whole slide scanner. Ideal exposure for each channel was determined based on samples with the brightest intensity and set for the whole set of slides to run as a batch.

[00359] Brain sections from mice treated with 3.10C2, Para09, or control gp120 IgG antibody (each antibody comprised a mIgG2a LALAPG backbone) were stained for the proliferation marker Ki67, and number of Ki67+/DAPI+ cells were calculated. Cells positive for Ki67 and DAPI were counted and averaged from two sections per animal.

B. Results

[00360] As shown in Fig. 27, Para.09 (at 80 mg/kg) significantly increased the number of Ki67+ cells three days post a single injection compared with isotype control-treated mice. A one-way ANOVA of Ki67+ cells found a significant treatment effect ($F(4, 15) = 3.477$ $P=0.0336$) with a significant difference between Para.09 (80 mg/kg) and control isotype (gp120, 80 mg/kg) by Tukey's post-hoc multiple comparison ($p<0.05$). This data confirms that Para.09 induces TREM2 pathway activation and increases cell proliferation *in vivo*.

Example 20: Effects of Anti-TREM2 Antibodies on Amyloid and Tau Pathology in a Murine Model for Human Alzheimer's Disease

[00361] Pathological hallmarks of Alzheimer's Disease (AD) include extracellular deposits of beta-amyloid peptides that form amyloid plaques and intracellular deposits of aggregated hyperphosphorylated tau called neurofibrillary tangles. These pathologies are followed by an increase in brain inflammation, including activated astrocytes and microglia, and neurodegeneration. Transgenic mice expressing human mutations in presenilin 2 and amyloid precursor protein, which cause familial forms of AD, (PS2APP mice) show similar age-dependent increases in A β pathology as seen in AD patients. PS2APP mice crossed to Tau mutant P301L mice (TauPS2APP mice) show additional hallmarks of AD pathology, including hyperphosphorylated Tau and neurodegeneration. Human TREM2 (hTREM2 BAC) expressing mice, in a mouse Trem2 knockout background, are bred to TauPS2APP mice in order to test whether activating human Trem2 using anti-TREM2 antibody enhances microglia activity and facilitates the removal of toxic amyloid-beta peptides, by engulfment or compaction into less toxic amyloid plaques. In this study, groups of 14-16 TauPS2APP-hTrem2 mice receive weekly or monthly (every 4 week) systemic injections of a low or high dose of anti-TREM2 antibody or a control IgG antibody for 16 weeks starting at 34 weeks of age.

Changes in brain atrophy by volumetric MRI are monitored by imaging mice at the beginning and end of treatment.

[00362] At the completion of dosing, plasma and brain samples are collected to measure antibody exposures by ELISA, one hemibrain is fixed in paraformaldehyde for immunohistochemical staining, and cortical and hippocampal tissue are collected for biochemical analysis. Histological staining for plaque formation is performed using an amyloid stain, such as methoxy-X04. Microglial clustering around plaques and changes in morphology are assessed by staining with a microglial marker such as Iba1 and Methoxy-X04. To determine if treatment alters the development of plaque-associated neurodegeneration (neuritic dystrophy), sections are co-stained for plaques, with methoxy-X04 and a lysosomal protein marker, e.g., LAMP1, which accumulates in the neuritic dystrophy surrounding the plaque.

[00363] The effect of anti-TREM2 antibody treatment on histological measures of pTau and neurodegeneration in the hippocampus is measured by staining for various forms of phosphorylated and aggregated tau (e.g. with AT8, PHF1, MC1, and p212/214 antibodies). Neurodegeneration is assessed by staining sections with an amino-cupric silver stain that detects degenerating axons and processes. Neurofilament light chain (NfL), a soluble marker of degenerating axons, is also measured by ELISA from the plasma and CSF.

Example 21: Effects of Anti-TREM2 Antibodies in a Multiple Sclerosis Model

[00364] Multiple sclerosis (MS) is a disease characterized by an autoimmune related demyelination in the CNS. In patients, the disease presents in episodes of symptoms such as ataxia, limb weakness, and optic neuritis among other neurological effects. Whether activation of the TREM2 pathway by anti-TREM2 antibodies accelerates remyelination is tested in a cuprizone-induced demyelination model of MS. Cuprizone is a toxic copper chelating agent that when introduced into rodent chow (.2 to .25%) reliably targets oligodendrocytes causing a demyelinating lesion along white matter tracts in the brain, which mimics the demyelination observed in human MS patients. Mice are typically treated for 4 weeks, at which time lesions of the corpus callosum are detectable by MRI. After removal from cuprizone chow, normal wild-type mice show an accumulation of degraded myelin (measured by staining for dMBP) 3 days

post-cuprizone treatment, decreased intact myelin (measured by Solochrome cyanine staining) and astrocytic (GFAP) and microglial (Iba1) infiltration into the lesion site. Increased precursor and mature oligodendrocytes (Olig2) in wild-type mice typically become elevated by day 3, supporting remyelination, which is typically complete by 14 days post-cuprizone treatment. Electron microscopy may also be used to quantify levels of remyelination in the white matter tracts.

[00365] The impact of anti-TREM2 antibody treatment on remyelination events is tested using hTREM2-BAC transgenic mice exposed to cuprizone chow for four weeks, to induce a lesion, and then treated with either an anti-TREM2 antibody or an isotype control antibody such as gp120, while the cuprizone chow is removed. Typically, each group comprises 5-10 mice. Groups include mice on control chow or cuprizone chow for 4 weeks, with the groups of mice on cuprizone chow for 4 weeks then placed on control chow for 3, 7, or 14 days. Mice receive a single high dose of anti-TREM2 or control antibody after the 4 weeks of cuprizone chow and brain and plasma samples are collected either 3, 7, or 14 days after the antibody injection. Stained sections of the corpus callosum lesions (e.g., 6-18 sections per subject) are quantified using high resolution imaging and automated analysis software (MATLAB). Samples from the 14 day post-antibody injection are measured for remyelination by electron microscopy.

[00366] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.

Sequence Table

[00367] The following table provides certain sequences described or cited in the text and figures herein. In SEQ ID Nos: 90, 92-93, and 95-101, TREM2 residues H157 and S158, the location of the cleavage site in the protein, are underlined.

Seq Id. No.	Description	Sequence
1	3.10C2.v1 heavy chain CDR1	NVWMH
2	3.10C2.v1 heavy chain CDR2	HIKAKSDNYATYYAESVKG
3	3.10C2.v1 heavy chain CDR3	LDY
4	3.10C2.v1 light chain CDR1	RSSRSLTSGITSLY
5	3.10C2.v1 light chain CDR2	RMSNLAS
6	3.10C2.v1 light chain CDR3	AQFLVYPYT
7	h3.10C2.V1 heavy chain variable region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVWMHWVRQASGKGLEWIAHIKAKSDNYATYYAESVKGGRFTISRDDSKTTIYLQMNSLKTEDTAVYYCTGLDYWGQGTITVTVSS
8	h3.10C2.V1 light chain variable region	DVVMTQSPPLSLPVTPEGEPASISCRSSRSLTSGITSLYWYLQKPGQSPQLLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLVYPYTFGQGTKVEIK
9	3.10C2.v1 heavy chain CDR1 (Chothia)	GFPFSNV
10	3.10C2.v1 heavy chain CDR2 (Chothia)	KAKSDNYA
11	PARA.09.v2 heavy chain CDR1	NVWLH
12	PARA.09 and PARA.09.v2 heavy chain CDR2	HIKAKSDNYATYYAESVKG
13	PARA.09 and PARA.09.v2 heavy chain CDR3	ILEY

Seq Id. No.	Description	Sequence
14	PARA.09 and PARA.09.v2 light chain CDR1	RSSRSLLTSKGITSLY
15	PARA.09 and PARA.09.v2 light chain CDR2	RMSNLAS
16	PARA.09 and PARA.09.v2 light chain CDR3	AQFLVYPYT
17	hPARA.09.V2 heavy chain variable region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVLHWVRQASGKGPEWVAHIK AKSDNYATYYAESVKGRFTISRDDSKNTVYLQMNSLKTEDTAVYYCTDILEY WGQGTLLTVSS
18	hPARA.09.V2 light chain variable region	DVVMTQSPLSLPVTGPGEPAISCRSSRSLLTSKGITSLYWYLQKPGQSPQLL IYRMSNLASGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLVYPYTFG QGTKVEIK
19	PARA.09 and PARA.09v2 heavy chain CDR1 (Chothia)	GFPFSNV
20	PARA.09 and PARA.09.v2 heavy chain CDR2 (Chothia)	KAKSDNYA
21	Human TREM2 NP_061838.1 (including signal sequence)	MEPLRLLILL FVTELSGAHN TTVFQGVAGQ SLQVSCPYS MKHWGRRKAW CRQLGEKGPC QRVVSTHNLW LLSFLRRWNG STAITDDTLG GTLTITLRNL QPHDAGLYQC QSLHGSEADT LRKVLVEVLA DPLDHRDAGD LWFPGESESF EDAHVEHSIS RSLLEGEIPF PPTSILLLLA CIFIILKILAA SALWAAAWHG QKPGTHPPSE LDCGHDPGYQ LQTLPLGLRDT
22	Human TREM2 (without signal sequence)	HN TTVFQGVAGQ SLQVSCPYS MKHWGRRKAW CRQLGEKGPC QRVVSTHNLW LLSFLRRWNG STAITDDTLG GTLTITLRNL QPHDAGLYQC QSLHGSEADT LRKVLVEVLA DPLDHRDAGD LWFPGESESF EDAHVEHSIS RSLLEGEIPF PPTSILLLLA CIFIILKILAA SALWAAAWHG QKPGTHPPSE LDCGHDPGYQ LQTLPLGLRDT
23	Soluble human TREM2 (TREM2 ectodomain)	HN TTVFQGVAGQ SLQVSCPYS MKHWGRRKAW CRQLGEKGPC QRVVSTHNLW LLSFLRRWNG STAITDDTLG GTLTITLRNL QPHDAGLYQC QSLHGSEADT LRKVLVEVLA DPLDHRDAGD LWFPGESESF EDAHVEH
24	3.10C2 heavy chain CDR1	NVWMH
25	3.10C2 heavy chain CDR2	HIKAKSDNYATYYAESVKG

Seq Id. No.	Description	Sequence
26	3.10C2 heavy chain CDR3	LDY
27	3.10C2 light chain CDR1	RSSKSLLGVRDITSLY
28	3.10C2 light chain CDR2	RMSNLAS
29	3.10C2 light chain CDR3	AQFLRYPYT
30	3.10C2 heavy chain variable region	EVQLVETGGSLVQPGKSLKLTCAISGFPFSNVWMHWVRQSPEKQLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTSIYLQMNSLKEDDTAIYYCTGLDYW GQGMVTVSS
31	3.10C2 light chain variable region	DTVLTQAPLSLSVTPGESASISCRSSKSLLGVRDITSLYWYLQKPGKSPQLL IYRMSNLASGVPDRFSGSGSETDFTLKISEVETEDVGVIYCAQFLRYPYTFG PGTKLELK
32	3.10C2 heavy chain CDR1 (Chothia)	GFPFSNV
33	3.10C2 heavy chain CDR2 (Chothia)	KAKSDNYA
34	3.50G1 heavy chain CDR1	NVWMH
35	3.50G1 heavy chain CDR2	HIKAKSDNYATYYAESVKG
36	3.50G1 heavy chain CDR3	LDY
37	3.50G1 light chain CDR1	RSNKSLLGIRDITSLY
38	3.50G1 light chain CDR2	RMSNLAS
39	3.50G1 light chain CDR3	AQFLRYPYT
40	3.50G1 heavy chain variable region	EVQLVETGGSLVQPGKSLKLTCAISGFPFSNVWMHWVRQSPEKQLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTSIYLQMNSLKDDDTAIYYCTGLDYW GQGMVTVSS

Seq Id. No.	Description	Sequence
41	3.50G1 light chain variable region	DTVLTQAPLSVSVTPGESASISCRSNKSLLGIRDITSLYWFLQKPGKSPQLL IYRMSNLASGVPDRFSGSGSETDFTLKI SEVETEDVG VYYCAQFLRYPYTFG PGTKLELQ
42	3.50G1 heavy chain CDR1 (Chothia)	GFPFSNV
43	3.50G1 heavy chain CDR2 (Chothia)	KAKSDNYA
44	3.18E5 heavy chain CDR1	NVWMH
45	3.18E5 heavy chain CDR2	HIKAKSDNYATYYAESVKG
46	3.18E5 heavy chain CDR3	LDY
47	3.18E5 light chain CDR1	RSNKSLLGIRDITSLY
48	3.18E5 light chain CDR2	RMSNLAS
49	3.18E5 light chain CDR3	AQFLRYPYT
50	3.18E5 heavy chain variable region	EVQLVETGGSLVQPGKSLKLT CATSGFPFSNVWMHWVRQSPEKQLEWIAHIK AKSDNYATYYAESVKG RFTISRDDSKTTIYLQMNSLKEADTAIYYCTGLDYW GQGVMVTVSS
51	3.18E5 light chain variable region	DTVLTQAPLSVSVTPGESASISCRSNKSLLGIRDITSLYWYLQKPGKSPQLL IYRMSNLASGVPDRFSGSGSETDFTLKI SEVETEDVG VYYCAQFLRYPYTFG PGTKLELK
52	3.18E5 heavy chain CDR1 (Chothia)	GFPFSNV
53	3.18E5 heavy chain CDR2 (Chothia)	KAKSDNYA
54	3.36F5 heavy chain CDR1	NVWMH
55	3.36F5 heavy chain CDR2	QIKGKSDNYATYYAESLQG

Seq Id. No.	Description	Sequence
56	3.36F5 heavy chain CDR3	LDY
57	3.36F5 light chain CDR1	RSNKSLSSKGITSLY
58	3.36F5 light chain CDR2	RMSNLAS
59	3.36F5 light chain CDR3	AQFLQYPYT
60	3.36F5 heavy chain variable region	[sequence provided in Fig. 3B]
61	3.36F5 light chain variable region	[sequence provided in Fig. 3A]
62	3.36F5 heavy chain CDR1 (Chothia)	GFTFTNV
63	3.36F5 heavy chain CDR2 (Chothia)	KGKSDNYA
64	3.27H7 heavy chain CDR1	NVWLH
65	3.27H7 heavy chain CDR2	QIKARSDNYATYYAESVKG
66	3.27H7 heavy chain CDR3	LDY
67	3.27H7 light chain CDR1	RSSRSLTSSKGITSLY
68	3.27H7 light chain CDR2	RMSNLAS
69	3.27H7 light chain CDR3	AQFLVYPYT
70	3.27H7 heavy chain variable region	EVQLVETGGSLVQPGGSLKLTCAATSGFPFSNVWLHWIRRSPEKQLEWVAQIK ARSDNYATYYAESVKGGRFIVSRDDSKTTIYLQMNNLKEEDTAIYYCTGLDYW GQGVMVTVSS

Seq Id. No.	Description	Sequence
71	3.27H7 light chain variable region	DVVLTAQAPLSVSVTPGESASISCRSSRSLLTSKGITSLYWYLQKPGMSPHLL IYRMSNLASGIPDRFSGSGSETDFTLKISEVEPEDVGVIYCAQFLVYPYTFG AGTKLELK
72	3.27H7 heavy chain CDR1 (Chothia)	GFPFSNV
73	3.27H7 heavy chain CDR2 (Chothia)	KARSDNYA
74	IGHV3-73*01 germline heavy chain	EVQLVESGGGLVQPGGSLKLSAASGFTFSGSAMHWVRQASGKGLEWVGRIR SKANSYATAYAASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRMDEVW GQGTTVTVSS
75	IGKV2-28*01 germline light chain	DIVMTQSPLSLPVTPGEPASISCRSSQSLLSNGYNYLDWYLQKPGQSPQLL IYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFG QGTKLEIK
76	3.10C2-H1 heavy chain variable region	EVQLVETGGSLVQPGKSLKLTCAATSGFPFSNVMMHWVRQSPKQLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTSIYLMNSLKEDDTAIYYCTGLDYW GQGMVTVSS
77	3.10C2-H3 heavy chain variable region	EVQLVETGGSLVQPGKSLKLTCAATSGFPFSNVMMHWVRQSPKQLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTSIYLMNSLKEDDTAIYYCTGLDYW GQGMVTVSS
78	3.10C2-H5 heavy chain variable region	EVQLVETGGSLVQPGKSLKLTCAATSGFPFSNVMMHWVRQSPKQLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTSIYLMNSLKEDDTAIYYCTGLDYW GQGMVTVSS
79	3.10C2-L1 light chain variable region	DTVLTQAPLSLSVTPGESASISCRSSKSLLGVRDITSLYWYLQKPGKSPQLL IYRMSNLASGVPDRFSGSGSETDFTLKISEVETEDVGVIYCAQFLRYPYTFG PGTKLELK
80	3.10C2-L5 light chain variable region	DTVLTQAPLSLSVTPGESASISCRSSKSLLGVRDITSLYWYLQKPGKSPQLL IYRMSNLASGVPDRFSGSGSETDFTLKISEVETEDVGVIYCAQFLRYPYTFG PGTKLELK
81	Para.09-H1 heavy chain variable region	EVQLVETGGSLVQPGKSLRLTCATSGFPFSNVWLHWVRQSPKHPWVAHIK AKSDNYATYYAESVKGRFTISRDDSKSSVFLQMNSLKEEDTAIYYCTDILEY WGQGTTLTVSS
82	Para.09-H5 heavy chain variable region	EVQLVETGGSLVQPGKSLRLTCATSGFPFSNVWLHWVRQSPKHPWVAHIK AKSDNYATYYAESVKGRFTISRDDSKSSVFLQMNSLKEEDTAIYYCTDILEY WGQGTTLTVSS
83	Para.09-H7 heavy chain variable region	EVQLVETGGSLVQPGKSLRLTCATSGFPFSNVWLHWVRQSPKHPWVAHIK AKSDNYATYYAESVKGRFTISRDDSKSSVFLQMNSLKEEDTAIYYCTDILEY WGQGTTLTVSS

Seq Id. No.	Description	Sequence
84	3.27H7-L1 light chain variable region	DVVLTAQAPLSVSVTPGESASISCRSSRSLTSGKITSLYWYLQKPGMSPHLL IYRMSNLASGIPDRFSGSGSETDFTLKISEVEPEDVGYYCAQFLVYPYTFG AGTKLELK
85	3.27H7-L6 light chain variable region	DVVLTAQAPLSVSVTPGESASISCRSSRSLTSGKITSLYWYLQKPGMSPHLL IYRMSNLASGIPDRFSGSGSETDFTLKISEVEPEDVGYYCAQFLVYPYTFG AGTKLELK
86	Human IgG1 Fc region	EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK
87	Human IgG1 N297G Fc region	EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK
88	Murine IgG2 Fc region	AKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHT FPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTI KPCPPCKCPAPNLLGGPSVFI FPPKIKDVLMI SLSPIVTCVVVDVSEDDPDV QISW FVNNVEVHTAQ TQTHREDYNSTLRVVSALPIQH QDWMSGKEFKCKVNN KDLPAPIERTISKPKG SVRAPQVYVLP PPEEEMTKKQVTLT CMVTD FMPEDI YVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVH EGLHNHHTTKSFSRTPGK
89	Murine IgG2 LALAPG Fc region	AKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHT FPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTI KPCPPCKCPAPNAAGGPSVFI FPPKIKDVLMI SLSPIVTCVVVDVSEDDPDV QISW FVNNVEVHTAQ TQTHREDYNSTLRVVSALPIQH QDWMSGKEFKCKVNN KDLGAPIERTISKPKG SVRAPQVYVLP PPEEEMTKKQVTLT CMVTD FMPEDI YVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVH EGLHNHHTTKSFSRTPGK
90	hTREM2 stalk 129-174	LADPLDHRDAGDLWFPGESFEDAHVE <u>HS</u> ISRSLLGEIIPFPPTS
91	hTREM2 stalk 129-148	LADPLDHRDAGDLWFPGESE
92	hTREM2 stalk 139-158	GDLWFPGESFEDAHVE <u>HS</u>
93	hTREM2 stalk 149-168	SFEDAHVE <u>HS</u> ISRSLLGEI
94	hTREM2 stalk 159-175	ISRSLLGEIIPFPPTSI
95	hTREM2 stalk 146-169	ESESFEDAHVE <u>HS</u> ISRSLLGEIIP

Seq Id. No.	Description	Sequence
96	hTREM2 stalk 146-161	ESESFEDAHVE <u>HS</u> ISR
97	hTREM2 stalk 151-165	EDAHVE <u>HS</u> ISRSLL
98	hTREM2 stalk 155-169	VE <u>HS</u> ISRSLLGEIP
99	hTREM2 stalk 152-161	DAHVE <u>HS</u> ISR
100	hTREM2 stalk 154-164	HVE <u>HS</u> ISRSLL
101	hTREM2 stalk 151-161	EDAHVE <u>HS</u> ISR
102	3.10C2 HC CDR3 (IMGT)	TGLDY
103	Para.01 HC CDR3 (IMGT)	ILAYS
104	Para.02 HC CDR3 (IMGT)	TLGAY
105	Para.03 HC CDR3 (IMGT)	TPGVY
106	Para.04 HC CDR3 (IMGT)	TRFDY
107	Para.05 HC CDR3 (IMGT)	REGFDY
108	Para.06 HC CDR3 (IMGT)	RGRLVD
109	Para.07 HC CDR3 (IMGT)	RNYFDY
110	Para.08 HC CDR3 (IMGT)	RSGPSY
111	Para.09 HC CDR3 (IMGT)	TDILEY
112	Para.10 HC CDR3 (IMGT)	TGLGDY
113	Para.11 HC CDR3 (IMGT)	TPAFDY
114	Para.12 HC CDR3 (IMGT)	TRLGDY
115	Para.13 HC CDR3 (IMGT)	TRQLGG
116	Para.14 HC CDR3 (IMGT)	TSGSLY
117	Para.15 HC CDR3 (IMGT)	TSPPDY
118	Para.16 HC CDR3 (IMGT)	LPKGFAY

Seq Id. No.	Description	Sequence
119	Para.17 HC CDR3 (IMGT)	PRDLGDY
120	Para.18 HC CDR3 (IMGT)	SLFFNYH
121	Para.19 HC CDR3 (IMGT)	SPRGFAY
122	Para.20 HC CDR3 (IMGT)	STAPFAY
123	Para.21 HC CDR3 (IMGT)	TFNNFDS
124	Para.22 HC CDR3 (IMGT)	TGSYFDY
125	Para.23 HC CDR3 (IMGT)	TLFFNYH
126	Para.24 HC CDR3 (IMGT)	TLGGYNY
127	Para.25 HC CDR3 (IMGT)	TPGNFNY
128	Para.26 HC CDR3 (IMGT)	TSGGFDY
129	Para.27 HC CDR3 (IMGT)	TSGYFDY
130	Para.28 HC CDR3 (IMGT)	TVTLGAY
131	Para.29 HC CDR3 (IMGT)	TYRGFDF
132	hPara.09.v2 Q100P Light Chain Variable Region	DVVMTQSPLSLPVTPEGEPASISCRSSRSLTSGKITSLYWYLQKPGQSPQLL IYRMSNLASGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLVYPYTFG PGTKVEIK
133	hPara.09.v2 Q100P Heavy Chain Variable Region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVWLHWVRQASGKGPEWVAHIK AKSDNYATYYAESVKGRFTISRDDSKNTVYLQMNSLKTEDTAVYYCTDILEY WGQGTTLTVSS
134	hPara.09.v2 I58V/Q100P Light Chain Variable Region	DVVMTQSPLSLPVTPEGEPASISCRSSRSLTSGKITSLYWYLQKPGQSPQLL IYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLVYPYTFG PGTKVEIK
135	hPara.09.v2 I58V/Q100P Heavy Chain Variable Region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVWLHWVRQASGKGPEWVAHIK AKSDNYATYYAESVKGRFTISRDDSKNTVYLQMNSLKTEDTAVYYCTDILEY WGQGTTLTVSS

Seq Id. No.	Description	Sequence
136	hPara.09.v2 Q100P/V104L Light Chain Variable Region	DVVMTQSPLSLPVTGPGEPAISCRSSRSLLTSKGITSLYWYLQKPGQSPQLL IYRMSNLASGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLVYPYTFG PGTKLEIK
137	hPara.09.v2 Q100P/V104L Heavy Chain Variable Region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVWLHWVRQASGKGPEWVAHIK AKSDNYATYYAESVKGRFTISRDDSKNTVYLMNSLKTEDTAVYYCTDILEY WGQGTTLTVSS
138	hPara.09.H5 -3.10C2.L10 Light Chain Variable Region	DTVMTQSPLSLPVTGPGEPAISCRSSSKSLGVRDITSLYWYLQKPGQSPQLL IYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLRYPYTFG PGTKVEIK
139	hPara.09.H5 -3.10C2.L10 Heavy Chain Variable Region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVWLHWVRQASGKGPEWVAHIK AKSDNYATYYAESVKGRFTISRDDSKNTVYLMNSLKTEDTAVYYCTDILEY WGQGTTLTVSS
140	Alt-R CRISPR-Cas9 crRNA 1	TTGTAGATTCGCGAGCGTAA
141	Alt-R CRISPR-Cas9 crRNA 2	AATGGTGAGAGTGCCACCCA
142	Alt-R CRISPR-Cas9 crRNA 3	TACCAGTGCCAGAGCCTCCA
143	H3.10C2.H1.hIgG1.N297G	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVMMHWVRQASGKGLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTTIYLMNSLKTEDTAVYYCTGLDYW GQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKV DKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMEALHNHYTQKSLSLSPGK
144	hPara.09.H5 .hIgG1.N297 G (also called hPara.09.v2 .hIgG1.N297 G)	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVWLHWVRQASGKGPEWVAHIK AKSDNYATYYAESVKGRFTISRDDSKNTVYLMNSLKTEDTAVYYCTDILEY WGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTK VDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMEALHNHYTQKSLSLSPGK

Seq Id. No.	Description	Sequence
145	h3.10C2.v1 Q100P Light Chain Variable Region	DVVMTQSPLSLPVTPEGEPASISCRSSRSLLTSKGITSLYWYLQKPGQSPQLL IYRMSNLASGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLVYPYTFG PGTKVEIK
146	h3.10C2.v1 Q100P Heavy Chain Variable Region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVMMHWVRQASGKGLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTTIYLQMNSLKTEDTAVYYCTGLDYW GQGT'TVTVSS
147	h3.10C2.v1 I58V/Q100P Light Chain Variable Region	DVVMTQSPLSLPVTPEGEPASISCRSSRSLLTSKGITSLYWYLQKPGQSPQLL IYRMSNLASGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLVYPYTFG PGTKVEIK
148	h3.10C2.v1 I58V/Q100P Heavy Chain Variable Region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVMMHWVRQASGKGLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTTIYLQMNSLKTEDTAVYYCTGLDYW GQGT'TVTVSS
149	h3.10C2.v1 Q100P/V104L Light Chain Variable Region	DVVMTQSPLSLPVTPEGEPASISCRSSRSLLTSKGITSLYWYLQKPGQSPQLL IYRMSNLASGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLVYPYTFG PGTKLEIK
150	h3.10C2.v1 Q100P/V104L Heavy Chain Variable Region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVMMHWVRQASGKGLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTTIYLQMNSLKTEDTAVYYCTGLDYW GQGT'TVTVSS
151	h3.10C2.H1- 3.10C2.L10 Light Chain Variable Region	DTVMTQSPLSLPVTPEGEPASISCRSSKSLGVRDITSLYWYLQKPGQSPQLL IYRMSNLASGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLRYPYTFG PGTKVEIK
152	h3.10C2.H1- 3.10C2.L10 Heavy Chain Variable Region	EVQLVESGGGLVQPGGSLKLSCATSGFPFSNVMMHWVRQASGKGLEWIAHIK AKSDNYATYYAESVKGRFTISRDDSKTTIYLQMNSLKTEDTAVYYCTGLDYW GQGT'TVTVSS
153	hPara.09.H5 -3.10C2.L10 CDR L1	RSSKSLGVRDITSLY

Seq Id. No.	Description	Sequence
154	hPara.09. H5- 3.10C2.L10 CDR L2	RMSNLAS
155	hPara.09. H5- 3.10C2.L10 CDR L3	AQFLRYPYT
156	hPara.09. H5- 3.10C2.L10 CDR H1	NVWLH
157	hPara.09. H5- 3.10C2.L10 CDR H2	HIKAKSDNYATYYAESVKG
158	hPara.09. H5- 3.10C2.L10 CDR H3	ILEY
159	h3.10C2.H1- 3.10C2.L10 light chain CDR1	RSSKSLLGVRDITSLY
160	h3.10C2.H1- 3.10C2.L10 light chain CDR2	RMSNLAS
161	h3.10C2.H1- 3.10C2.L10 light chain CDR 3	AQFLRYPYT
162	h3.10C2.H1- 3.10C2.L10 heavy chain CDR1	NVWMH
163	h3.10C2.H1- 3.10C2.L10 heavy chain CDR2	HIKAKSDNYATYYAESVKG
164	h3.10C2.H1- 3.10C2.L10 heavy chain CDR3	LDY
165	Human IgG1 Fc LALAPG	EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNYHTQKSLSLSPGK
166	Human IgG4 Fc	ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYFP

Seq Id. No.	Description	Sequence
		SDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS VMHEALHNHYTQKSLSLGLGK
167	Human IgG4 Fc S228P	ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQED PEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVSVLTVHLQDNLNGKEYKCK VSNKGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS VMHEALHNHYTQKSLSLGLGK
168	3.17A9 light chain	DIQMTQSPSFLSASVGDRTINCKVSNVDRNLNHWYQQNLGEPKPLINFAN SLQTGVP SRFGSGSGTDFTLTITSSLPEDVATYFCLQHNSWPLTFGSGTKL EIKRADAAPT VSI FPPSSEQLTSGGASVVCFLNNFY PKDINVKWKIDGSE RQ NGVLNSWTDQDSKDYSTYSMSSTLT LTKDEYERHNSYTCEATHKTSTSPIVKS FNRNEC
169	3.17A9 heavy chain	EVQLQQSGAELGKPGT SIKLCKVSGFNIRSTFMHWNQRP GKGLEWIGRID PANGNTVYGEKFKNKATLTADTSSNTAYMQLSQLKSDDTAIYFCALEFGVSW FEYWGQGT LTVTVSSAKTTAPSVYPLAPVCGD TTGSSVTLGCLVKGYFPEPVT LTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASS TKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFI FPPKIKDVLMI SLSPIV TCVVVDVSEDDPDVQISW FVNNVEVHTAQTQTHREDYNSTLRVVSALPIQH Q DWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLP PPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDS DGSYFMYSKLRVEKK NWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK
170	1.16B8 light chain	DIQMTQTPSSMPASLGERVTISCRASQGISNYLNHWYQQKPDGTIKPLIYYTS NLQSGVPSRFGSGSGTDYSLTITSSLEPEDFAMYYCQQYDSSPWTFGGGTKL EIKRADAAPT VSI FPPSSEQLTSGGASVVCFLNNFY PKDINVKWKIDGSE RQ NGVLNSWTDQDSKDYSTYSMSSTLT LTKDEYERHNSYTCEATHKTSTSPIVKS FNRNEC
171	1.16B8 heavy chain	EVQLVESGGGLVQPG RSLKLSCAASGFTFSDSAMA WVRQAPKKGLEWVATII YDTSSTYYRDSVKGRFTISRDN AKSTLYLQMDSLRSEDTATYYCALFGVDVM DAWGQGASVT VSSAKTTAPSVYPLAPVCGD TTGSSVTLGCLVKGYFPEPVT L TWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASST KVDKKIEPRGPTIKPCPPCKCPAPNAAGGPSVFI FPPKIKDVLMI SLSPIVT CVVVDVSEDDPDVQISW FVNNVEVHTAQTQTHREDYNSTLRVVSALPIQH QD WMSGKEFKCKVNNKDLGAPIERTISKPKGSVRAPQVYVLP PPEEEMTKKQVT LTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDS DGSYFMYSKLRVEKK N WVERNSYSCSVVHEGLHNHHTTKSFSRTPGK
172	Murine Kappa (light chain) constant region	RADAAPT VSI FPPSSEQLTSGGASVVCFLNNFY PKDINVKWKIDGSE RQNGV LNSWTDQDSKDYSTYSMSSTLT LTKDEYERHNSYTCEATHKTSTSPIVKS FNR NEC
173	Sequence for Alt-R CRISPR-Cas9 crRNA	TTGTAGATTCCGCAGCGTAA
174	Sequence for Alt-R CRISPR-Cas9 crRNA	AATGGTGAGAGTGCCACCCA
175	Sequence for Alt-R	TACCAGTGCCAGAGCCTCCA

Seq Id. No.	Description	Sequence
	CRISPR-Cas9 crRNA	
176	hPara.09v2 light chain	DVVMTQSPLSLPVTPEGEPASISCRSSRSLLTSKGITSLYWYLQKPGQSPQLL IYRMSNLASGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQFLVYPYTFG QGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSS PVTKSFNRGEC
177	hTREM2 stalk domain comprising peptide residues 129-175 (Fig. 2A)	LADPLDHRDAGDLWFPGESSESFEDAHVE <u>HS</u> ISRSLLEGEIPFPPTS

What is Claimed is:

1. An isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 11, 19, or 62; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 10, 12, 20, 55, 63, 65, or 73; and a CDR-H3 comprising the amino acid sequence as follows: X₁-X₂-X₃-Y, wherein X₁ and X₂ together are either I-L or L, and wherein X₃ is either D or E.
2. An isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 11, 19, or 62; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 10, 12, 20, 55, 63, 65, or 73; and a CDR-H3 comprising the amino acid sequence as follows: X₁-X₂-X₃-Y, wherein X₁ and X₂ together are either I-L or L, and wherein X₃ is either D or E; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, 27, 37, 47, 57, or 67; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, 29, 39, 49, 59, or 69.
3. An isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 11, or 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 10, 12, or 20; and a CDR-H3 comprising the amino acid sequence as follows: X₁-X₂-X₃-Y, wherein X₁ and X₂ together are either I-L or L, and wherein X₃ is either D or E; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
4. The isolated antibody of any one of claims 1-3, wherein the antibody has one or more of the following properties:

- (a) specifically binds to the stalk domain of TREM2;
 - (b) does not bind to soluble TREM2 (sTREM2);
 - (c) specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);
 - (d) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site;
 - (e) shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry);
 - (f) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM at 37 °C by surface plasmon resonance (SPR); and
 - (g) specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM at 37 °C by surface plasmon resonance (SPR).
5. The isolated antibody of any one of claims 1-4, wherein the antibody has a VH sequence derived from rat IGHV6-8 germline segments and/or wherein the antibody has a VL sequence derived from rat IGKV2S11 germline segments.
6. The antibody of any one of claims 1-5, wherein the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, 27, or 67; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, 29, or 69.
7. The antibody of any one of claims 1-6, wherein the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

8. The antibody of any one of claims 1-7, wherein:
- (a) the heavy chain variable region (VH) comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 or 9; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2 or 10; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and wherein the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; or
 - (b) the heavy chain variable region (VH) comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11 or 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12 or 20; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; and wherein the light chain variable region (VL) comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
9. The antibody of any one of claims 1-8, wherein the antibody comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7, 17, 30, 40, 50, 60, 70, 76, 77, 78, 81, 82, 83, 133, 135, 137, 139, 146, 148, 150, or 152.
10. The antibody of any one of claims 1-8, wherein the antibody comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7, 17, 133, 135, 137, 139, 146, 148, 150, or 152.
11. The antibody of any one of claims 1-10, wherein the antibody comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8, 18, 31, 41, 51, 61, 71, 79, 80, 84, 85, 132, 134, 136, 138, 145, 147, 149, or 151.

12. The antibody of any one of claims 1-10, wherein the antibody comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8, 18, 132, 134, 136, 138, 145, 147, 149, or 151.

13. The antibody of any one of claims 1-12, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7, 17, 133, 135, 137, 139, 146, 148, 150, or 152.

14. The antibody of any one of claims 1-13, wherein the antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 8, 18, 132, 134, 136, 138, 145, 147, 149, or 151.

15. An isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises:

- (a) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6;
- (b) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6;
- (c) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR-H3 comprising the amino acid sequence of SEQ

- ID NO: 13; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16;
- (d) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16;
- (e) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 24, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 25, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 27, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 29;
- (f) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 34, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 35, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 36; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 37, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 38, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 39;
- (g) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 47, a CDR-L2 comprising

- the amino acid sequence of SEQ ID NO: 48, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 49;
- (h) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 54, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 55, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 56; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 57, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 59; or
- (i) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 64, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 65, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 66; and a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 67, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 69.
16. The antibody of claim 15, wherein the antibody
- (a) comprises the CDRs of claim 15(a) and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7;
- (b) comprises the CDRs of claim 15(b) and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 7;
- (c) comprises the CDRs of claim 15(c) and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 17;
- (d) comprises the CDRs of claim 15(d) and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 17;

- (e) comprises the CDRs of claim 15(e) and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 30;
 - (f) comprises the CDRs of claim 15(f) and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 40;
 - (g) comprises the CDRs of claim 15(g) and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 50;
 - (h) comprises the CDRs of claim 15(h) and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 60; or
 - (i) comprises the CDRs of claim 15(i) and further comprises a VH that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 70.
17. The antibody of claim 15 or 16, wherein the antibody
- (a) comprises the CDRs of claim 15(a) and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8;
 - (b) comprises the CDRs of claim 15(b) and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 8;
 - (c) comprises the CDRs of claim 15(c) and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 18;
 - (d) comprises the CDRs of claim 15(d) and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 18;

- (e) comprises the CDRs of claim 15(e) and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 31;
 - (f) comprises the CDRs of claim 15(f) and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 41;
 - (g) comprises the CDRs of claim 15(g) and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 51;
 - (h) comprises the CDRs of claim 15(h) and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 61; or
 - (i) comprises the CDRs of claim 15(i) and further comprises a VL that is at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 71.
18. The antibody of claim 15, 16, or 17, wherein the antibody
- (a) comprises the CDRs of claim 15(a) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 7;
 - (b) comprises the CDRs of claim 15(b) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 7;
 - (c) comprises the CDRs of claim 15(c) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 17;
 - (d) comprises the CDRs of claim 15(d) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 17;
 - (e) comprises the CDRs of claim 15(e) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 30;
 - (f) comprises the CDRs of claim 15(f) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 40;
 - (g) comprises the CDRs of claim 15(g) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 50;

- (h) comprises the CDRs of claim 15(h) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 60; or
 - (i) comprises the CDRs of claim 15(i) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 70.
19. The antibody of any one of claims 15-18, wherein the antibody
- (a) comprises the CDRs of claim 15(a) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 8;
 - (b) comprises the CDRs of claim 15(b) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 8;
 - (c) comprises the CDRs of claim 15(c) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18;
 - (d) comprises the CDRs of claim 15(d) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18;
 - (e) comprises the CDRs of claim 15(e) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 31;
 - (f) comprises the CDRs of claim 15(f) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 41;
 - (g) comprises the CDRs of claim 15(g) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 51;
 - (h) comprises the CDRs of claim 15(h) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 61; or
 - (i) comprises the CDRs of claim 15(i) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 71.
20. The antibody of any one of claims 15-18, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 8.

21. The antibody of any one of claims 15-18, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 18.
22. The antibody of any one of claims 15-18, wherein the antibody comprises a VL comprising from 1 to 5 amino acid substitutions in the framework region compared to human IGKV2-28*01 germline, optionally wherein the amino acid substitutions comprise Q100P and/or V104L.
23. The antibody of claim 15-18, wherein the antibody:
- (a) comprises the CDRs of claim 15(a) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 145;
 - (b) comprises the CDRs of claim 15(b) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 145;
 - (c) comprises the CDRs of claim 15(a) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 147;
 - (d) comprises the CDRs of claim 15(b) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 147;
 - (e) comprises the CDRs of claim 15(a) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 149;
 - (f) comprises the CDRs of claim 15(b) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 149;
 - (g) comprises the CDRs of claim 15(a) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 151;
 - (h) comprises the CDRs of claim 15(b) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 151;
 - (i) comprises the CDRs of claim 15(c) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 132;
 - (j) comprises the CDRs of claim 15(d) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 132;

- (k) comprises the CDRs of claim 15(c) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 134;
 - (l) comprises the CDRs of claim 15(d) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 134;
 - (m) comprises the CDRs of claim 15(c) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 136;
 - (n) comprises the CDRs of claim 15(d) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 136;
 - (o) comprises the CDRs of claim 15(c) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 138; or
 - (p) comprises the CDRs of claim 15(d) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 138.
24. The isolated antibody of any one of claims 15-23, wherein the antibody has one or more of the following properties:
- (a) specifically binds to the stalk domain of TREM2;
 - (b) does not bind to soluble TREM2 (sTREM2);
 - (c) specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);
 - (d) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site;
 - (e) shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry);
 - (f) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or 100-500 pM or 100-200 pM at 37 °C by surface plasmon resonance (SPR); and
 - (g) specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4

pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR).

25. An isolated antibody that specifically binds triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises:

- (a) a VH comprising the amino acid sequence of SEQ ID NO: 146 and a VL comprising the amino acid sequence of SEQ ID NO: 145;
- (b) a VH comprising the amino acid sequence of SEQ ID NO: 148 and a VL comprising the amino acid sequence of SEQ ID NO: 147;
- (c) a VH comprising the amino acid sequence of SEQ ID NO: 150 and a VL comprising the amino acid sequence of SEQ ID NO: 149; or
- (d) a VH comprising the amino acid sequence of SEQ ID NO: 152 and a VL comprising the amino acid sequence of SEQ ID NO: 151.

26. The isolated antibody of claim 25, wherein the antibody has one or more of the following properties:

- (a) specifically binds to the stalk domain of TREM2;
- (b) does not bind to soluble TREM2 (sTREM2);
- (c) specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);
- (d) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site;
- (e) shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry); and
- (f) specifically binds to human and cynomolgus TREM2 with a K_D of less than 1 nM, less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, or less than 0.3 nM, or 100-500 pM or 100-200 pM at 37 °C by surface plasmon resonance (SPR).

27. An isolated antibody that specifically binds triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises:

- (a) a VH comprising the amino acid sequence of SEQ ID NO: 133 and a VL comprising the amino acid sequence of SEQ ID NO: 132;
- (b) a VH comprising the amino acid sequence of SEQ ID NO: 135 and a VL comprising the amino acid sequence of SEQ ID NO: 134;
- (c) a VH comprising the amino acid sequence of SEQ ID NO: 137 and a VL comprising the amino acid sequence of SEQ ID NO: 136; or
- (d) a VH comprising the amino acid sequence of SEQ ID NO: 139 and a VL comprising the amino acid sequence of SEQ ID NO: 138.

28. The isolated antibody of claim 27, wherein the antibody has one or more of the following properties:

- (a) specifically binds to the stalk domain of TREM2;
- (b) does not bind to soluble TREM2 (sTREM2);
- (c) specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94);
- (d) specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site;
- (e) shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry); and
- (f) specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR).

29. The antibody of any one of claims 1-28, wherein the antibody has one or more of the following characteristics:

- (a) induces luciferase reporter activity in Jurkat-NFAT luciferase reporter cells expressing human TREM2;
- (b) decreases levels of sTREM2 *in vivo* in plasma;
- (c) inhibits shedding of sTREM2 in Jurkat-NFAT luciferase reporter cells expressing human TREM2;
- (d) induces tyrosine phosphorylation in human MDM cells;
- (e) induces SYK phosphorylation in human MDM cells;
- (f) enhances survival of human iPSC-derived microglia in absence of IL-34 and CSF-1;
- (g) inhibits shedding of sTREM2 in human iPSC-derived microglia;
- (h) induces SYK phosphorylation in human iPSC-derived microglia; and
- (i) increases total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia (e.g., as described in the assay of Example 17 herein).

30. The antibody of any one of claims 1-29, wherein the antibody has a low off-target binding score (e.g. a score of < 1) in an off-target binding assay (e.g., as described in Example 10 herein).

31. The antibody of any one of claims 1-30, which is an antibody fragment, such as an Fv, single-chain Fv (scFv), Fab, Fab', or (Fab')₂.

32. The antibody of any one of claims 1-30, which is an IgG antibody, such as an IgG1, IgG2, IgG3, or IgG4 antibody.

33. The antibody of claim 32, wherein the antibody comprises a wild-type, human IgG1 or IgG4 Fc region.

34. The antibody of claim 33, wherein the antibody comprises a human IgG1 Fc region comprising (a) an N297G substitution, (b) L234A, L235A, and P329G substitutions (LALAPG substitutions), or (c) N297G, M428L, and N434S substitutions.
35. The antibody of claim 33 or 34, wherein the antibody has reduced effector function, or is effectorless, or does not bind to FcγR.
36. The antibody of any one of claims 1-35, wherein the antibody comprises a human IgG1 Fc region comprising an N297G substitution.
37. The antibody of any one of claims 1-36, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 144 and/or a light chain comprising the amino acid sequence of SEQ ID NO: 176.
38. The antibody of any one of claims 1-36, wherein the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 but lacking the C-terminal lysine of SEQ ID NO: 144 or lacking the C-terminal glycine and lysine of SEQ ID NO: 144 and/or a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176.
39. The antibody of any one of claims 1-36, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 144 and/or a light chain consisting of the amino acid sequence of SEQ ID NO: 176.
40. The antibody of claim 33, wherein the antibody comprises a human IgG4 Fc region comprising an S228P substitution or comprising S228P, M252Y, S254T, and T256E substitutions.
41. The antibody of any one of claims 1-30 or 32-36 or 40, which is a full length antibody.

42. The antibody of any one of claims 1-30 or 32-36 or 40, which is an IgG antibody lacking a C-terminal lysine in the heavy chain constant region.

43. An isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 17 and/or a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 18.

44. An isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 and/or a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176.

45. An isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144 but lacking the C-terminal lysine of SEQ ID NO: 144 or lacking the C-terminal glycine and lysine of SEQ ID NO: 144 and/or a light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176.

46. An isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 144 and/or a light chain consisting of the amino acid sequence of SEQ ID NO: 176.

47. The isolated antibody of any one of claims 43-46, wherein the antibody specifically binds to the TREM2 stalk domain and does not bind to soluble TREM2 (sTREM2), and wherein the antibody specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site and/or specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity

than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94).

48. The isolated antibody of any one of claims 43-46, wherein the antibody specifically binds to the TREM2 stalk domain and does not bind to soluble TREM2 (sTREM2), and wherein the antibody is a TREM2 agonist.

49. An isolated antibody that specifically binds to triggering receptor expressed on myeloid cells-2 (TREM2), wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11 or 19; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12 or 20; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13, and further wherein the antibody specifically binds to the TREM2 stalk domain and does not bind to soluble TREM2 (sTREM2), wherein the antibody is a TREM2 agonist, and wherein the antibody specifically binds to a TREM2 epitope spanning the H157-S158 cleavage site and/or specifically binds to a TREM2 polypeptide consisting of amino acids 146-161 (SEQ ID NO: 96) or 151-165 (SEQ ID NO: 97) with higher affinity than to a TREM2 polypeptide consisting of amino acids 139-158 (SEQ ID NO: 92) and/or 159-175 (SEQ ID NO: 94).

50. The isolated antibody of any one of claims 43-49, wherein the antibody shows reduced binding affinity to a TREM2 stalk domain polypeptide comprising D152A, H157A, and I159A substitutions compared to a wild-type TREM2 stalk domain polypeptide (e.g., as measured by bilayer interferometry) and/or specifically binds to human and cynomolgus TREM2 with a K_D of less than 100 pM, less than 50 pM, less than 10 pM, less than 7 pM, less than 5 pM, less than 4 pM, less than 3 pM, or less than 2 pM, or 10-50 pM or 10-25 pM at 37 °C by surface plasmon resonance (SPR).

51. The isolated antibody of any one of claims 43-50, wherein the antibody has one or more of the following characteristics:

- (a) induces luciferase reporter activity in Jurkat-NFAT luciferase reporter cells expressing human TREM2;
- (b) decreases levels of sTREM2 *in vivo* in plasma;
- (c) inhibits shedding of sTREM2 in Jurkat-NFAT luciferase reporter cells expressing human TREM2;
- (d) induces tyrosine phosphorylation in human MDM cells;
- (e) induces SYK phosphorylation in human MDM cells;
- (f) enhances survival of human iPSC-derived microglia in absence of IL-34 and CSF-1;
- (g) inhibits shedding of sTREM2 in human iPSC-derived microglia;
- (h) induces SYK phosphorylation in human iPSC-derived microglia; and
- (i) increases total A β plaque intensity and/or average X04 plaque intensity in presence of A β oligomers in human iPSC-derived microglia (e.g., as described in the assay of Example 17 herein).

52. The antibody of any one of claims 43-51, wherein the antibody has a low off-target binding score (e.g. a score of < 1) in an off-target binding assay (e.g., as described in Example 10 herein).

53. The antibody of any one of claims 47-52, wherein the VH comprises the amino acid sequence of SEQ ID NO: 17, 133, 135, 137, or 139, or wherein the antibody comprises a heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144.

54. The antibody of any one of claims 47-53, wherein the antibody comprises a human IgG1 Fc region comprising (a) an N297G substitution, (b) L234A, L235A, and P329G substitutions (LALAPG substitutions), or (c) N297G, M428L, and N434S substitutions.

55. The antibody of any one of claims 47-54, wherein the antibody has reduced effector function, or is effectorless, or does not bind to Fc γ R.

56. The antibody of any one of claims 1-55, which is a bispecific or multispecific antibody, or which is conjugated covalently or noncovalently to at least one other molecule.
57. The antibody of claim 56, wherein the antibody is conjugated covalently or noncovalently to at least one other molecule, wherein the at least one other molecule comprises a detection label and/or a drug.
58. A pharmaceutical composition comprising an antibody of any one of claims 1-57 and a pharmaceutically acceptable carrier.
59. An isolated nucleic acid or set of two or more nucleic acids encoding the antibody of any of claims 1-57.
60. An isolated vector comprising one or more nucleic acids encoding the heavy chain and the light chain of the antibody of any one of claims 1-57.
61. An isolated host cell comprising the nucleic acid of claim 59 or the vector of claim 60.
62. A method of producing an antibody that specifically binds to TREM2 comprising culturing the host cell of claim 60 under conditions suitable for the expression of the antibody.
63. The method of claim 62, further comprising recovering the antibody from the host cell.
64. An antibody produced by the method of claim 62 or 63.

65. A method of treating a condition associated with TREM2 loss of function in a subject in need thereof, comprising administering the antibody of any one of claims 1-57 or the pharmaceutical composition of claim 58 to the subject.
66. A method of reducing levels of sTREM2 in a subject in need thereof, comprising administering the antibody of any one of claims 1-57 or the pharmaceutical composition of claim 58 to the subject.
67. The method of claim 65 or 66, wherein the condition is, or wherein the subject suffers from, a neuroinflammatory or neurodegenerative disease.
68. The method of claim 67, wherein the neuroinflammatory or neurodegenerative disease is Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Nasu-Hakola disease, Guillain-Barré Syndrome (GBS), lysosomal storage disease, sphingomyelinlipidosis (Neimann-Pick C), mucopolysaccharidosis II/IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, neuro-Behcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, stroke, transverse myelitis, traumatic brain injury, or spinal cord injury.
69. The method of claim 68, wherein the disease is Alzheimer's disease.
70. The method of claim 68, wherein the disease is MS.
71. An antibody of any one of claims 1-57 or a pharmaceutical composition of claim 58 for use in treating a condition associated with TREM2 loss of function in a subject in need thereof.
72. An antibody of any one of claims 1-57 or a pharmaceutical composition of claim 58 for use in reducing levels of sTREM2 in a subject in need thereof.
73. The antibody for use of claim 71 or 72, wherein the condition is, or wherein the subject suffers from, a neuroinflammatory or neurodegenerative disease.

74. The antibody for use of claim 73, wherein the neuroinflammatory or neurodegenerative disease is Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Nasu-Hakola disease, Guillain-Barré Syndrome (GBS), lysosomal storage disease, sphingomyelinlipidosis (Neimann-Pick C), mucopolysaccharidosis II/IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, neuro-Behcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, stroke, transverse myelitis, traumatic brain injury, or spinal cord injury.

75. The antibody for use of claim 74, wherein the disease is Alzheimer's disease.

76. The antibody for use of claim 74, wherein the disease is MS.

77. Use of an antibody of any one of claims 1-57 or a pharmaceutical composition of claim 58 in the preparation of a medicament for treating a condition associated with TREM2 loss of function in a subject in need thereof.

78. Use of an antibody of any one of claims 1-57 or a pharmaceutical composition of claim 58 in the preparation of a medicament for reducing levels of sTREM2 in a subject in need thereof.

79. The use of claim 77 or 78, wherein the condition is, or wherein the subject suffers from, a neuroinflammatory or neurodegenerative disease.

80. The use of claim 79, wherein the neuroinflammatory or neurodegenerative disease is Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Nasu-Hakola disease, Guillain-Barré Syndrome (GBS), lysosomal storage disease, sphingomyelinlipidosis (Neimann-Pick C), mucopolysaccharidosis II/IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, neuro-Behcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, stroke, transverse myelitis, traumatic brain injury, or spinal cord injury.

81. The use of claim 80, wherein the disease is Alzheimer's disease.
82. The use of claim 80, wherein the disease is MS.

Campaign	Species	Immunogen and method	Animals fused	Human TREM2 ELISA positives	Human TREM2 FACS positives	Unique clones
1	SD rats	Human TREM2 pDNA genegun	3	88	71	15
3	SD rats	Human TREM2 ECD protein	3	900	346	174
5	SD rats	Human TREM2 EV	2	366	270	5
6	TREM2 KO mice	Human TREM2 ECD TREM2	5	18	18	5
8	TREM2 KO mice	Human TREM2 pDNA HTV	6	278	242	30

Fig. 1




Fig. 2A

Peptide	3.10C2	3.18E5	3.50G1
Stalk	1.91	1.85	2.18
129-148	0.19	0.28	0.19
139-158	0.37	0.51	0.43
149-168	2.10	1.45	1.28
159-175	0.07	0.07	0.08
146-169	1.65	1.43	1.49
146-161	2.95	2.89	2.52
151-165	2.52	2.42	2.32
155-169	0.13	0.14	0.13
152-161	0.12	0.15	0.14
154-164	0.39	0.40	0.26
151 to 161			

Fig. 2B

Kabat number	CDRL1 - Kabat
3.10C2	DTVLTQAAPLSLSVTPGESASISCRS
3.50G1	DTVLTQAAPLSVSVTPGESASISCRS
3.18E5	DTVLTQAAPLSVSVTPGESASISCRS
3.36F5	DTVLTQAAPLSVSVTPGESASISCRS
3.27H7	DTVLTQAAPLSVSVTPGESASISCRS
Kabat number	CDRL2 - Kabat
3.10C2	QKPGKSPQLLIYRMNSNLA
3.50G1	QKPGKSPQLLIYRMNSNLA
3.18E5	QKPGKSPQLLIYRMNSNLA
3.36F5	QKPGKSPQLLIYRMNSNLA
3.27H7	QKPGKSPQLLIYRMNSNLA
Kabat number	CDRL3 - Kabat
3.10C2	TEDVGVYYCAQFLRYPPYTFGPGTKLELK
3.50G1	TEDVGVYYCAQFLRYPPYTFGPGTKLELK
3.18E5	TEDVGVYYCAQFLRYPPYTFGPGTKLELK
3.36F5	TEDVGVYYCAQFLRYPPYTFGPGTKLELK
3.27H7	TEDVGVYYCAQFLRYPPYTFGPGTKLELK

Fig. 3A

Kabat number	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30													
3.10C2	E	V	Q	L	V	E	T	G	G	S	L	V	Q	P	G	K	S	L	K	L	T	C	A	T	S	G	F	F	F	S	N	V	M	H	W	V	R	Q	S	P	E		
3.50G1	E	V	Q	L	V	E	T	G	G	S	L	V	Q	P	G	K	S	L	K	L	T	C	A	T	S	G	F	F	F	S	N	V	M	H	W	V	R	Q	S	P	E		
3.18E5	E	V	Q	L	V	E	T	G	G	S	L	V	Q	P	G	K	S	L	K	L	T	C	A	T	S	G	F	F	F	S	N	V	M	H	W	V	R	Q	S	P	E		
3.36F5	E	V	Q	L	V	E	T	G	G	S	L	V	Q	P	G	K	S	L	K	L	T	C	A	T	S	G	F	F	F	S	N	V	M	H	W	V	R	Q	S	P	E		
3.27H7	E	V	Q	L	V	E	T	G	G	S	L	V	Q	P	G	G	S	L	K	L	T	C	A	T	S	G	F	F	F	S	N	V	M	V	L	H	W	I	R	R	S	P	E
Para.09	E	V	Q	L	V	E	T	G	G	S	L	V	Q	P	G	K	S	L	R	L	T	C	A	T	S	G	F	F	F	S	N	V	M	V	L	H	W	V	R	Q	S	P	E

Kabat number	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									
3.10C2	K	Q	L	E	W	I	A	H	I	K	A	K	S	D	N	Y	A	T	Y	A	E	S	V	K	G	R	F	T	I	S	R	D	D	S	K	T	S	I	Y	L	Q																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
3.50G1	K	Q	L	E	W	I	A	H	I	K	A	K	S	D	N	Y	A	T	Y	A	E	S	V	K	G	R	F	T	I	S	R	D	D	S	K	T	S	I	Y	L	Q																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
3.18E5	K	Q	L	E	W	I	A	H	I	K	A	K	S	D	N	Y	A	T	Y	A	E	S	V	K	G	R	F	T	I	S	R	D	D	S	K	T	S	I	Y	L	Q																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
3.36F5	K	Q	L	E	W	V	G	Q	I	K	G	K	S	D	N	Y	A	T	Y	A	E	S	L	Q	G	R	F	T	I	S	R	D	D	S	K	T	S	I	Y	L	Q																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
3.27H7	K	Q	L	E	W	V	Q	I	K	A	K	S	D	N	Y	A	T	Y	A	E	S	V	K	G	R	F	T	I	S	R	D	D	S	K	T	S	I	Y	L	Q																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Para.09	K	H	P	E	W	V	A	H	I	K	A	K	S	D	N	Y	A	T	Y	A	E	S	V	K	G	R	F	T	I	S	R	D	D	S	K	S	S	V	F	L																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					

[illegible]

Fig. 3B




Fig. 4

Fab fragment	TREM2 residue												
	S	F	E	D	A	H	V	E	H	S	I	S	R
	149	150	151	152	153	154	155	156	157	158	159	160	161
3.10C2													
3.50G1													
Para.09-L27H7													
3.47B1													
9F5													
AL2p-31													
14D3													
14D8													

149	A	F	E	D	A	H	V	E	H	S	I	S	R
150	S	A	E	D	A	H	V	E	H	S	I	S	R
151	S	F	A	D	A	H	V	E	H	S	I	S	R
152	S	F	E	A	A	H	V	E	H	S	I	S	R
153	S	F	E	D	G	H	V	E	H	S	I	S	R
154	S	F	E	D	A	A	V	E	H	S	I	S	R
155	S	F	E	D	A	H	A	E	H	S	I	S	R
156	S	F	E	D	A	H	V	A	H	S	I	S	R
157	S	F	E	D	A	H	V	E	A	S	I	S	R
158	S	F	E	D	A	H	V	E	H	A	I	S	R
159	S	F	E	D	A	H	V	E	H	S	A	S	R
160	S	F	E	D	A	H	V	E	H	S	I	A	R
161	S	F	E	D	A	H	V	E	H	S	I	S	A

Fig. 5

Kabat number	IGKV2-28*01	3.10C2	3.10C2-L1	3.10C2-L5
1	D	T	T	T
2	I	V	V	V
3	V	V	V	V
4	M	L	L	M
5	T	T	T	T
6	Q	Q	Q	Q
7	S	A	S	S
8	P	P	P	P
9	S	L	S	S
10	L	S	L	L
11	S	L	S	S
12	P	S	P	P
13	V	V	V	V
14	T	T	T	T
15	P	P	P	P
16	G	G	G	G
17	E	E	E	E
18	P	S	P	P
19	A	A	A	A
20	S	A	S	S
21	I	S	I	I
22	S	S	S	S
23	C	C	C	C
24	R	R	R	R
25	S	S	S	S
26	S	S	S	S
27	Q	K	K	K
27e	S	S	S	S
27h	S	S	S	S
27c	L	L	L	L
27d	H	G	G	G
27e	S	V	V	V
28	N	R	D	R
29	G	I	I	G
30	Y	I	I	Y
31	N	T	T	N
32	Y	T	T	Y
33	L	S	S	L
34	D	L	L	D
35	W	Y	Y	W
36	Y	L	L	Y

Kabat number	IGKV2-28*01	3.10C2	3.10C2-L1	3.10C2-L5
38	Q	K	Q	Q
39	K	P	K	K
40	P	P	P	P
41	G	G	G	G
42	Q	K	Q	Q
43	S	S	S	S
44	S	P	S	S
45	Q	L	Q	Q
46	L	L	L	L
47	L	L	L	L
48	I	Y	I	I
49	Y	Y	Y	Y
50	L	L	L	L
51	G	S	G	G
52	S	N	S	S
53	N	R	N	N
54	R	A	R	R
55	A	S	A	A
56	S	G	S	S
57	A	G	A	A
58	V	V	V	V
59	P	P	P	P
60	D	D	D	D
61	R	R	R	R
62	F	F	F	F
63	S	S	S	S
64	G	G	G	G
65	S	S	S	S
66	S	S	S	S
67	S	S	S	S
68	G	G	G	G
69	T	T	T	T
70	D	D	D	D
71	F	F	F	F
72	T	T	T	T
73	L	L	L	L
74	K	K	K	K
75	I	I	I	I
76	S	S	S	S
77	R	R	R	R
78	V	E	V	V
79	E	E	E	E



Kabat number	IGKV2-28*01	3.10C2	3.10C2-L1	3.10C2-L5
80	A	T	A	A
81	E	E	E	E
82	D	D	D	D
83	V	V	V	V
84	G	G	G	G
85	V	V	V	V
86	Y	Y	Y	Y
87	Y	Y	Y	Y
88	C	A	C	C
89	M	Q	M	M
90	Q	A	Q	Q
91	A	F	A	A
92	L	L	L	L
93	Q	R	Q	Q</

Fig. 6A

[illegible]

SUBSTITUTE SHEET (RULE 26)

9/41

**Fig. 7A****Fig. 7B**

Kabat number IGKV2-28*01 3.27H7 3.27H7-L1 3.27H7-L6	37	D	I	V	M	T	Q	S	P	L	S	L	P	V	T	P	G	E	P	A	S	I	S	C	R	S	S	Q	S	L	L	H	S	N	G	Y	N	Y	L	D	W	Y	L								
	36																																																		
	35	D	V	L	T	Q	A	P	L	S	V	S	V	T	P	G	E	S	A	S	I	S	C	R	S	S	R	S	S	R	S	L	L	T	S	K	G	I	T	S	L	Y	W	Y	L						
	34	D	V	V	L	T	Q	S	P	L	S	L	P	V	T	P	G	E	P	A	S	I	S	C	R	S	S	R	S	L	L	T	S	K	G	I	T	S	L	Y	W	Y	L								
	33	D	V	V	M	T	Q	S	P	L	S	L	P	V	T	P	G	E	P	A	S	I	S	C	R	S	S	R	S	L	L	T	S	K	G	I	T	S	L	Y	W	Y	L								
																																										CDR L1 - Kabat									
																																										CDR L1 - Contact									
Kabat number IGKV2-28*01 3.27H7 3.27H7-L1 3.27H7-L6	38	Q	K	P	G	Q	S	P	Q	L	L	I	Y	L	G	S	N	R	A	S	G	V	I	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	K	I	S	R	V	E							
	37																																																		
	36	Q	K	P	G	M	S	P	H	L	L	I	Y	R	M	S	N	L	A	S	G	I	P	D	R	F	S	G	S	G	S	E	T	D	F	T	L	K	I	S	R	V	E								
	35	Q	K	P	G	Q	S	P	Q	L	L	I	Y	R	M	S	N	L	A	S	G	I	P	D	R	F	S	G	S	G	S	E	T	D	F	T	L	K	I	S	R	V	E								
	34	Q	K	P	G	Q	S	P	Q	L	L	I	Y	R	M	S	N	L	A	S	G	I	P	D	R	F	S	G	S	G	S	E	T	D	F	T	L	K	I	S	R	V	E								
																																										CDR L2 - Kabat									
																																										CDR L2 - Contact									
Kabat number IGKV2-28*01 3.27H7 3.27H7-L1 3.27H7-L6	80	A	E	D	V	G	V	Y	Y	C	M	Q	A	L	Q	T	P	W	T	F	G	Q	G	T	K	V	E	I	K																						
	79																																																		
	78	P	E	D	V	G	V	Y	Y	C	A	Q	F	L	V	Y	P	Y	T	F	G	A	G	T	K	L	E	L	K																						
	77	A	E	D	V	G	V	Y	Y	C	A	Q	F	L	V	Y	P	Y	T	F	G	Q	G	T	K	V	E	I	K																						
	76	A	E	D	V	G	V	Y	Y	C	A	Q	F	L	V	Y	P	Y	T	F	G	Q	G	T	K	V	E	I	K																						
																																										CDR L3 - Kabat									
																																										CDR L3 - Contact									

Fig. 8A






Fig. 8B

Kabat number h3.10C2.v1	CDR L1 - Kabat																			
	D	V	V	M	T	Q	S	P	L	S	L	P	V	T	P	G	E	P	A	S
Kabat number h3.10C2.v1	CDR L2 - Kabat																			
	Q	K	P	G	Q	S	P	Q	L	L	I	Y	R	M	S	N	L	A	S	G
Kabat number h3.10C2.v1	CDR L3 - Kabat																			
	A	E	D	V	G	V	Y	Y	C	A	Q	F	L	V	Y	P	Y	T	F	G

Fig. 9A

Kabat number h3.10C2.v1	CDR H1 - Kabat																			
	E	V	Q	L	V	E	S	G	G	L	V	Q	P	G	G	S	L	K	L	S
Kabat number h3.10C2.v1	CDR H2 - Kabat																			
	K	G	L	E	W	I	A	H	I	K	A	K	S	D	N	Y	A	T	Y	A
Kabat number h3.10C2.v1	CDR H3																			
	M	N	S	L	K	T	E	D	T	A	V	Y	C	T	G	L	D	Y	W	G

Fig. 9B


*Fig. 10**Fig. 11*

Kabat number	CDR L1 - Kabat																			
	37	36	35	34	33	32	31	30	29	28	27c	27b	27a	27	26	25	24	23	22	21
hPara.09.v2	D	V	V	M	T	Q	S	P	L	S	L	P	V	T	P	G	E	P	A	S
Kabat number	CDR L2 - Kabat																			
	67	66	65	64	63	62	61	60	59	58	57	56	55	54	53	52	51	50	49	48
hPara.09.v2	Q	K	P	G	Q	S	P	Q	L	L	I	Y	R	M	S	N	L	A	S	G
Kabat number	CDR L3 - Kabat																			
	107	106	105	104	103	102	101	100	99	98	97	96	95	94	93	92	91	90	89	88
hPara.09.v2	A	E	D	V	G	V	Y	C	A	Q	F	L	V	Y	P	Y	T	F	G	Q

Fig. 12A

Kabat number	CDR H1 - Kabat																			
	42	41	40	39	38	37	36	35	34	33	32	31	30	29	28	27	26	25	24	23
hPara.09.v2	E	V	Q	L	V	E	S	G	G	L	V	Q	P	G	G	S	L	K	L	S
Kabat number	CDR H2 - Kabat																			
	81	80	79	78	77	76	75	74	73	72	71	70	69	68	67	66	65	64	63	62
hPara.09.v2	K	G	P	E	W	V	A	H	I	K	A	K	S	D	N	Y	A	T	Y	A
Kabat number	CDR H3 - K																			
	113	112	111	110	109	108	107	106	105	104	103	102	101	100	99	98	97	96	95	94
hPara.09.v2	M	N	S	L	K	T	E	D	T	A	V	Y	C	T	D	I	L	E	Y	W

Fig. 12B

*Fig. 15*




Fig. 16










Fig. 17



22/41

**Fig. 18A****Fig. 18B**

*Fig. 19A**Fig. 19B*

*Fig. 19C**Fig. 20A*

25/41

*Fig. 20B**Fig. 20C*

26/41




Fig. 20D





Fig. 21






Fig. 22C




Fig. 23A





Fig. 23B

*Fig. 23C*




Fig. 23D




Fig. 23E




Fig. 24A




Fig. 24B







Fig. 24C

**Fig. 25A****Fig. 25B**

*Fig. 25C*




FIG. 26A




Fig. 26B




FIG. 26C




FIG. 26D




FIG. 26E





FIG. 26F

*Fig. 27*

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2022/028920

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61P25/28 C07K16/28 A61K39/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61P A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2020/172450 A1 (DENALI THERAPEUTICS INC [US]) 27 August 2020 (2020-08-27) e.g. example 5; paragraphs 297, 405; the whole document -----	1-82
X	WO 2018/015573 A2 (DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E V (DZNE) [DE] E) 25 January 2018 (2018-01-25) e.g. example 3; fig. 7; the whole document -----	1-82
X	US 2020/277373 A1 (CHEN HANG [US] ET AL) 3 September 2020 (2020-09-03) e.g. fig. 4; paragraph 233; the whole document ----- -/--	1-82



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

5 September 2022

Date of mailing of the international search report

15/09/2022

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Gruber, Andreas

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2022/028920

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:
 - ☒ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2022/028920

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2020/140545 A1 (BRAND VERENA [DE] ET AL) 7 May 2020 (2020-05-07) e.g. paragraphs 12, 565; the whole document -----	1-82
X	SCHLEPCKOW KAI ET AL: "Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region", EMBO MOLECULAR MEDICINE, vol. 12, no. 4, 10 March 2020 (2020-03-10), XP055776027, US ISSN: 1757-4676, DOI: 10.15252/emmm.201911227 Retrieved from the Internet: URL:https://onlinelibrary.wiley.com/doi/full-xml/10.15252/emmm.201911227> e.g. abstract; the whole document -----	1-82
X	DECZKOWSKA ALEKSANDRA ET AL: "The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway", CELL, ELSEVIER, AMSTERDAM NL, vol. 181, no. 6, 11 June 2020 (2020-06-11), pages 1207-1217, XP086181113, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2020.05.003 [retrieved on 2020-06-11] e.g. page 1213, right-hand column, paragraph 1; the whole document -----	1-82
X	PRICE BRITTANI R. ET AL: "Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition", JOURNAL OF NEUROINFLAMMATION, vol. 17, no. 1, 1 December 2020 (2020-12-01), XP055797689, DOI: 10.1186/s12974-020-01915-0 Retrieved from the Internet: URL:https://jneuroinflammation.biomedcentral.com/track/pdf/10.1186/s12974-020-01915-0.pdf> e.g. page 10, right-hand column; the whole document -----	1-82

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2022/028920

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2020172450	A1	27-08-2020	AR 118144 A1	22-09-2021
			AU 2020226754 A1	16-09-2021
			CA 3130086 A1	27-08-2020
			CL 2021002206 A1	22-04-2022
			CN 113614110 A	05-11-2021
			CO 2021012230 A2	30-09-2021
			EA 202192294 A1	24-12-2021
			EC SP21069105 A	18-11-2021
			EP 3927743 A1	29-12-2021
			IL 285651 A	30-09-2021
			JP 2022520868 A	01-04-2022
			KR 20210135518 A	15-11-2021
			MA 55025 A	29-12-2021
			PE 20211979 A1	05-10-2021
			SG 11202108734V A	29-09-2021
			TW 202045543 A	16-12-2020
			US 2022073609 A1	10-03-2022
			US 2022119522 A1	21-04-2022
			WO 2020172450 A1	27-08-2020
			WO 2020172457 A1	27-08-2020
WO 2018015573	A2	25-01-2018	AU 2017300040 A1	24-01-2019
			CA 3030785 A1	25-01-2018
			CN 109641961 A	16-04-2019
			EP 3487886 A2	29-05-2019
			IL 264000 A	31-01-2019
			JP 2019531332 A	31-10-2019
			US 2019185565 A1	20-06-2019
			WO 2018015573 A2	25-01-2018
US 2020277373	A1	03-09-2020	CA 3075285 A1	21-03-2019
			CN 111448212 A	24-07-2020
			EP 3681909 A1	22-07-2020
			JP 2020534277 A	26-11-2020
			US 2020277373 A1	03-09-2020
			WO 2019055841 A1	21-03-2019
US 2020140545	A1	07-05-2020	AU 2019363230 A1	22-04-2021
			BR 112021006640 A2	20-07-2021
			CA 3116289 A1	23-04-2020
			CL 2021000909 A1	19-11-2021
			CN 113038988 A	25-06-2021
			CO 2021004560 A2	30-04-2021
			CR 20210176 A	30-06-2021
			EC SP21025707 A	31-05-2021
			EP 3866928 A1	25-08-2021
			IL 281738 A	31-05-2021
			JP 2022504751 A	13-01-2022
			KR 20210076945 A	24-06-2021
			MA 53905 A	19-01-2022
			PE 20211217 A1	05-07-2021
			PH 12021550764 A1	13-12-2021
			SG 11202102577W A	29-04-2021
			TW 202028243 A	01-08-2020
			US 2020140545 A1	07-05-2020
			UY 38407 A	29-05-2020
			WO 2020079580 A1	23-04-2020